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Abstract: producing Epo are the fetal liver and the adult kidney, but ectopic Epo expression can be found
also in other organs, including the brain. In response to anemia or inspiratory hypoxia, Epo synthesis
is transcriptionally induced by activation of the hypoxia-inducible factor (HIF) pathway, allowing the
binding of HIF-2 to a hypoxia response element (HRE) within the EPO gene. The availability of liver-
derived cell models as well as in vivo studies permitted the characterization of the Epo transcriptional
regulation in the liver, leading to the finding that the 3’ HRE is the regulatory element responsible for
the induction of hepatic Epo expression in hypoxia. Reporter transgenic mouse models demonstrated
that a region encompassing -14 to -6 kb upstream of the transcription start site (TSS) of EPO gene
contains the renal regulatory enhancers involved in the regulation of renal Epo and, it has been termed
kidney inducible element (KIE). Within the KIE, we previously identified by in silico analysis a novel
5’ HRE located at -9.2 kb from the TSS of EPO. We showed that this 5’ HRE is highly conserved
among species and that drives exogenous reporter gene expression in hypoxia. Because the liver-specific
3’ HRE is dispensable for renal Epo regulation and a renal cell culture model was missing until recently,
we investigated the contribution of the novel 5’ HRE and the well-established 3’ HRE by endogenous
gene editing (CRISPR/Cas9) of both HREs in Kelly as well as Hep3B and HepG2 cells, capable of
producing Epo in a hypoxia-inducible manner. We showed that while in hepatic cells the 3’ but not
the 5’ HRE is required, in neuronal cells both the 5’ and the 3’ HREs contribute to regulate hypoxia-
inducible endogenous Epo expression. Moreover, we identified two not yet reported HREs within the
EPO promoter, termed pHRE1 and pHRE2, in line with a weak but significant promoter-driven reporter
gene induction. While in hepatoma cells HIF interacted mainly with the distal 3’ HRE, in neuronal cells,
HIF bound most strongly the EPO promoter, weaker the 3’ HRE and not at all the 5’ HRE, suggesting
that the 5’ HRE acts in a non-canonical way by recruiting other transcription factors rather than HIF.
We additionally generated 5’/3’ double mutant Kelly cells and could show that both distal 5’ and 3’
HREs functionally cooperate with HIF binding to promoter HREs. These findings provide new insights
into brain Epo regulation and they might be of help to recapitulate renal Epo regulation as renal Epo-
producing (REP) cells show neuronal features. Due to the lack of a renal cell culture model able to
produce Epo in a hypoxia-inducible manner, the study of renal Epo transcriptional regulation has been
constrained. Therefore, we generated a novel transgenic mouse model to isolate fresh primary REP cells
and we established a new method to culture both, primary cells and immortalized clonal cell lines, which
we named fibroblastoid atypical interstitial kidney (FAIK) cells. By two simultaneous stimuli, hypoxia
and tamoxifen, we were able to temporally and conditionally tag the REP cells with red fluorescence
due to permanent activation of tdTomato reporter gene and negatively select the CreERT2 expressing
cells through inactivation of the diphtheria toxin receptor (DTR) as non-CreERT2 expressing cells died
in presence of diphtheria toxin. This mouse model is, thus, useful to generate primary REP culture and
clonal REP cell lines that can be adopted as model to study hypoxic renal Epo regulation. We also
applied a novel chromogenic in situ hybridization method to visualize on a single cell level Epo mRNA
molecules as well as other HIF target genes in neuroblastoma, hepatoma and FAIK cells. We provided
initial evidence for an inherent cell-to-cell variability of the Epo hypoxic transcript pattern not observed
with constitutively expressed transcripts. This PhD work focussed on the transcriptional regulation of
erythropoietin and on the DNA regulatory elements enhancing Epo expression in neuroblastoma and
hepatoma cell lines. We could show that, in contrast to the liver, in the brain, Epo regulation occurs
through a complex interplay between the distal 5’ and 3’ HREs and Epo promoter, demonstrating that
several HREs can cooperate in oxygen-regulated gene expression in a cell-type specific manner.
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Erythropoietin is the prime hormone regulating red blood cell homeostasis. The main organs 
producing Epo are the fetal liver and the adult kidney, but ectopic Epo expression can be found 
also in other organs, including the brain. In response to anemia or inspiratory hypoxia, Epo 
synthesis is transcriptionally induced by activation of the hypoxia-inducible factor (HIF) pathway, 
allowing the binding of HIF-2 to a hypoxia response element (HRE) within the EPO gene. The 
availability of liver-derived cell models as well as in vivo studies permitted the characterization of 
the Epo transcriptional regulation in the liver, leading to the finding that the 3' HRE is the 
regulatory element responsible for the induction of hepatic Epo expression in hypoxia. Reporter 
transgenic mouse models demonstrated that a region encompassing -14 to -6 kb upstream of 
the transcription start site (TSS) of EPO gene contains the renal regulatory enhancers involved 
in the regulation of renal Epo and, it has been termed kidney inducible element (KIE). Within the 
KIE, we previously identified by in silico analysis a novel 5' HRE located at -9.2 kb from the TSS 
of EPO. We showed that this 5' HRE is highly conserved among species and that drives 
exogenous reporter gene expression in hypoxia.  
Because the liver-specific 3' HRE is dispensable for renal Epo regulation and a renal cell culture 
model was missing until recently, we investigated the contribution of the novel 5' HRE and the 
well-established 3' HRE by endogenous gene editing (CRISPR/Cas9) of both HREs in Kelly as 
well as Hep3B and HepG2 cells, capable of producing Epo in a hypoxia-inducible manner. We 
showed that while in hepatic cells the 3' but not the 5' HRE is required, in neuronal cells both the 
5' and the 3' HREs contribute to regulate hypoxia-inducible endogenous Epo expression. 
Moreover, we identified two not yet reported HREs within the EPO promoter, termed pHRE1 and 
pHRE2, in line with a weak but significant promoter-driven reporter gene induction. While in 
hepatoma cells HIF interacted mainly with the distal 3' HRE, in neuronal cells, HIF bound most 
strongly the EPO promoter, weaker the 3' HRE and not at all the 5' HRE, suggesting that the 5' 
HRE acts in a non-canonical way by recruiting other transcription factors rather than HIF. We 
additionally generated 5'/3' double mutant Kelly cells and could show that both distal 5' and 3' 
HREs functionally cooperate with HIF binding to promoter HREs. These findings provide new 
insights into brain Epo regulation and they might be of help to recapitulate renal Epo regulation 
as renal Epo-producing (REP) cells show neuronal features.  
Due to the lack of a renal cell culture model able to produce Epo in a hypoxia-inducible manner, 
the study of renal Epo transcriptional regulation has been constrained. Therefore, we generated 




method to culture both, primary cells and immortalized clonal cell lines, which we named 
fibroblastoid atypical interstitial kidney (FAIK) cells. By two simultaneous stimuli, hypoxia and 
tamoxifen, we were able to temporally and conditionally tag the REP cells with red fluorescence 
due to permanent activation of tdTomato reporter gene and negatively select the CreERT2 
expressing cells through inactivation of the diphtheria toxin receptor (DTR) as non-CreERT2 
expressing cells died in presence of diphtheria toxin. This mouse model is, thus, useful to 
generate primary REP culture and clonal REP cell lines that can be adopted as model to study 
hypoxic renal Epo regulation.   
We also applied a novel chromogenic in situ hybridization method to visualize on a single cell 
level Epo mRNA molecules as well as other HIF target genes in neuroblastoma, hepatoma and 
FAIK cells. We provided initial evidence for an inherent cell-to-cell variability of the Epo hypoxic 
transcript pattern not observed with constitutively expressed transcripts.  
This PhD work focussed on the transcriptional regulation of erythropoietin and on the DNA 
regulatory elements enhancing Epo expression in neuroblastoma and hepatoma cell lines. We 
could show that, in contrast to the liver, in the brain, Epo regulation occurs through a complex 
interplay between the distal 5' and 3' HREs and Epo promoter, demonstrating that several HREs 












1.1 History of erythropoietin: from biochemistry to sport 
 
Erythropoietin (Epo) is a glycoprotein hormone acting as the main regulator of erythropoiesis. 
Its physiological role becomes crucial when the delivery of oxygen to tissues/organs is 
compromised leading to low arterial O2 partial pressure (pO2) and, thus, low blood O2 
content, inducing Epo to stimulate the red blood cell (RBC) production in order to restore the 
blood O2 carrying capacity [1]. The relationship between the O2 content of the blood and the 
red blood cell synthesis has been described for the first time by the French anatomist 
François-Gilbert Viault. In 1890, during a 23 days trip to the highlands of Peru (Marococha, 
4500 m), Viault measured an increase of his RBC from 5 to 8 million per μl blood, indicating 
that at high altitude the rarefied air, containing a low number of O2 molecules per air volume, 
stimulated an adaptive response of the human body to increase the RBC number as well as 
the blood O2 carrying capacity meeting the metabolic demand of the organism [2]. In 1906, 
Paul Carnot and Claude Deflandre of Paris proposed for the first time a hormonal regulation 
of erythropoiesis after observing that the injection of serum (5-9 mL) from anaemic donor 
rabbits into healthy recipient rabbits stimulated the production of the recipient’s RBC by 20-
40% within 1-2 days [3]. This reaction suggested the existence of a hormone, first called 
“hemopoietine”, present in the donor’s serum, which triggers the production of new 
erythrocytes. In 1948, Eva Bonsdorff and Eeva Jalavisto from Helsinki coined the specific 
term “erythropoietin” (Epo) [3]. However, the prove for an oxygen-dependent humoral factor 
regulating the RBC count came only later as attempts to validate the experiments of Carnot 
and Deflandre were unsuccessful. In 1953, Erslev administered large quantities of plasma 
(17 mL/kg, 50-200 mL, once a day for four days) from anaemic rabbits to normal rabbits 
resulting in the stimulation of erythropoiesis [4]. This convincing experiment demonstrated 
that the erythropoietic factor could pass through the anaemic to the normal blood and raise 
the amount of RBC. Indirect evidence supporting the hypothesis of Epo as an erythropoiesis 
regulator was provided by experiments of Reissmann, who in 1950 reported augmented RBC 
production in parabiotic rat-pairs where the circulation systems of both animals were 
connected by flaps of skin with one rat exposed to low oxygen tension (hypoxic condition) 
and the other to normal oxygen tension (normoxic condition). Reissmann explained this 
result by either the presence of erythropoietin in the blood of the rats or its transfer from the 
hypoxic to the normoxic rat [5]. Successively, Jacobson and Nathan, in 1957 and 1964, 
respectively, performed organ ablation experiments, in rats and humans, respectively, and 
concluded that the kidney is the major but not the exclusive site of Epo production [6] [7]. 






turned out to be an unsuccessful strategy due to the release of proteolytic enzymes after 
tissue homogenization [8]. Therefore, his next steps to isolate Epo relied on the plasma of 
anaemic sheep and on urine from Argentinians with severe iron deficiency, but again these 
attempts revealed to be a fail, although important chemical properties about Epo as a protein 
were characterized. Importantly, on the Christmas day of 1975, Dr. Miyake brought to 
Chicago a package, almost like a Christmas gift, containing 2550 L of urine from Japanese 
patients suffering from aplastic anaemia in Kumamato City. Together with Goldwasser and 
colleagues, they finally managed to purify 8 mg of human Epo [9]. From that moment, the 
study of Epo took off and thanks to the determination of the amino acid sequence and to the 
recombinant DNA technology, two independent groups cloned the human EPO gene in 1985  
[10] [11]. It became clear that a new era for Epo just started: pure Epo could help to broaden 
the knowledge about its function, regulation and therapeutical benefit. Soon, several clinical 
trials demonstrated the effectiveness of recombinant human Epo (rhEpo) for the treatment of 
anaemia related to chronic kidney disease. Eschbach et al. showed that, after receiving 
intravenous injections of rhEpo (doses between 15 and 500 units per kilogram of body 
weight) three times weekly after dialysis, the haematocrit of 11 out of 18 anaemic patients 
with end-stage renal disease (Hct= 20 ± 2) raised to 35% and no organ dysfunction or toxic 
side effects were reported, indicating that rhEpo is a valid theraupetical agent, which can 
abolish the requirement for transfusions and correct anaemia, improving the quality of life of 
thousands of chronic renal disease patients [12] [13]. Because Epo is a complex glycoprotein 
having 40% of its total molecular weight glycosylated, rhEpo has been mainly expressed in 
Chinese hamster ovary (CHO) cells for the large-scale pharmaceutical manufacture as 
mammalian cells ensure post-translational modifications including glycosylation. rhEpos 
deriving from CHO cells named epoetin-α (e.g. Epogen®) or epoetin-β (e.g. Epogin®) belong 
to the first-generation recombinant Epo or erythropoiesis stimulating agents (ESA) and have 
been used for 20 years in clinics. While the amino acid sequence is identical to endogenous 
Epo, such epoetins display a different glycosylation pattern despite being produced in the 
same mammalian cell host and having the same clinical efficacy. In fact, epoetin-α is more 
homogenous, showing less basic isoforms than epoetin-β. The reasons for such 
glycosylation differences can be attributed to the variability of the host cell, the transfected 
plasmids, the cell culture conditions and the downstream purification process [14]. As soon 
as the patent for these drugs expired, many more biosimilar recombinant Epo products 
entered the market, tagged as second-generation ESAs. These new biomolecules have a 
different glycosylation pattern and improved pharmacokinetic properties. For example, 
darbepoetin-α (e.g. Aranesp®), was obtained through modification of the amino acid 
sequence by site-directed mutagenesis, resulting in hyperglycosylated Epo, having an 






that allowed reducing the frequency of drug administration. rhEpo was further improved by 
chemical modification, leading to the PEGylated Epo or CERA, ‘’continuous erythropoiesis 
receptor activator’’, with a longer plasma half-life than darbepoetin-α [15]. Surprisingly, in 
1996, by random phage display peptide libraries, Nicholas et al., identified small peptidic 
molecules with no structural analogy to Epo, capable of binding the extracellular domain of 
Epo receptor (EpoR) and of triggering its activation and an erythropoietic response in a cell-
based context as well as in vivo. The discovery of these small Epo mimetics opened the 
possibility for a low cost therapy against anaemia in a long run, although further 
investigations about their mechanism of actions are required since serious adverse events 
were reported [16]. Remarkably, nowadays, rhEpo can be considered the most successful 
therapeutical application of recombinant DNA technology, reaching the largest market of 
biopharmaceuticals with annual sales rates of ∼1010 Euro [15].  
Because recombinant Epo stimulates the production of new RBC increasing the blood 
oxygen carrying capacity and the amount of oxygen delivered to the muscles, it is not hard to 
imagine how fine the borderline between Epo use and Epo abuse is. In fact, rhEpo has been 
illegally adopted as a performance-enhancing drug and thus in 1990 it was banned by the 
International Olympic Committee (IOC) Medical Commission due to its potent doping function 
in endurance sports where an intense aerobic effort is required like cycling and cross-country 
skiing. Epo abuse became a scandal worldwide and the hormone Epo well-known also to the 
non-scientific community. Famous athletes admitted to have misused rhEpo to enhance 
artificially their performance during sport competitions, like the American cyclist Lance 
Armstrong who revealed their systematic doping with Epo for years. The detection of Epo in 
sport has been challenging due to multiple reasons: difficulty to differentiate between 
endogenous Epo and recombinant Epo; short plasma half-life (8.5 ± 2.4 hours when 
administered intravenously and 19.4 ± 10.7 hours when administered sub-cutaneously; 
undetectable in urine after 3-4 days of injection) [17] [18]. However, direct and indirect 
diagnostic tests have successfully been developed to measure Epo in endurance athletes. 
The direct test allow for the detection of Epo in urine by exploiting the different biochemical 
properties due to the different glycosylation pattern of endogenous and recombinant Epo that 
confers distinct net electrical charges and thus isoelectric points. Therefore, the endogenous 
and synthetic Epo can be distinguished by electrophoretic separation according to the 
isoelectric point. The indirect test, instead, rely on the determination of parameters that 
indirectly confirm the presence of Epo in the bloodstream like the haematocrit, reticulocytosis 
and macrocytosis, which reflect increased bone marrow activity. Additionally, the assessment 
of the soluble form of the transferrin receptor (sTfR) is useful to diagnose not only the 






are increased when erythropoiesis is stimulated and in conditions of iron deficiency occurring 
during anemia, or when the iron demand is elevated as in the case of stimulated 
erythropoiesis. On the other hand, sTfR values are decreased when the iron levels are 
augumented, a condition that can be found during doping as athletes often accompany the 
rhEpo injections with iron supplementation in order to supply the newly formed RBC with 
adequate amounts of iron [20]. Of note, injections of rhEpo can have dangerous side effects 
as the formation of new RBC induced by Epo in the bone marrow renders the blood viscous, 
thus, resulting in a high risk of thrombosis. Indeed, the enhanced haematocrit (above 50%) 
and the blood viscosity can provoke heart failure, a fatal event that caused the suspicious 
death of some athletes during sleep when the heart rate is slower [21]. An increase of the 
haematocrit does not correlate linearly with improved endurance as shown by transgenic 
mice carrying additional copies of the Epo gene having 90% haematocrit but low aerobic 
performance [22]. What value of haematocrit gives then the maximal oxygen carrying 
capacity? Exercising wild-type mice administered with an ESA (acute model) and transgenic 
mice overexpressing Epo (chronic model) were shown to reach the highest maximal oxygen 
uptake at haematocrit levels of 58% and 68%, respectively [22]. Surprisingly and in 
agreement with this study, the Finnish cross-country skier Eero Mantyranta, winner of two 
gold medals at the 1964 Winter Olympic Game, was identified to carry a mutation in the Epo 
receptor (EpoR) gene that caused prolonged activation of EpoR and of erythropoiesis 
keeping low the plasma Epo levels. Mantyranta’s blood oxygen carrying capacity was 
increased by 25–50% and his haematocrit was of about 68%, close to the optimal value for 
improved sport performance as verified by in vivo studies [22, 23]. Such genetic mutation 
conferred him a great advantage, being considered as “natural doping” [18].  
Epo plays clearly an essential role in sustaining the adaptive process of the human body to 
conditions of reduced oxygen availability by enhancing the number of RBC when the oxygen 
supply is limited. However, it is important to keep in mind that Epo is not only a therapeutic 
agent, which saved the life of milions of anaemic patients, but also that an excessive use of 
recombinant Epo causes increased blood viscosity, eventually leading to heart failure and 
death. Therefore, it is necessary to keep the Epo levels within a specific range. The actual 
dose of rhEpo recommended in the therapy against anaemia varies between individual 
patients, depending on their specific clinical condition but remains in the range of 75 to 120 
IU/kg per week including iron supplementation to maintain haemoglobin (Hb) levels of 11 to 
13 g/dl [21].  
Although Epo therapy is very efficient, it remains still expensive as anaemic patients affected 
by kidney diseases need lifelong rhEpo injections. Therefore, the study of Epo regulation in 






into Epo dysregulation during renal pathologies. The knowledge of the genetic elements as 
well as the proteins contributing to modulate Epo expression will open the possibility in the 
near future to design new drug targets and develop a new Epo therapy based on smaller and 
cheaper molecules [21].  
1.2 Physiological role of Epo 
 
Epo is the master regulator of red blood cell homeostasis. By stimulating erythropoiesis, Epo 
maintains the balance between the ∼120 days old removed RBC and the newly produced 
RBC. In presence of reduced oxygen tension in the tissue (hypoxia), decreased content of 
haemoglobin or reduced number of RBC (anaemia), Epo production is stimulated in the adult 
kidney and the fetal liver whereas the adult liver contributes only about 15% to Epo 
production [24] [25]. Newly produced Epo is then secreted into the bloodstream, reaches the 
bone marrow where it binds its specific receptor (EpoR) and activates erythropoiesis, 









Figure 1. Epo regulates red blood cell formation upon tissue hypoxia or anaemia. 
1.2.1 Erythropoietic function 
 
The primary function of Epo is the regulation of erythropoiesis. Erythropoiesis occurs in the 
fetal liver during development and in the bone marrow at adulthood. Particularly, Epo must 
ensure that the RBC mass and the haemoglobin concentration remain constant day by day 
and that in case of haemorrhage, the recovery of the RBC count is fast [1]. The modus 
operandi of Epo consists in supporting the survival, proliferation and differentiation of 
erythroid progenitor cells in the bone marrow. The EpoR is located on the surface of the 






mature erythroblast. Erythropoiesis is a slow-acting process, where the amount of new 
erythroblasts becomes significant only after 3-4 days following an increase in plasma Epo [1]. 
The erythropoietic action of Epo can also be influenced by hormonal factors: erythropoiesis is 
further stimulated by androgens, increasing haemoglobin concentration and red blood cell 
counts in men, while in women erythropoiesis is less stimulated by oestrogens, leading to 
decreased values of haematocrit and haemoglobin concentration compared to men [1]. 
Interestingly, notwithstanding the sex differences in haematocrit and haemoglobin 
concentration, the plasma Epo levels between women and men remain similar, indicating 
that the lower Hct and Hb values of women belong to a physiological range [26]. As shown in 
Figure 2, erythropoiesis starts in the adult bone marrow from the pluripotent hematopoietic 
stem cells (HSC), which differentiate into immature erythroid progenitor burst-forming unit 
erythroid (BFU-E) cells that in turn differentiate into CFU erythroid (CFU-E) cells. Erythroid 
progenitors (BFU-E and CFU-E) are capable to form colonies of maturing erythroid cells in 
vitro. Morphologically, erythroid precursors are distinguished as proerythroblasts (Pro EB), 
basophilic erythroblasts (baso EB), polychromatophilic erythroblasts (Poly EB), and 
orthochromatic erythroblasts (Ortho EB). The maturation of CFU erythroid precursor to 
proerythroblast is Epo-dependent as shown by the presence of EpoR that sensitises the 
CFU-E cells to Epo. The differentiation into erythrocytes elicited by Epo causes three major 
effects: Epo acts as anti-apoptotic factor, thus promoting the erythroid progenitor survival; 
Epo stimulates cellular expansion and cell division by inducing RNA polymerase activity and 
DNA synthesis; Epo enhances the production of transferrin receptor, integral membrane 









Figure 2. Stimulation of erythropoiesis through Epo. From [27]. 
Downstream the proerythroblast stage the differentiation steps are independent from Epo. 
The erythrocyte maturation takes place within erythroblastic islands, composed of 






the ortho EB to form two cell populations: reticulocytes (RET), which are irregularly shaped 
cells containing haemoglobin and residual organelles (the reticulum) [28] and pyrenocytes 
(“extruded nuclei”) containing condensed nucleus surrounded by a lipid bilayer and thin rim 
of cytoplasm [29].  
The erythropoiesis process described so far, which takes place in the late stage of fetal life in 
the liver and in the postnatal bone marrow is called “definite erythropoiesis”, to distinguish it 
from the “primitive erythropoiesis”, occurring in the early embryonic developmental stage. In 
fact, the first blood cells of the mammalian embryos originate from “blood islands” of the yolk 
sac. Studies in mouse embryos highlighted the role of a unique erythroid progenitor termed 
Egypt-CFC emerging from the yolk sac at E7.25, peaking at E8.25 and undetectable at E9.0 
[30]. In vitro, Egypt-CFC like their definitive erythroid progenitors requires Epo for developing 
the colonies of maturing erythroid cells. The primitive erythroid cells undergo progressive 
morphological maturation similar to their definitive counterparts between E9.5 and E12.5: 
symmetric cell division, accumulation of haemoglobin, reduction of cell size, nuclear piknosis 
and decrease in RNA content.  
The switch in the expression between embryonic, fetal and adult globin genes depends on 
the activation of specific transcription factors which regulate the expression of adult globin 
genes but not embryonic globin gene [31]. Indeed, the transcription regulators Sox6 and 
Bcl11A have been found exclusively in definitive erythroid cells, where they suppress the 
expression of embryonic globin genes [32]. Importantly, by employing specific antibodies 
against embryonic mouse globin, it has been discovered that primitive mouse erythroblast 
cells lose their nuclei between E12.5-E16.5 of gestation [33], confuting the misconception 
that primitive erythroblast remain nucleated for the whole lifespan in the fetal circulation. 
Epo in primitive and definitive erythropoiesis 
The role of Epo in primitive erythropoiesis has been debated for a long time. While previously 
small amounts of Epo have been detected in the early mouse yolk sac [34], EpoR protein 
has been quantified on the surface of maturing primitive erythroblast in the fetal hamster [35] 
and EpoR transcripts were found in yolk sac blood islands between E7.5–E8.5 and in the 
yolk sac of E9.6–11.5 mouse embryos [36]. In contrast to previous in vivo studies [37], recent 
studies highlighted the involvement of EpoR signaling through primitive erythropoiesis as 
EpoR-null mouse embryos showed reduction of cell proliferation and increased apoptosis 
[34]. New findings elucidating the role of Epo in primitive erythropoiesis come from the study 
by Suzuki et al., who demonstrated that Epo is required for the maturation of the embryonic 
erythroid cells since Epo knock-out mouse embryos (Epo-KO) were moderately and severely 






with previous observations [37] [38]. Surprisingly, by dissecting these mouse embryos, the 
group of Yamamoto was able to detect Epo mRNA levels exclusively in the head region of 
E8.5 embryos appearing as the first Epo producing tissue during mouse embryogenesis as 
well as in the head and fetal liver of E9.5 and E10.5 embryos (Figure 3) [39]. Additionally, 
they reported that Epo production switches from the head region to fetal liver at E11.5 during 
mouse development. To define the specific cellular type able to produce Epo during 
embryonic mouse development, Suzuki et al. employed transgenic mouse lines carrying GFP 
reporter transgenes encompassing different length fragments within the 5’ upstream region 
of the Epo gene. They could show that cells of the neuronal tissue, a subpopulation of neural 
and neural crest cells, exhibited reporter green fluorescence indicating that they were 
capable to express Epo. Therefore, Epo appears to support erythropoiesis already during 
mouse development [39]. The importance of Epo as main regulator of definitive 
erythropoiesis has been proved through Epo or EpoR knock-out animal studies. Both Epo-/- 
and EpoR-/- mice were reported to have yolk sac erythropoiesis heavily decreased and 
impaired definitive erythropoiesis, which leads to embryonic lethality by E13-E15 due to 
severe anemia [37], demonstrating a crucial role for Epo and EpoR in erythropoiesis. 
Additionally, in fetal livers derived from Epo-/- and EpoR-/- mice both BFU-E and CFU-E 
progenitors were found, showing that the deficiency in erythropoiesis does not occur at 
erythroid progenitor stage and thus the major function of Epo is to trigger proliferation and 






Figure 3. Embryonic neuronal tissues transiently express Epo during mouse gestation. Left 
panel: Wild-type (left) and Epo-KO embryos (right) at the indicated stages (E10.5 and E11.5). Scale 
bars, 1.0 mm. Right panel: Transgenic mouse embryos at E8.5 (b,c), E9.5 (e) and E10.0 (g). GFP-
positive cells are observed in or around the neural folds (orange arrowheads) at E8.5; the fetal liver 
(dotted circle) at E9.5; in optic vesicle (orange arrow) and otic vesicle (orange E) at E9.5; in otic 
vesicle (orange E) and neural tube at E10.0 (orange NT). Scale bars, 0.5 mm (b,e) and 0.2 mm (c,g). 
Adapted from [39]. 
In fact, Epo prevents apoptosis of the CFU-E progenitors by acting as prosurvival signal 
upon EpoR binding at the CFU-E surface, as verified by in vitro experiments where in the 






Plasma Epo concentration  
Several transgenic mouse models overexpressing Epo were shown to be affected by 
erythrocytosis having increased number of RBC, hematocrit and haemoglobin levels [42] [43] 
[44]. These results highlight the aspect that erythropoiesis is dependent on Epo levels and, 
therefore, it is necessary to maintain Epo concentration in the physiological range to avoid 
either excessive erythropoiesis, leading to polycythemia, or heavily reduced erythropoiesis, 
causing anemia. How much Epo do we have in our body at physiological condition? Plasma 
Epo concentration varies between 6 and 10 mU/mL in healthy humans, independent of 
gender, with maximum peak at around midnight and minimum peak at around noon [45] [46]. 
However, the absolute concentration of Epo in the blood is not a sufficient parameter to verify 
whether Epo production in our body is adequate, but rather the Epo production in relation to 
the oxygen availability indicated by the haemoglobin concentration is a more reliable 
parameter to estimate the formation of Epo [21]. Indeed, an inverse semilogarithmic 
relationship between plasma Epo concentration and haemoglobin concentration or 
hematocrit exists (Figure 4), which has been discovered through studies in humans and 
mice, and is independent of the method employed to induce the reduction in haemoglobin 








Figure 4. Inverse semilogarithmic relationship between plasma Epo concentration and 
hematocrit in anaemic rat. From [47]. 
Upon hypoxic or anemic stimuli Epo plasma concentration can increase up to 1000-fold (10 
nmol/liter), depending on the degree of severity during anemia or inspiratory hypoxia [21]. 
However, human studies demonstrated that moderately raised levels of Epo such as 100 
pmol/liter are sufficient to trigger erythropoiesis; therefore, it remains unclear why the plasma 
Epo concentration is so highly increased in anemia or arterial hypoxia. Surprisingly, in case 






typical inverse relationship between Epo plasma concentration and hematocrit/haemoglobin 
is not anymore valid as it flattens, indicating that Epo production is inappropriately decreased 
in those patients and the reason why is still unknown [48] [49]. 
Stimuli for Epo production 
The stimulus for Epo production is not the decrease in arterial oxygen tension but the 
reduction of oxygen partial pressure in Epo-producing tissues, occurring when the Hb O2 
saturation is decreased (hypoxemia) or the oxygen-carrying capacity of the blood is reduced 
(anemic hypoxia). Hypoxemia can be caused by a decline in ambient tension of oxygen (e.g. 
high altitude), by pulmonary dysfunction (e.g. pulmonary edema, hypoventilation) or by heart 
disease (e.g. right to left shunt). Anemia can be caused by blood loss (e.g. hemorrhage), 
defective erythropoiesis or hemolysis due to infections like malaria, or as a consequence of a 
hemoglobinopathy, a disease characterized by red blood cells having scarce functional 
haemoglobin. Moreover, the oxygen affinity of haemoglobin plays a pivotal role in regulating 
the oxygen release to the tissues. In fact, when the oxygen affinity of haemoglobin is 
elevated, the O2 binding increases, the degree of O2 saturation raises, impairing the oxygen 
release to the tissues and elevating Epo levels. On the contrary, a reduced oxygen affinity of 








Figure 5. Plasma Epo kinetics during acute inspiratory hypoxia. Time course of plasma Epo 
concentrations in rats exposed to inspiratory hypoxia (60 mmHg) in a normobaric atmosphere. Epo 
levels start increasing after a delay (phase 1), then Epo levels increase linearly (phase 2) reaching a 
peak (phase 3) and declining (phase 4). Finally, Epo levels reach a steady-state level (phase 5). From 
[21]. 
The kinetics of Epo response to a decreased oxygen tension (Figure 5) has been deeply 
analyzed: following a drop of O2 tension in the alveoli, and consequently in arterial plasma, 
Epo levels begin to increase after 60 to 90 min from the onset of the hypoxic stimulus and 






reaches a peak between 12 and 24 h in rodents and within 48 h in humans [51]. After that, 
Epo diminishes to a steady-state level that is lower than the peak but higher than the 
baseline with Epo levels inversely related to the severity of the inspiratory hypoxia [21]. 
Interestingly, the decline of plasma Epo concentration is correlated with a decrease in Epo 
mRNA levels and takes place before the increase of RBCs. By Northern blot analysis, 
Eckardt et al. showed that the early reduction in Epo production is not caused by a negative 
feedback regulation through Epo itself but rather due to a decrease in renal Epo mRNA 
content, which the author assumed to be caused by reduced Epo mRNA stability [52]. 
Subsequent studies focused on Epo mRNA stability reported a 50-fold increase of Epo 
mRNA levels in response to hypoxia or CoCl2 by Northern blot analysis and an increase of 
Epo gene transcription of only 10-fold by nuclear run-off experiments, indicating that both the 
rate of gene transcription and post-translational events regulate Epo mRNA levels [53]. Later, 
Rondon et al. found that the erythropoietin mRNA-binding protein (ERBP) binds to 
pyrimidine-rich 120-bp region in the 3' UTR of Epo mRNA and that the ERBP complex 
formation was increased under hypoxia conditions [54]. A follow-up study from the same 
group demonstrated that Epo mRNA stability is enhanced due to the binding of ERBP to the 
3' UTR of Epo mRNA and confirmed that the increase of Epo mRNA stability in hypoxia is 
accompanied by an increase in ERBP complex synthesis [55].   
Finally, the Epo response to hypoxia is threshold-dependent: reduction of arterial pO2 to a 
certain threshold (about half of the normal arterial pO2 value) has only a small influence on 
circulating Epo levels whereas a further decrease of oxygen tension below this threshold 
induces an exponential increase of plasma Epo levels in humans and rodents [56] [52].  
1.2.2 Non-erythropoietic function of Epo 
 
Epo exerts non-hematopoietic effects beyond its classical erythropoietic function. In fact, Epo 
mRNA together with EpoR mRNA and/or EpoR protein expression have been reported in 
non-hematopoietic tissues (Figure 6), including megakaryocytes [57], endothelial cells [58] 
[59], brain [60], placenta [61], testis [62], vascular smooth muscle cells [63], and in several 
cancer tissues. Since the endogenous levels of Epo detected in all these organs/tissues are 
lower than in the kidney, it has been hypothesized that such small amounts of Epo act locally 
following paracrine/autocrine mechanisms. However, the physiological relevance of such 
observations is still a matter of debate. Sinclar and collegues, for example, were able to 
detect only very low levels of EpoR transcripts in extra-hematopoietic Epo-producing human 
endothelial, cardiac, neuronal and renal cells. As the authors could not detect the EpoR 
protein on the cellular surface, at that time they suggested the lack of specificity of previous 






reported failure of EpoR downstream signalling activation after in vitro administration of high 
doses of recombinant Epo in non-hematopoietic tissues [64] [65]. Endothelial cells from 
caesarean section-derived HUVECs are the first non-hematopoietic cell type to be reported 
to express EpoR, to bind Epo and to have functional Epo-EpoR axis, leading to a proliferative 
response, angiogenesis [66] and protection from apoptosis [67] [68]. Endothelial cells are 
known to express endothelial nitric oxide (NO) synthase (eNOS), which synthetize NO to 
regulate vascular tone and blood flow. In vitro studies performed under hypoxic conditions 
combined with recombinant Epo treatment showed increased EpoR mRNA and protein 
levels, activation of EpoR signalling pathway through enhanced AKT1 (Rac-alpha 
serine/threonine protein kinase) as well as stimulation of NO production, while in normoxic 
conditions no Epo mediated AKT1 activation was detected and only few transcripts of EpoR 












Figure 6. Non-erythropoietic effects of Epo. Epo is a cytoprotective agent acting in an 
autocrine/paracrine manner on several non-hematopoietic tissues, including the brain, the heart, blood 
vessels and the kidneys. From [70]. 
Interestingly, transgenic mice overexpressing Epo (tg6) and having high haematocrit did not 
develop hypertension as the increased levels of circulatory eNOS and NO ensured 
appropriate modulation of the vascular tone. In line with these in vitro experiments, 
recombinant Epo administration in rodents also stimulated NO production [71] [72] [73]. The 
increase in NO amounts might be considered as an acute response to facilitate the oxygen 






red blood cells upon hypoxia is completed [74]. It has been also shown that Epo can 
stimulate angiogenesis after tissue injury by acting synergistically with VEGF (Vascular 
Endothelial Growth Factor), promoting vascular integrity of the endothelial barrier [75]. The 
involvement of Epo/EpoR axis in angiogenesis has been also confirmed by EpoR-/- mice, 
which exhibited severe vascular defects as well as reduced complexity of the vessel network 
already at E10.5, 3 days before the embryonic lethality [76].  
The anti-apoptotic and proliferative effects of the Epo/EpoR signalling as well as the 
enhanced NO production have been observed also in brain [77] and in heart [78]. The heart 
is prone to be affected by hypoxia as in infarction and atherosclerosis. Of note, EpoR has 
been detected on cardiomyocytes and during development EpoR-/- mice exhibit ventricular 
hyperplasia due to inadequate cell proliferation and myocardium expansion [38]. In animal 
models of heart infarction and ischemia-reperfusion injury, Epo treatment reduced the 
cardiac damage showing a cardio protective effect [79] [80]. Fiordaliso et al. employed a 
carbomylated form of recombinant Epo with no erythropoietic effect that did not increase the 
haematocrit while protecting the myocardium [81]. The proposed mechanism behind the 
cardio protection assumes the opening of potassium channels and the activation of signalling 
pathways downstream EpoR such as JAK/STAT, P13K/akt, and p38 MAPK, that inhibit 
apoptosis, stimulating proliferation [82]. The involvement of EpoR has been proven through 
EpoR-/- mice rescued with an erythroid specific EpoR transgene that showed less STAT3 
phosphorylation due to lack of functional EpoR in cardiomyocytes. Furthermore, while the 
reduction of cardiac ischemia/reperfusion injury mediated by Epo treatment induces NO 
production by increased eNOS activity in cardiomyocytes [83], EpoR expression restricted to 
hematopoietic and endothelial cells showed a similar increase in eNOS activity in coronary 
artery endothelium and myocardial ischemia protection as in wild-type animals [78], 
indicating that the endothelial cell response to Epo is sufficient to trigger an acute cardio 
protection.    
As mentioned above, EpoR expression has been also found in cancer tissues, suggesting 
the possibility to treat anaemia associated with chemotherapy with recombinant Epo, 
promoting the increase of haemoglobin and haematocrit. On the other hand, several clinical 
studies reported increased thrombosis [84] and high risk of tumour growth via the activation 
of Epo/EpoR signalling causing stimulation of cancer cell proliferation in addition to enhanced 
tumour oxygenation due to the erythropoietic effect of Epo treatment [85] [86] [87].     
Recently, the existence of two different pathways responsible for the erythropoietic and non-
erythropoietic functions of Epo has been proposed since a new potential isoform of EpoR 






EpoR in bone marrow, inducing its homodimerization to activate proliferation and 
differentiation to mature red blood cells, locally paracrine and autocrine Epo produced in 
healthy tissue that surrounds the tissue damage, binds in the nanomolar range an isoform of 
low-affinity EpoR, which heterodimerizes and activates anti-apoptotic and pro-survival 
signalling cascades with cytoprotective effects that protect the tissue from further injury [88] 
[89].  
Surely, the discovery of non-erythropoietic effects of Epo opens an interesting area of 
research as well as the possibility of new therapies based on modified and non-erythropoietic 
versions of recombinant Epo (e.g. carbomylated Epo) which avoid potential erythropoietic 
side-effects but support the protection of the non-erythropoietic tissue during ischemia-
reperfusion, trauma, cytotoxicity or inflammation [90]. In this regard, Brines et al. 
demonstrated that rhEpo can reach the central nervous system (CNS) and accumulate in the 
cerebrospinal fluid (CSF) in a time and dose dependent-manner, opening the possibility to 
apply intravenous administration of rhEpo to patients affected by brain disorders. In contrast 
to previous studies, claiming that Epo could not cross the blood brain barrier (BBB) due to its 
impermeability to highly glycosylated molecules, the authors suggested that Epo could cross 
the BBB by transcytosis upon binding of EpoR molecules,which were found to be localised 
around brain capillaries within astrocytic endfeet and on the luminal side of capillary 
endothelial cells. Since the cerebral ischemia is associated with an opening of the BBB, the 
intravenous application of Epo could be a promising treatment of brain disorders [91]. 
1.3. Structure of Epo and Epo Receptor   
 
Structure of erythropoietin 
Erythropoietin is a glycoprotein hormone of 165 amino acids, synthesized as a precursor 
protein containing a signal peptide (residue 1-27), removed, during protein maturation. The 
structural architecture of Epo consists in an up-up-down-down four-α-helical bundle topology 
(Figure 7) αA (residue 8-26); αB (residue 55-83); αC (residue 90-112); αD (residue 138-161)) 
with two mini-α-helices located between the carboxy-terminus of the AB loop and the helix C 
as well as two short antiparallel β-strands in positions 39-41 and 133-135, respectively. The 
whole structure is stabilized by two disulphide bridges between Cys7 and Cys161, 
connecting the long antiparallel helices αA and αD, whereas the other antiparallel helices αB 
and αC are connected by a short loop. The long AB loop is required for the interaction 
between Epo and EpoR and it is linked to the αA through the second disulphide bond, 
Cys29- Cys33. The hydrophobic core of Epo is composed by non-polar amino acids of the 






Phe148, Leu153, and Tyr156 located at the internal surface of the αD helix [92] [93]. 
Erythropoietin is highly glycosylated as the carbohydrate portion amounts to more than 40% 
of the total molecular weight of 30.400 Da. The protein backbone comprises three N-
glycosylation sites (Asn24, Asn38, and Asn83) and a single O-glycosylation site (Ser126). 
While the N-glycosylation sites are conserved in Chordata from fish to primates, suggesting a 
functional relevance of such post-translational modifications, the functional importance of the 
O-glycosylation site (Ser126) remains unknown [94]. In line with these observations, it has 
been reported that the therapeutic activity of Epo depends on the three aforementioned N-
glycans as without them Epo has a very short-life, from 5 to 6 hours (average of endogenous 
human Epo half-life) [56] to few minutes, as well as almost complete loss of its functionality in 









Figure 7. Three-dimensional structure of the human Epo molecule. 3-D structure of human 
erythropoietin obtained by nuclear magnetic resonance spectroscopy. Structural data were taken from 
the Protein Data Bank (http://www.rcsb.org/structure/1BUY; PDB ID: 1BUY; [97]) and displayed using 
the NGL Viewer [94].  
Interestingly, Erbayraktar and colleagues demonstrated that a modified version of Epo 
molecule “asialoerythropoietin”, lacking completely the erythropoietic function, shows strong 
neuroprotection [98]. Overall, it appears evident that the carbohydrate structures have a 
pivotal role for the biological activity of erythropoietin. In fact, they are crucial for the binding 
of Epo with its receptor and the subsequent activation of the signalling cascade downstream 
[21]. The glycosylation of Epo is also important to maintain its survival while it circulates into 
the bloodstream as shown by increased clearance of deglycosylated Epo in liver in vivo [21].  
The amino acid sequence of Epo exhibits high degree of interspecies similarity in mammals 
and the protein structure is highly conserved. Human Epo is 91% identical to monkey Epo, 






conservation of the disulphide bridge linking Cys7 and Cys161 (NH2 and COOH termini) and 
of the N-glycosylation sites has been reported [99].  
Although it has not been yet clarified whether Epo exists in lower organisms, the presence of 
Epo genes has been identified in teleost fishes such as fugu, zebra fish and trout [100] as 
well as in the amphibious Xenopous laevis [101].     
Structure of Epo Receptor, EpoR 
EpoR is encoded by a single copy gene with highly conserved sequence, encompassing 
eight exons. The erythroid Epo Receptor is a single-pass plasma membrane glycoprotein of 
484 amino acids with a molecular weight between 72 and 78 kDa, which is mainly expressed 
as homodimer on the cellular surface of the erythroid progenitor CFU-E. The Epo-R belongs 
to the type I cytokine receptor superfamily and shares structural motifs with members of this 
receptor family, including two extracellular fibronectin type III-like domains, four similarly 
spaced cysteine residues forming two disulphide bonds in the extracellular region and a 
conserved Trp-Ser-X-Ser-Trp (WSXWS) motif in proximity to the transmembrane domain 
[102]. In addition to the extracellular region, EpoR contains a transmembrane segment as 
well as a cytosolic domain with no enzymatic functionality associated with the Janus tyrosine 
kinase 2 (JAK2) (Figure 8A). The activation of the EpoR signalling cascade takes place upon 
ligand binding, which induces dimerization and reorientation of EpoR monomers, bringing the 
two pre-associated JAK2 proteins close to each other and stimulating transactivation of JAK2 
by phosphorylation [103]. As shown in Figure 8B, EpoR is a dimeric receptor, bound by a 
single Epo molecule in a 2:1 EpoR:Epo ratio [103].  







Figure 8. Structure of the human Epo receptor, EpoR. A) The EpoR comprises an extracellular 
region with circa 230 amino acids folding into two fibronectin III-like domains containing the WSXWS 
motif close to the membrane-spanning segment; one transmembrane segment and a cytosolic domain 
of ̴ 230 amino acids with no enzymatic activity. The cytosolic proximal region is associated with the 
Janus tyrosine kinase 2 (JAK2) (red boxes). From https://kidneynccr.bio-med.ch. B) 3-D structure of 






were taken from the Protein Data Bank (http://www.rcsb.org/structure/1EER PDB ID: 1EER; [103]) and 
displayed using the NGL Viewer [104].   
Interestingly, EpoR dimer forms already during protein translation of the receptor and is then 
transported to the plasma membrane where it binds its ligand [105]. The EpoR-Epo complex 
revealed the existence of two Epo binding sites within EpoR: one high affinity binding site 
with a dissociation constant of approximately 1 nM, including a motif with a hydrophobic core 
surrounded by hydrophilic amino acids and a second binding site which interacts with Epo 
using a different set of residues, having a dissociation constant of 1 μM [106]. Taking into 
consideration both the high and the low affinity interactions between EpoR and its ligand, a 
sequential binding model for Epo-mediated activation of EpoR has been proposed, in which 
Epo binds first the high affinity site of one receptor chain and then the second lower affinity 
site within the second receptor chain [107]. The importance of receptor dimerization has 
been validated by mutating either Epo molecule in R103A or EpoR in the binding regions for 
Epo, resulting in the impairment of EpoR signalling cascade activation in hematopoietic cells 
[107] [108].  
1.4 Epo Receptor signalling  
 
As mentioned above, the signal transduction mediated by EpoR is initiated by ligand binding. 
Once Epo is bound, a conformational change with re-organization of EpoR monomers 
occurs, leading to transphosphorylation of the two cytosolic receptor associated Janus 
tyrosine kinase 2 (JAK2) proteins. As depicted in Figure 8A, JAK2 proteins are constitutively 
bound to the intracellular domains of EpoR and function as chaperone, assisting the transit of 
EpoR from the endoplasmic reticulum to the plasma membrane [109]. Notably, Jak2-/- 
animals die during embryogenesis at E12-E13 due to severe anaemia, similarly to Epo-/- and 
EpoR-/- mice, suggesting a pivotal role for JAK2 in Epo-dependent definitive erythropoiesis 
[110]. Phosphorylated and activated JAK2 kinases are able to phosphorylate tyrosine 
residues located in the membrane-distal portion of the cytoplasmic region of EpoR, which 
serve as docking sites for intracellular signalling molecules containing SRC homology 2 
(SH2) domains such as STAT5, phosphatidyl-inositol 3-kinase (PI-3K) and the SH2 adaptor 
protein C (SHC) (Figure 9). As soon as these proteins are bound to EpoR, they become 
activated through phosphorylation and activate different signalling pathways, which include 
the signal transducer and activator of transcription (STAT) pathway, the phosphatidylinositol 
3'-kinase/protein kinase B (PI-3K/PKB) pathway and the MAPK (mitogen-activated protein 
kinases)  pathway [111]. 
As represented by Figure 9, in erythroid cells phosphorylated STAT5 dissociate from EpoR, 






TTN5AA in the promoter of target genes [112] [113], activating the transcription of genes 
involved in survival, proliferation and differentiation of erythroid precursors, such as Bcl-xL. 
Bcl-xL is an anti-apoptotic protein, reported to inhibit apoptosis by modulating the activation 
of caspase proteases as well as by avoiding the release of cytochrome C from mitochondria 
through a mechanism that remains still unknown [114] [115]. The PI-3K/PKB pathway 
involves activation of the phosphatidylinositol 3'-kinase (PI-3K) and conversion of its catalytic 
domain of phosphatidylinositol (3,4)-bisphosphate (PIP2) lipids to phosphatidylinositol 
(3,4,5)-trisphosphate (PIP3) (Figure 9). Then, protein kinase B (PKB/Akt) binds PIP3 at the 
plasma membrane, becomes activated and translocates to the nucleus where it activates the 
transcription of pro-survival genes. Furthermore, the MAPK pathway comprises the binding 
of the adaptor protein SHC and growth factor receptor-bound protein 2 (GRB2) at 
phosphorylated tyrosine docking sites of EpoR (Figure 9), leading to the activation of 
RAS/RAF, MEK as well as the extracellular-regulated kinases 1/2 (ERK1/2), that in turn 
activate the transcription factor AP1 (activator protein 1) that regulates cellular differentiation, 










Figure 9. Scheme of Epo receptor signalling. From [116]. 
EpoR signalling can be inhibited by the cytokine-inducible SH2 protein 3 (CIS3), named also 
suppressor of cytokine signalling (SOC-3), which is able to bind to phosphorylated EpoR and 
JAK2 [117]. Finally, the effect of Epo is completed by dephosphorylation of EpoR, executed 
by the tyrosine phosphatase SHP-1 (Src homology phosphatase-1), followed by 
internalization of Epo-EpoR complex, which is considered a major mechanism to degrade 






the duration of EpoR signalling by degrading the Epo receptor molecules [118]. Interestingly, 
while mutations of the extracellular domain of EpoR activate constitutively the receptor due to 
the formation of an intermolecular disulphide bond, the deletion of an inhibitory signalling 
element within the carboxy-terminal end of EpoR increases Epo affinity and is associated 
with erythrocytosis [119].       
1.5 Sites of Epo production and Epo-producing cells 
 
In mammals, the main Epo-producing organs are the fetal liver and the adult kidney. In fact, 
organ ablation studies demonstrated that, while the liver is the main site of Epo production 
during fetal life, the kidney becomes the predominant source of Epo from birth on until 
adulthood [120].  
Liver  
 
In the fetus, the liver is a suitable organ for Epo production as its structure matches the 
functional aspects of the fetal circulation. Oxygenated blood coming from the maternal side 
of the placenta to the fetus needs to pass through the ductus venous, bypassing the liver and 
flowing directly to the heart. This results in a condition of relative hypoxia of the hepatic 
tissue, which is thought to be responsible in stimulating Epo production in the fetal liver, that, 
however, remains significantly lower compared to adult mammals [25]. Moreover, the 
mammalian fetal arterial blood pO2 is much lower than that of maternal blood, leading to local 
hypoxia sensed by hepatic oxygen receptors which increase Epo levels in the serum and 
amniotic fluid, as measured in sheep and rat fetus [121] [122]. Although evidence are 
missing, the local hepatic hypoxia together with the placenta aging process have been 
proposed to trigger the activation of the renal oxygen sensors and the switch of Epo 
production in the kidney [25]. The induction of hepatic Epo is ensured by the presence of 
local oxygen tension gradients as demonstrated by in situ hybridization studies where Epo 
mRNA has been found preferentially in pericentral areas of the hepatic lobules, which have 
lower pO2 than periportal areas [123]. The discovery of the fetal liver as primary site of Epo 
production was crucial for the progress of the Epo research field as allowed the cloning of 
human Epo by preparing Epo cDNA from human fetal liver [10]. Intriguingly, experiments in 
anephric animals revealed that the adult liver can also contribute to Epo production to an 
extent of about 5-15%, depending on the severity of the hypoxic stimulus [25]. Generally, the 
hepatocytes are less sensitive to hypoxia-induced Epo production than the REP cells and 
this might explain why the adult liver does not compensate for the production of Epo when 






In anaemic rat livers, in situ hybridization studies showed Epo mRNA signal predominantly in 
hepatocytes and, rarely, in interstitial nonparenchymal liver cells [124]. Furthermore, in 
anaemic transgenic mice carrying the human Epo gene, human Epo mRNA was also 
detected mainly in hepatocytes and to a lower extent in interstitial liver cells [123]. Additional 
studies using freshly isolated cells from hypoxic rat livers confirmed the localization of Epo 
mRNA in hepatocytes as well as showed that Epo mRNA expression from normoxic isolated 
hepatocytes is stimulated upon hypoxia in vitro [125]. Overall, these experimental 
approaches demonstrated that two different cellular populations, the hepatocytes and non-
parenchymal cells express Epo and stimulate Epo synthesis upon hypoxia. The non-
parenchymal cell population has been further analysed by Maxwell and collegues using 
anaemic transgenic Epo-reporter mouse carrying the marker SV40 large T antigen inserted 
into the 5’ untranslated region of the Epo gene by homologous recombination into the native 
Epo locus [126]. By immunolabeling and immunoelectron microscopy, the author could 
characterize the non-parenchymal cells as Ito cells, hepatic stellate cells also known as 
lipocytes. These cells have many common features with renal interstitial Epo-producing cells 
(see below) besides expressing Epo. First, they both are located between the capillaries and 
the parenchymal cells showing a dense network of processes. Then, they both proliferate 
and differentiate to myofibroblasts in response to injury and express the surface enzyme 
ecto-5'-nucleotidase, a fibroblast marker whose synthesis is enhanced in hypoxia [127] [128]. 
Although cultured Ito cells might provide a suitable model to study the hepatic regulation of 
erythropoietin in hypoxia, no cell culture lines have been derived so far, neither from hepatic 
Ito cells nor renal fibroblasts. [126]. In contrast, in 1987 Golberg and colleagues were 
successful in developing liver-derived cellular models capable to maintain Epo production 
under culture conditions. These cells, called Hep3B and HepG2, have been generated from 
human hepatic carcinoma and are able to express Epo mRNA in an oxygen-dependent 
manner. Since their discovery they became the most widely used in vitro models to study 
Epo regulation [129]. Finally, due to the lack of the feedback regulation of renal erythropoietin 
during chronic hypoxia (unpublished results from our lab) and their hepatic nature, HepG2 
and Hep3B cannot represent an appropriate model to study Epo regulation in the kidney. 
In mice, Epo mRNA expression has been detected in the kidneys already from mid-gestation 
on, whereas in rats renal Epo transcripts increased after birth and hepatic Epo transcripts 
dramatically decreased in adulthood [130]. In humans, the liver contributes to Epo production 
not only in fetal, but also in neonatal life and the switch from fetal liver to adult kidney occurs 
several months after birth [131]. Since the switch from fetal liver to adult kidney occurs in a 
species-specific manner, it is unlikely that changes in oxygenation happening during birth 






fetal liver to adult kidneys? An important aspect to take into consideration is that kidney 
maturation in many species is not yet complete at birth. Indeed, only when the formation of 
the organ is reached, the kidney acquires either its functions of excretion and reabsorption or 
hormone (Epo) production. The latter depends on the kidney oxygen-sensing capacity, which 
is gained as soon as the structure of the organ is fully mature and completely functional [21].  
Kidney 
 
As mentioned before, the kidney is the major Epo-producing organ in adulthood. The reason 
behind can be found in the observation that the kidney is the main oxygen-sensing organ in 
the body, in addition to aortic and carotid bodies. Both the aortic and carotid bodies, which 
are located on the aortic arch and on the carotid artery, respectively, are characterized by the 
presence of peripheral chemoreceptors, which are able to detect changes in partial pressure 
of oxygen and changes in partial pressure of carbon dioxide and pH in arterial blood. A 
decrease in arterial pO2 is immediately sensed by the chemoreceptors that transmit this 
information to the respiration control centre of the brain stem which triggers an increase in 
alveolar ventilation to counteract the low oxygen partial pressure. Interestingly, while the 
aortic and carotid chemoreceptors are located in a highly perfused tissue, which allows them 
to sense only changes in partial pressure of oxygen, the kidney is able to detect changes in 
actual oxygen content of the blood due to its specific organ structure [132] [133]. Moreover, 
ablation of the arterial chemoreceptors has no significant effect on Epo production in 
response to hypoxia, suggesting that the regulation of Epo is independent of chemosensors 
while affected by local oxygen sensing in kidney [134]. The primary functions of the kidney 
are blood filtering, water and nutrient reabsorption, electrolyte excretion as well as urine 
production and excretion. The kidney is able to execute these complex functions due to its 
highly organized anatomical structure and vasculature. The kidney can be divided in three 
different regions, which are, from outside to inside, the cortex, the medulla and the renal 
sinus. Cortex and medulla form together the renal parenchyma that includes millions of 
nephrons, whereas the renal sinus is the cavity below the renal parenchyma that is 
connected to the outside environment through the hilum. The nephron is the functional unit of 
the kidney which works as an independent unit producing a small amount of urine. The 
nephron is composed by a filtering component, namely renal corpuscle, and a tube, known 
as renal tubule, specialized for reabsorption and secretion, which drains from the renal 
corpuscle into the collecting duct. Of note, the peculiar architecture of the renal vasculature 
might explain why the kidney is the ideal organ for local oxygen sensing as well as for the 
regulation of Epo production. Blood is supplied to each kidney by one renal artery coming 






vein leaves the kidney to connect to the inferior vena cava. The renal artery branches in 
anterior and posterior vessels that run in front or behind the renal pelvis. Within the renal 
sinus, the arteries divide into interlobar arteries, which enter the renal parenchyma near renal 
papillae and ascend the medullary pyramids, forming the arcuate arteries that run parallel to 
the renal capsule giving rise to arches over the medullary pyramids. Arcuate arteries 
branches into interlobular arteries within the medullary rays, which divide into afferent 
arterioles that enter the glomerulus and constitute the glomerular capillary network. Blood 
leaves the glomerulus through efferent arterioles, which separate into peritubular capillaries 
or descending vasa recta (straight vessels), depending on whether they associate with 
superficial/midcortical nephrons or juxtamedullary nephrons within the medulla. While the 
peritubular capillaries supply blood to the cortex, the vasa recta travel parallel to the renal 
tubule within the medulla and, like the tubule, turn back at different depths towards the 
corticomedullary junction in the medulla (Figure 10). Venous blood is returned through 
interlobular veins in the cortex, through arcuate veins in the mid-cortex region and through 
ascending vasa recta that fuse to arcuate veins [132]. Interestingly, several studies showed 
that a large oxygen gradient resides along the renal cortico-medullary axis. Such oxygen 
gradient results from blood flow inhomogeneity between cortex and medulla as well as from 








Figure 10. Renal peritubular vascular anatomy. From [137]. 
While the renal cortex is supplied by 90% of renal blood flow, only 20% of renal blood flow 
reaches the medulla [138] due to the unique and heterogenous renal vasculature. In addition, 
descending vasa recta (arterial straight vessels) and ascending vasa recta (venous straight 
vessels) run in a countercurrent manner, allowing shunt diffusion of oxygen between the 
arterial and venous vessels, which reduces the tissue pO2. As a consequence, tissue pO2 






medulla and down to about 10 mmHg near the papillary tip [139]. Intriguingly, the very steep 
gradient of oxygen tension (40 to 70 mmHg; up to 42 mm Hg per 10 μm) occurring in the 
renal cortex might explain the oxygen sensitivity of the renal Epo producing cells as well as 
their particular distribution. Importantly, such renal oxygen gradient is unaffected by changes 
in organ perfusion as the more blood flow, the more sodium reabsorption through the tubular 
system, the more oxygen consumption in renal proximal tubule cells but also the more 
oxygen supply reaches the kidney. Therefore, the ratio between renal blood flow (oxygen 
supply) and oxygen consumption is kept constant, rendering the kidney the ideal organ to 
sense small changes in local tissue pO2 resulting from changes in blood oxygen content 
rather than blood flow. In fact, the oxygenation of the EPO-producing cells depends mainly 
on the oxygen carrying capacity of the blood. Moreover, the presence of proximal tubular 
cells having high oxygen consumption in close proximity to the Epo-producing cells ensures 
that the pericellular oxygen tension is determined by haemoglobin unloading and not by 
variations in arterial blood pO2 due to possible lung function alterations. In this regard, it has 
been reported that inhibition of sodium reabsorption of proximal tubules decreases hypoxia-
induced Epo production, highlighting the strategical location of the Epo-producing cells in the 
vicinity of the proximal tubule cells [140]. Similarly to the oxygen-sensitive cells of the carotid 
body, which detect changes in oxygen tension in arterial blood and modulate accordingly the 
respiration, the renal Epo-producing cells sense changes in local tissue oxygen tensions and 
stimulate Epo production as shown by studies in isolated perfused kidneys, where Epo 
mRNA expression in the perfusate was increased in response to changes in oxygen tension 
[141] [142].   
Renal Epo-producing (REP) cells 
 
Attempts to identify and localize the REP cells have been particularly challenging due to the 
fact that, in contrast to other hormones, Epo is not stored in the cells producing it. While 
immunoistochemical approaches generated ambiguous results, in situ hybridization revealed 
to be a more reliable method to study the renal Epo-producing cells [21].  Epo mRNA has 
been localized to peritubular cells in the renal cortex by in situ hybridization. The renal Epo-
producing cells are peritubular, interstitial, fibroblast-like cells located along the 
corticomedullary oxygen gradient at the border between cortex and medulla (juxtamedullary 
cortex), which appears to be the perfect location to sense small variations in local oxygen 
tension due to presence of local oxygen gradients [143] [144] [145]. In fact, oxygenation of 
REP cells depends on the O2 diffusion driven by pO2. During inspiratory hypoxia or anaemia, 
pO2 falls, thus, less oxygen diffuses to the juxtamedullary cortex leading to the increase of 














Figure 11. Schematic representation of the renal tubular system and the countercurrent oxygen 
exchange, forming the cortico-medullary oxygen gradient (blue to white background). In 
hypoxia, the oxygen gradient is shifted to the outer cortex and the number of REP cells at the border 
between medulla and cortex increases. From [133].  
The first study demonstrating that REP cells are peritubular interstitial fibroblasts, localized 
mainly in the cortex and the outer medulla was performed by Maxwell and collegues in 1993. 
They generated a genetically modified mouse, in which the SV40 large T antigen was under 
the regulatory control of the Epo gene locus, allowing the identification of REP cells by 
immunohistochemistry using anti-T antigen antibodies. In response to hypoxia or anaemia, 
the expression of Epo/SV40 large T antigen was induced and the accumulation of SV40 
large T antigen was detected in nuclei of cortical peritubular interstitial fibroblasts, expressing 
the fibroblast marker 5’-ectonucleotidase (CD73), but not in other types of peritubular cells 
[146]. This elegant work proved that renal fibroblasts are the most promising candidates of 
renal Epo-producing cells among the other proposed cell types including tubular epithelial 
cells, glomerular mesangial cells and interstitial fibroblasts [147]. Successively, the 
Yamamoto group was able to unequivocally localize the REP cells and confirm the previous 
in vivo findings of Maxwell et al., by two complementary approaches, the BAC transgenic 
mice and the green fluorescent protein (GFP) reporter knock-in mice. The BAC transgenic 
mice (Tg-EpoGFP) carry a transgenic construct in which GFP expression is directly 
controlled by the 180 kb regulatory region of the mouse Epo locus by replacing the region 
spanning exon II to intron IV of the Epo gene, were sufficient to recapitulate kidney and liver 
specific Epo expression and allowed the labelling of Epo-producing cells by GFP expression. 
On the other hand, the GFP knock-in mice (KI-EpoGFP) ensured more specific targeting of 
the REP cells as GFP cDNA was knocked-in the endogenous Epo gene leading to GFP 
expression controlled by endogenous Epo regulation. Both strategies were able to detect 






of GFP-positive interstitial cells significantly increased, showing appropriate oxygen-
dependent regulation. Moreover, these GFP-positive cells, located in the renal interstitium 
and induced upon hypoxic or anaemic stress, are fibroblast-like cells expressing the 
fibroblast markers CD73 and platelet-derived growth factor receptor β (PDGFR-β). These 
cells have dendrite-like processes and express also neural genes like microtubule-
associated protein 2 (MAP2), nerve growth factor receptor (NGFR) and neurofilament light 
peptide (NFL). In contrast, REP cells showed no staining for blood vessel (platelet 
endothelial cell adhesion molecule 1, PECAM or cluster of differentiation 31, CD31) or 







Figure 12. Localization and characterization of Epo-producing cells in renal interstitium from 
Epo-GFP transgenic mice. GFP expression (brown) was detected in the peritubular interstitial cells 
(arrows in D) with long projections (arrowheads in D) between the proximal tubules (PT) and vessels 
(V). REP cells (green) from anemic kidneys of transgenic mice costained with cell lineage markers 
(red) were negative for CD31 (F) and Mac1 (G), but positive for MAP2 (H) and NFL (I). From [149].   
As mentioned before (Figure 3), Suzuki et al. observed Epo production in neural and neural 
crest cells of E8.5–E11.5 embryos, supporting the hypothesis of neuronal origin of REP cells 
as already suspected by a previous work of Asada and collegues, who discovered that most 
of interstitial fibroblasts in the kidney derived from myelin protein 0 (P0)-positive neural crest 
cells and that less than 20% of P0 lineage-derived cortical fibroblast co-express Epo, CD73 
and PDGFR-β in Tg-EpoGFP mice [39] [150]. Interestingly, the number of GFP-positive cells 
in Tg-EpoGFP or KI-EpoGFP are considerably lower than those of Inherited Super-Anemic 
Mice (ISAM), which are transgene-rescued mice carrying a 8-kb transgene containing the 
liver but not kidney Epo regulatory elements, sufficient to rescue the embryonic lethality of 
Epo null mice (EpoGFP/GFP). ISAM mice show Epo production restricted to the liver and 
develop adult onset severe chronic anaemia caused by defects in renal Epo synthesis, 
whereas Epo-producing cells in ISAM kidneys are well labelled by GFP expression under the 
regulation of Epo gene locus [151] [147]. While the above mentioned Tg-EpoGFP and KI-






express Epo, demonstrating that the EpoGFP-expressing cells consist in a small fraction of 
the total REP cells, they were not able to track the fate of the Epo-producing cells over time 
as the GFP expression is limited to the timeframe of active Epo production. Therefore, to 
identify the total population of REP cells, the Yamamoto group crossed the tdTomato 
reporter mouse line (R26RtdTomato) to new transgenic mice, in which the Cre-recombinase 
was expressed under the control of the 180 kb regulatory region of the mouse Epo locus (Tg-
EpoCre). This mouse model (R26RtdTomato:TgEpoCre) allowed for the detection of Epo-Cre 
positive cells through the expression of red fluorescence in cells that expressed Cre and thus 
Epo at least once in their life [152] [153]. When R26RtdTomato:TgEpoCre mice were 
crossed to ISAM animals leading to the generation of ISAM-REC, the EpoCre transgene was 
induced by chronic severe anaemia typical of the ISAM mice and tdTomato fluorescence was 
detected in almost all fibroblast-like interstitial cells expressing both PDGFRβ and CD73 in 
cortex and outer medulla, representing all the cells capable to produce Epo (total REPCs), 










Figure 13. Renal Epo-producing (REP) cells are peri-capillary fibroblast-like CD73-positive 
cells. ON-REPs expressing EpoGFP (green) and CD73 (white) within the total REP population 
expresses tdTomato (red) from a kidney section of ISAM-REC. The fibroblast-like REP cells are 
distributed in peri-capillary but not in peri-arterial interstitial spaces of the kidneys. Nuclei are stained 
with DAPI (Merge). Abbreviations: A, artery; V, vein. Scale bar 100 μm. From [147]. 
Intriguingly, Yamazaki et al. observed that REP cells distribute around the peritubular 
capillaries but not around the larger vessels and calculated that approximately 10% of 
tdTomato positive cells express active Epo, thus being in a resting phase from Epo 






Remarkably, a recent work from the Haase group found that REP cells of the adult mouse 
kidney were derived from FoxD1-expressing stromal cells, which surround the cap 
mesenchyme during kidney development, giving rise to cortical and medullary renal 
interstitial fibroblast, pericytes, mesangial cells and vascular smooth muscle cells. 
Furthermore, the authors suggested that the renal Epo-producing cells, derived from FOXD1-
expressing stromal progenitors were heterogeneous in response to stimuli of Epo production 
[154]. 
Several efforts have been made to isolate REP cells from mouse kidneys in order to obtain 
an in vitro kidney-derived cell culture model for oxygen-regulated Epo expression. None of 
these attempts was able to provide a reliable kidney-derived cell line with hypoxic Epo 
regulation as renal interstitial fibroblasts tend to lose the capability to produce Epo in vivo 
and when induced to proliferate in vitro as the Epo locus is only transiently activated by 
oxygen-dependent stimuli.  
Brain 
 
Epo and EpoR are expressed in the CNS already during human fetal development between 
7 and 16 weeks after gestation, with increasing levels from 8 to 24 weeks [155]. Epo and 
EpoR mRNA have been detected in the brain of mice [60], monkeys and humans [156]. In 
human brain, the expression of Epo has been localized to the temporal cortex, hippocampus 
and amygdala [157] as well as to the CSF of human adults [158] and neonates [159]. The 
main cellular sources of brain-derived Epo are astrocytes [156] and neurons [160], whereas it 
remains unclear whether brain endothelial cells are capable to produce Epo [157]. EpoR 
mRNA has been found in a broad variety of cerebral cells, including neurons and astrocytes 
[160], endothelial cells [59] [161] as well as microglial cells [162]. The endogenous Epo 
production in brain, astrocytes and neurons occurs locally, suggesting that Epo may act 
outside the bone marrow in a paracrine or autocrine manner in response to hypoxia [156]. 
Importantly, Epo has been shown to cross the BBB despite its low permeability thus 
representing a new frontier in the treatment of brain disorders [163] [164].  
While the kidney produces Epo only temporarily during hypoxia, neuronal Epo expression is 
upregulated upon a hypoxic stimulus and the increase in Epo levels in the brain is continuous 
[165]. Hypoxic Epo transcripts increase between 3- and 20-fold in the brain compared to the 
200-fold induction in the kidney. Therefore, the hypoxic stimulation of the EPO gene in the 
brain seems to be similar to the kidney even though the Epo mRNA levels in the brain are 
lower [157]. Intriguingly, primary mouse astrocytes showed 100-fold Epo mRNA levels in 






Epo gene in hypoxia [166]. Additionally, hippocampal neurons in vitro showed hypoxia-
mediated upregulated EpoR mRNA levels [167]. On the other hand, proinflammatory 
cytokines (IL-1β, IL-6, or TNF-α) decreased both Epo and EpoR expression in astrocytes, 
whereas human neurons cultured in presence of TNF-α showed increased expression of 
EpoR [162]. Anaemia and ischemic conditions were both reported to enhance EpoR 
expression in vivo by rendering the neuronal cells more sensitive to Epo response [89]. 
Notably, neuronal Epo and EpoR proteins have a smaller molecular weight than their 
counterparts in the periphery as they possess different amount of sialic acid [168] [169]. 
Epo has been suggested to have a physiological role in the brain as Epo and EpoR are 
highly expressed in the embryonic brain [170]. Epo-/- and EpoR-/- mice, which die in utero due 
to the lack of definitive erythropoiesis and severe anaemia, have been reported to exhibit a 
thinning of the neuroepithelium and smaller brain size with incomplete closure of the neural 
tube at E10.5 as well as increased apoptosis of neuronal cells, harvested from EpoR null 
mice at E10.5 that did not show yet a significant anaemic phenotype, indicating a role of 
erythropoietin in brain development [171]. The physiological effect of Epo in the brain has 
been evaluated in neurons both, in vitro and in vivo. Several studies suggested that brain-
derived Epo is a physiological neurotrophic factor before, during or after neuronal injury 
[172]. The first evidence for Epo-mediated neuroprotection was provided by the in vivo work 
of Sakanaka et al. who demonstrated that infusion of exogenous Epo (2.5–25 units/day) in 
gerbils with mild (2.5 mins) brain ischemia is neuroprotective against ischemic damage of 
hippocampal CA1 neurons [173]. Furthermore, hypoxia-induced Epo has been shown to 
promote the production of neuronal progenitors acting on forebrain neural stem cells [174]. 
Thus, brain-derived Epo may represent an endogenous protective factor for neurons against 
both mild ischemia and tissue hypoxia [157]. On the cellular level, brain-derived Epo has 
been suggested to be involved in the regulation of calcium flux in neuronal cells [175] as well 
as in the stimulation of dopamine release [176]. Thus, it is believed that Epo might promote 
neuronal function and viability through activation of calcium channels and release of 
neurotransmitters [157]. In addition, the physiological effect of brain-derived Epo has been 
linked to angiogenesis: brain capillary endothelial cells have been showed to express two 
forms of EpoR mRNA [161]. Because endothelial cells express EpoR and react to Epo, it is 
believed that endothelial cells and haematopoietic cells derived from the same mesenchymal 
precursor, the so-called haemangioblast [177], which clarifies why endothelial cells possess 
the EpoR [178]. Furthermore, studies performed in mice with cerebral infarct have shown 
that brain endothelial cells display a staggered induction of EpoR and Epo, with Epo 
following EpoR protein [89]. However, it remains unclear whether the production of Epo 






neuronal cells [172]. Importantly, the endothelial response to Epo leads not only to 
endothelial cell proliferation and angiogenesis, but also to increased expression of 
endothelial nitric oxide synthase (eNOS) that produces the vasodilator nitric oxide (NO) 
improving the oxygenation of the hypoxic tissue [69]. Of note, it has been shown that Epo 
promotes maturation and differentiation of oligodendrocytes and the proliferation of 
astrocytes in vitro [179].  
In summary, tissue hypoxia and cerebral ischemia stimulate the transcription of oxygen-
regulated genes such as Epo and vascular endothelial growth factor (VEGF) in neuronal 
cells through hypoxia-inducible factors. While Epo acts mainly on neurons triggering 
neuroprotection and apoptosis prevention, VEGF induces proliferation of endothelial cells 
and new vessels formation (angiogenesis), which decreases the oxygen diffusion distance 
and thus increases the oxygenation of the hypoxic tissue [180].   
Until recently, it was thought that the anti-apoptotic function of brain-derived Epo involved the 
same erythropoietic Epo/EpoR axis [181]. However, in 1990, Anagnostou and colleagues 
performed receptor-protein crosslinking studies and observed that the EpoR in endothelial 
cells was constituted by only one associated protein of ∼45 kDa [182], rather than two larger 
ones of ∼110 kDa and ∼95 kDa, typical of the erythroid EpoR [183]. In addition, such 
endothelial EpoR was present at much higher density but at lower affinity for Epo, compared 
to its counterpart in erythroid cells (∼5 nM versus ∼200 pM, respectively) [182]. 
Successively, neuronal-like PC12 cells were reported to possess EpoR with very low Epo 
affinity (∼20 nM), which also gave a single crosslinked product but different from the 
endothelial cells [161]. The existence of EpoR with nanomolar affinities for Epo confirmed 
that Epo may act locally in the brain via an autocrine or a paracrine way, as the circulating 
Epo levels are too low (1-5 pM) to signal through the endothelial EpoR (∼2 nM) [181]. Taken 
together, these findings suggested that a different type of EpoR exist and that it should 
contain the erythroid subunit as increased tissue EpoR mRNA was found following ischemia 
whereas anti-EpoR antibodies abolished neuroprotection [184]. Studies in the IL-3-
dependent murine cell line, Baf3, showed association of EpoR with the β common receptor 
subunit βCR, which is also present in interleukin-3 (IL-3), granulocyte-macrophage colony-
stimulating factor (GMCSF) and IL-5 receptors (Figure 14) [185]. Although it remains unclear 
whether the βCR subunit is associated with Epo-R [186], βCR knock-out mice confirmed that 
the βCR subunit is required for tissue protection as shown by the fact that Epo had no 
protective effect in the presence of the EpoR. However, a role for homodimeric EpoR in 
tissue protection cannot be excluded yet. Intriguingly, Brines et al. postulated that this new 
non-erythroid receptor, able to specifically trigger tissue protection, consist of one EpoR 






proposed that βCR exists as a preformed homodimer consisting of intertwined extracellular 
domains and that Epo induces the formation of a heterotrimer composed by EpoR monomer 
in the centre and βCR homodimer at the sides of EpoR. (Figure 15) [181]. The formation of 
such Epo-EpoR-βCR complex results in the interaction of the intracellular domains and 
subsequent activation of the Janus tyrosine kinase 2 (JAK2), which then initiates signalling 
cascades mediating tissue protection.  
 






Figure 14. Structure of Epo receptor subunits mediating neuroprotection, erythropoiesis and 
cytoprotection. Epo-R belongs to a subfamily of the type I cytokine receptor superfamily, which also 
includes the β common receptor (βCR) and the granulocyte-macrophage colony-stimulating factor 
(GMCSF) receptor. These receptors share several structural features: the “tryptophan-serine-any 
amino acid-Trp-Ser” (WSxWS) motif at the extracellular domain, near the plasma membrane as well 
as 4 cysteine residues more distally distributed. The intracellular domain of the βCR is a signalling 








Figure 15. Proposed structure of the Epo-mediated heterotrimer involved in tissue protective 
signalling. From [181].   
As shown in Figure 16, the tissue-protective molecular pathway triggered by Epo is partially 
similar to the erythropoietic pathway as it involves the mitogen-activated protein kinase 






factor-кB (NF-кB) pathways. In contrast to the erythropoietic pathway, the recruitment of the 












Figure 16. Epo mediates a signalling pathway involved in tissue protection. The black lines 
indicate the pathways shared by the erythropoietic and the tissue protective signalling whereas the red 
lines highlight the specific secondary messengers leading to tissue protection. Note that Epo 
modulates also the activity of calcium channels through phospholipase C (PLC), reducing the release 
of excitatory neurotransmitters and enhancing the nitric oxide production. From [181].      
The key secondary messengers of the tissue protective pathway include the glycogen 
synthase kinase 3β (GSK3β) that in turn inhibits the mitochondrial permeability transition 
pore [187] that is implicated in cell death through cell caspase activation; the inhibitor of кB 
(IкB) that is directly inhibited by JAK2, leading to the activation of NF-кB and the consequent 
transcription of anti-apoptotic genes; the protein kinase B (PKB/Akt) that has a direct 
inhibitory effect on GSK3β, and B-cell leukaemia/lymphoma (BCL) family 2-associated death 
protein (BAD), a pro-apoptotic protein. Finally, a specific tissue-protective function of MAPK 
and PKB/Akt is the indirect prevention of the caspase activation through the increase of anti-
apoptotic proteins belonging to the BCL family [181].    
The discovery of a putative Epo heteroreceptor with lower affinity for Epo than the bone 
marrow and with tissue-protective functions opens new horizons toward clinical applications. 
In fact, the possibility to engineer non-erythropoietic Epo molecules having only a tissue-
protective activity is tempting. So far, three approaches were successful [181]. First, the 
removal of sialic acid on Epo resulted in asialo-erythropoietin with a half-life of only several 






Second, mutations at either the EpoR binding site or the intracellular domain activating the 
signaling cascade in Epo produce molecules that are unable to bind to EpoR homodimer and 
that trigger tissue-protective effects [189]. Third, carbamylation of erythropoietin confers full 
non-erythropoietic tissue protection [189].  
In conclusion, given the high potential of neuroprotective Epo for the treatment of several 
neuropathologies caused by tissue injury, clinical trials need to be carried-out in order to 








The evolution of atmospheric oxygen (O2) 
Oxygen is essential for survival of animals, plants, aerobic organisms and has a central role 
in driving the evolution of life on Earth [190]. The composition of the terrestrial atmosphere 
has markedly changed during ∼4,500 million years since our planet formed, strongly 
influencing the development of living organisms [191]. For the first half of Earth’s history, no 
oxygen was present on our planet, which was inhabited only by single cell-organisms. 
Indeed, our life-giving gas started to appear only ∼2.4 billion years ago, when the so-called 
Great Oxygenation Event (GOE) took place. There is evidence that the first 
photosynthetically active single cell-organisms evolved about 3.0 billion years ago. What 
triggered the Earth oxygenation? Ancestral microorganisms, the cyanobacteria, developed 
the ability to utilize sunlight energy and water to fuel their own metabolism producing sugars 
through the process of photosynthesis resulting in the generation of molecular oxygen (O2). 
Nowadays, it is believed that cyanobacteria augmented the oxygen levels in the atmosphere 
during the GOE, transforming the Earth’s atmosphere and contributing to the beginning of life 
[192]. Since O2 is highly reactive and a toxic by-product of cyanobacteria’s photosynthesis, 
initially, it was eliminated from the atmosphere via oxidation of inorganic minerals (e.g. iron). 
Then, minerals became saturated with oxygen and the oxygen levels rose up, especially due 
to the active metabolism of cyanobacteria [193]. In presence of oxygen, most of unicellular 
anaerobic organisms could not survive but complex organisms, the eukaryotes, formed 
through the symbiosis with different bacteria families. By engulfing an aerobic prokaryote and 
establishing an endosymbiotic relationship [194], eukaryotes evolved special membrane-
enclosed compartments, the mitochondria, able to either resist to the toxic effect of oxygen or 
exploit its chemical energy to generate the high energy molecule adenosine triphosphate 
(ATP) in a much more efficient manner than the anaerobic metabolism. In fact, while 
anaerobic glycolysis leads to the production of only 2 ATP molecules per glucose molecule, 
the aerobic respiration generate virtually 30 ATP molecules per each metabolized glucose 
via glycolysis and citric acid cycle [195]. The development of mitochondria as energy cell 
factories fuelled by oxygen ensured the survival of eukaryotes, which were evolutionary 
selected to live in oxygen-enriched atmosphere. The abundant oxygen supply assured by 
photosynthesis and the oxidative phosphorylation through mitochondria matched and 









(Patho-)Physiological Hypoxia  
The cells of our body are exposed to different oxygen levels depending on a wide range of 
factors: organ anatomy, blood perfusion, oxygen consumption of the specific tissue as well 
as the physiological condition (e.g. exercise, rest, and high altitude). As shown in Table 1, 
cells belonging to distinct organ/tissue are exposed to diverse physiological oxygen tensions, 
which are lower than 160 mmHg (the partial pressure of O2 in the air at sea level, equivalent 
to 21% O2) [197]. Oxygen is distributed in tissues through gradients of partial pressure of O2 
(pO2). In blood capillaries, the pO2 gradients occur longitudinally along or radially from the 
vessels, varying between approximately 100 mmHg in arterial blood and 40 mmHg in mixed 
venous blood. In the kidney, the partial pressure of O2 drops from 50-70 mmHg in the cortex 
to 10-20 mmHg in the medulla [198]. As many cell types are not able to store large amounts 
of oxygen, they are particularly sensitive to any condition in which the oxygen demand 
exceeds the oxygen supply (hypoxia) [199]. The insufficient availability of molecular oxygen 
within the cellular microenvironment causes hypoxia, which represents a harmful threat for 
the physiological functions of our body [190].  
Organ/Tissue pO2 (mmHg) 
Air (sea level) 160 
Inspired air (tracheus) 150 
Air in the alveoli 110 
Arterial blood 100 
Venous blood 40 
Brain 33.8 ± 2.6 
Lung 42.8 
Liver 40.6 ± 5.4 
Kidney cortex 72 ± 20 
Kidney medulla 10 - 20 
Muscle 29.2 ± 1.8 
Cell 9.9 - 19 
 
Table 1. Mean values of oxygen partial pressure (pO2) in the microenvironment of different 
human tissues. Adapted from [197].  
In healthy humans, physiological hypoxia is found in several processes including new blood 






(vasculogenesis), wound healing and the adaptation to exercise and high altitude. However, 
tissue hypoxia is also related to diverse pathophysiological conditions such as 
atherosclerosis and stroke, where the vascular occlusion impedes oxygenation causing 
tissue ischemia; chronic inflammation, in which the increased metabolism and oxygen 
demand of the inflamed tissues cause hypoxia; and cancer, where the tumour growth 
augments the oxygen consumption, leading to hypoxia [190].      
As multicellular organisms need a constant supply of oxygen for their survival, they evolved 
specific mechanisms based on systemic and cellular responses to adapt to hypoxia. The 
mammalian systemic response takes place when the entire organism is exposed to low pO2 
as for example at high altitude and consists of a series of changes involving mainly the 
respiratory and cardiovascular systems. The cellular response concerns all cells of our body, 
which are able to respond to hypoxia, and includes the activation of oxygen-sensitive 
pathways within the cell, leading to the stabilization of the transcriptional regulator known as 
the hypoxia-inducible factor (HIF). The systemic and cellular responses are certainly linked 
mechanisms that developed during evolution not only to adapt to hypoxia but especially to 
maintain O2 homeostasis [200].     
1.6.1 Systemic response to hypoxia: adaptation to high altitude 
 
High altitude is defined as elevations above 1500 m sea level at which the atmospheric 
pressure (PATM) declines exponentially [201]. The absolute concentration of each gas 
composing the atmospheric air remains unchanged with increasing altitude [198]. At 5500 m 
(base camp used in ascents to Mount Everest) PATM is 380 mmHg that is half the value at sea 
level (760 mmHg) and pO2 is 80 mmHg (21% of 380 mmHg). However, our body can still 
meet the oxygen demands of healthy people at such elevation. At the peak of Mount Everest, 
the highest point on Earth (8848 m above sea level), PATM is only 255 mmHg and pO2 is only 
53 mmHg and there hypoxia becomes a severe problem. While ascending a mountain, our 
body reacts to reduced ambient pO2 by activating compensatory responses, which varies 
between individuals. An intrinsic protective mechanism is found in the sigmoid-shape curve 
of haemoglobin (Hg), which ensures that oxygen saturation of haemoglobin in arterial blood 
decreases little at altitude up to 3000 m as pO2 is between 80 and 60 mmHg corresponding 
to the relatively flat portion of the O2–Hb dissociation curve, allowing oxygen content in 
arterial blood to be slightly affected. However, with elevation, the oxygen uptake by the 
pulmonary-capillary blood gradually slows down as the alveolar-capillary pO2 gradient at the 
beginning of the capillary falls. As a consequence, oxygen deficiency in arterial blood or 
insufficient loading of haemoglobin (hypoxemia) causes a reduction in the absolute O2 






oxygen at altitude through short-term and long-term adaptation mechanisms. Their effects 
are summarized in Table 2 and discussed below. 
Short-term adaptation to high altitude 
During the first hours at high altitude, our body responds to hypoxemia by increasing the 
heart rate (tachycardia) so that tissues are faster perfused and by enhancing the respiratory 
frequency or the tidal volume (hyperventilation) (Table 2). As previously mentioned, 
peripheral chemoreceptors, located in carotid and aortic bodies, are able to sense a 
reduction in pO2 in arterial blood as well as signal to cells in the medulla oblongata 
(brainstem) to increase ventilation and heart rate. The peripheral chemoreceptors contain 
chemosensitive cells called type I or glomus cells with neuronal features, able to release 
neurotransmitters including catecholamines and acetylcholine [132]. Mechanistically, low pO2 
inhibits O2-sensitive K
+ channels located at the plasmamembrane of the glomus cells, 
leading to membrane depolarization that stimulates the opening of voltage-gated Ca2+ 
channels increasing the concentration of cytosolic Ca2+ [200]. The augmented amount of 
cytosolic Ca2+ provokes neurotransmitter release and consequent activation of either the 
carotid sinus nerve in carotid bodies or the vagus nerve in aortic bodies, which both signal to 
the cardiorespiratory centre of the medulla oblongata to increase ventilation. Importantly, 
hyperventilation increases pO2 but at the same time causes respiratory alkalosis (↑ pH, ↓ 
pCO2) as the exhalation of CO2 occurs faster than its production. Respiratory alkalosis is an 
inhibitory stimulus for the peripheral and central chemoreceptors, which decreases 
ventilation, bringing the body close to the physiological ventilation rate. Over a prolonged 
exposure at high altitude, CO2 accumulates, normalizing respiratory hypocapnia (↓ pCO2) 
and pH decreases in cerebrospinal fluid (CSF) to counteract respiratory alkalosis. In case the 
pH in CSF lowers too much, central chemoreceptors sense the increased [H+] and stimulate 
ventilation to reduce the CO2 and the H
+ levels. In addition to the respiratory effects, 
peripheral chemoreceptors exert also cardiovascular effects: tachycardia, increased cardiac 
output (↑ CO) and pulmonary vasoconstriction [132]. Pulmonary vasocontriction may occur 
via a direct action of low pO2 on the pulmonary vascular smooth-muscle cells with a 
molecular mechanism similar to the one described above for the glomus cells, where hypoxia 
inhibits K+ channels and, ultimately, releases Ca2+ from the intracellular storages to trigger 
myocyte contraction and vasoconstriction of the lung tissue to divert the blood flow away 
from the underventilated alveoli toward the ventilated alveoli. Of note, our body adapts to this 
compensatory mechanism in order to correct the ventilation/perfusion mismatch occurring in 
both underventilated and ventilated alveoli. Pulmonary vasoconstriction increases the blood 
pressure within the arteries of the lungs and, thus, the resistance of the pulmonary 






Long-term adaptation to high altitude 
While vasoconstriction occurs in the pulmonary circulation, in the systemic circulation, blood 
vessels vasodilate to optimize the oxygen delivery to the metabolizing cells of the peripheral 
tissues. Particularly, vasodilation takes place within the endothelial smooth muscle cells in 
the following way: nitric oxide (NO), produced from L-arginine in endothelial cells of blood 
vessels by nitric oxide synthase (NOS), activates guanylate cyclase (GC) that converts 
guanylate triphosphate (GTP) to cyclic guanylate monophosphate (cGMP). Through cGMP-
dependent protein kinase G several phosphorylation events occur until the intracellular 
concentration of Ca2+ decreases and the relaxation of smooth muscle cells take place. 
Moreover, prolonged high altitude causes a decrease of heart rate (HR) and cardiac output 
to sea levels values, which, initially, leads to reduced oxygen delivery but, then, is 
compensated by vasodilation of peripheral vessels that maximize the oxygen distribution to 
the tissues. Another cardiovascular effect caused by high altitude is tissue angiogenesis 
leading to increased vascularity, triggered by growth factors released by hypoxic tissues 
such as vascular endothelial growth factor (VEGF) and fibroblast growth factor (FGF) [132] 
[202]. In the lung, angiogenesis enhances the capillary surface, improving oxygen diffusion 
and counteracts the effects of pulmonary vasoconstriction (↓ blood flow and ↑ vascular 
resistance), leading to an increase in pulmonary diffusing capacity [132].  
 
Table 2. Overview of the physiological changes occurring during short-term and long-term 
adaptation to high altitude. The short-term adaptation indicates a period from minutes to hours 
whereas the long-term adaptation refers to a prolonged exposure from few days to weeks. 
Abbreviations: RBC= red blood cells; [Hb]= haemoglobin concentration; Hct= haematocrit; HIFs= 
hypoxia inducible factors; HR= heart rate; CO= cardiac output; VEGF= vascular endothelial growth 
factor; 2,3 BPG= 2,3 bisphosphoglycerate. 
Moreover, hypoxia stimulates the RBCs to produce more 2,3 bisphosphoglycerate (BPG) 
and its accumulation (↑ 2,3 BPG) reduces the affinity of haemoglobin for oxygen as 2,3 BPG 
binds the allosteric site of haemoglobin, destabilizing the interaction with oxygen and 
promoting oxygen release. 
Short-term adaptation Long-term adaptation 
↑ Ventilation  ↑ Epo, ↑ RBC, ↑ [Hb], ↑ Hct,  
Respiratory alkalosis (↓ pO2, ↑ pH) Systemic vasodilation, ↓ HR, ↓ CO 
Tachycardia (↑ CO, ↑ HR) ↑ Angiogenesis, ↑ VEGF  
Pulmonary vasoconstriction 
↑ vascular resistance 






The kidneys also play a role in the long-term adaptation to altitude: they decrease the rate of 
acid secretion to the lumen of the renal tubules (↑ [H+] in blood) and increase the excretion of 
bicarbonate in the urine (↓ [HCO3-] in blood) to counteract the respiratory alkalosis by 
lowering the alkali blood pH towards more physiological values (Table 2).  
Although the mechanism remains unclear, it has been demonstrated that hypoxic stimulation 
of the carotid bodies and increases sodium and water excretion in the kidneys causing 
diuresis (↑ urinary flow) and reduced plasma volume until the haematological response takes 
place [203]. 
Altitude Sickness 
When ascending rapidly to high altitude, hypoxia can cause initially mild symptoms in 
susceptible individuals including headache, fatigue, nausea and decline in cognition, which 
are progressive with increasing altitude. Ascents can develop acute mountain sickness 
(AMS), a clinical condition comprising more severe symptoms such as dizziness, dyspnoea, 
sleep disturbance, peripheral oedema, vomiting, which develop within the first days. During 
the acclimatization phase, a series of side effects might appear like fatigue, shortness of 
breath (dyspnoea) and alternative periods of cessation of breath (apneas) caused by the 
inhibition of hyperventilation due to too low pCO2 (hypocapnia).  
In the brain, vasodilation of cerebral vessels result in brain swelling and headache and 
increased capillary pressure, which can provoke capillary leakage and disruption of the blood 
brain barrier (BBB), leading to accumulation of fluid in the brain causing, ultimately, cerebral 
oedema. In the lung, an increase in vessel permeability (↑ VEGF) and pulmonary transmural 
pressure lead eventually to damage of capillaries, accumulation of liquids and, ultimately, 
high altitude pulmonary oedema. Both pulmonary and cerebral oedema can be fatal if not 
properly diagnosed and treated. Certainly, the most effective treatment for AMS is 
descending to lower altitude and providing oxygen by portable hyperbaric chambers to the 
sick subjects. Protective factors against AMS include, primarily, slow ascent (no more than 
300 to 600 m per day) to ensure a gradual acclimatization to progressive altitude, and then, if 
symptoms occur despite slow ascent, acetazolamide (diuretic and inhibitor of carbonic 
anhydrase) and dexamethasone (corticosteroid that counteracts the cause of cerebral 
oedema) can be administered for prophylaxis or treatment of AMS [204] [132]. After 
prolonged residence at high altitude, chronic mountain sickness (CMS) may develop, mainly 
caused by the erythropoietic response promoting overproduction of red blood cells (RBC), 
reaching a very high haematocrit (Hct > 65%). Polycythaemia is a haematological pathology 
that provokes an increase in blood viscosity and vascular resistance conferring a high risk of 






myocardial infarction and stroke due to both higher blood viscosity and obstruction of blood 
supply to heart and brain, respectively [205].  
Humans adapted to live at high altitude 
Since the exposure to hypoxia leads to many physiological changes that can be dangerous 
for the human health, how is it possible that three populations, Tibetans, Andeans and 
Ethiopians could reside for millennia in a permanent hypoxic environment? The explanation 
can be found in the fact that hypoxia applied a selective pressure on these ethnic groups 
who overcame the low oxygen tension through unique physiological and genetic adaptations. 
Interestingly, these three populations have developed diverse adaptation mechanisms in 
terms of haematological response, pulmonary and cardiovascular changes as well as genetic 
modifications (Table 3). Tibetans show selectively low haemoglobin levels and low arterial 
oxygen saturation, whereas Andeans present higher haemoglobin concentrations and low 
oxygen saturation and Ethiopians display haemoglobin levels and oxygen saturation similar 
to sea-levels individuals [206]. Epo levels are also lower among Tibetans compared to 
Andeans reflecting the haemoglobin concentrations [207]. The typical hypoxic ventilator 
response (HVR) is not found in Andeans, who show no increase in resting ventilation [208], 
while Tibetans show sea-level HVR and higher resting rate compared to Asian and European 
populations acclimatized at the same altitude [209]. Particularly, Tibetans show a resting 
ventilation rate (19.7 L/min) 1.5 higher than Andeans [210] 
Phenotype Andean Tibetan Ethiopian 
Resting ventilation No increase 50% higher NR 
Hypoxic ventilatory response Low ∼ Sea-level value NR 
Arterial O2 saturation Elevated No increase Elevated 
Haemoglobin concentration Elevated Minimal increase Minimal increase 
Pulmonary arterial pressure Elevated Minimal increase Elevated 
Nitric oxide Elevated Elevated NR 
Birth weight Elevated Elevated NR 
 
Table 3. Physiological adaptation to hypoxia among high altitude populations. NR: not reported. 
From [211].  
As mentioned above, chronic pulmonary vasoconstriction is a common effect after hypoxia 
exposure and is present among Andeans likely due to the thickening of the pulmonary 
arterial walls [212], whereas Tibetans display only a minimal increase in HVR [213]. 






high altitude as it regulates blood flow and vascular resistance. Tibetans exhibit high levels of 
NO accompanied by increased blood flow but not vascular resistance, suggesting that the 
higher concentration of NO might counteract hypoxic vasocontriction. Surprisingly, despite 
elevated arterial oxygen saturation and pulmonary arterial pressure in Andeans, the levels of 
NO are also augmented. High altitude has serious effects on pregnancy and fetal growth and 
can cause intrauterine growth restriction (IUGR), leading to low birth weight. However, 
newborn Tibetans and Andeans appear to be protected from birth weight reduction [214].  
The distinct phenotypes described above for Tibetans, Andeans and Ethiopians suggest that 
differences in the adaptation to hypoxia occurred between these populations including 
modifications in specific genes and pathways [205]. Comparative genomic studies among 
these three populations analysed primarily the genes involved in the HIF pathway to screen 
for target genes for natural selection. Two SNPs within the HIF target gene EGLN1, encoding 
for the enzyme PHD2 which hydroxylases HIF, indicate that the lower hydroxylation of HIF 
leads to increased activation of the HIF pathway and consequent transcription of target 
genes contributing to the phenotypic adaptation of Tibetans [215]. Moreover, genome-wide 
studies identified also the gene EPAS1 encoding for HIF-2α as candidate that underwent the 
hypoxia pressure in Tibetans. Curiously, it has been postulated that EPAS1 may have a 
Denisovan origin, deriving from an extinct species of Homo found in Denisova cave (Siberia) 
[216]. Among Andeans, target genes involved in high altitude adaptation include variants in 
EGLN1, PRKAA1, linked to fetal growth and birth weight as well as SENP1, an enzymatic 
regulator of erythropoiesis that when down regulated ameliorates hypoxia tolerance [217]. 
Genomic scans performed among Ethiopians revealed genes involved in the adaptation to 
hypoxia belonging either to the HIF pathway such as ARNT2 and THRB or non-hypoxia-
related genes playing a role in pathogen defence, angiogenesis or calcium uptake [218].  
In conclusion, Andeans, Tibetan and Ethiopians adapted to high altitude through different 
genes and specific genetic changes and pathways. The possibility to link the genotype to the 
phenotype of these highlander populations is a future perspective of evolutionary biology that 
aims not only to expand the knowledge about the genetic variations under hypoxia selection 
but also to apply such information to discover the genetic elements causing chronic ischemic 







1.6.2 Cellular response to hypoxia: the PHD/FIH-HIF-pVHL pathway 
 
All nucleated mammalian cells respond to hypoxia by stabilizing the hypoxia–inducible 
factors (HIFs), the master regulators of oxygen homeostasis, leading to the activation of 
hundreds of genes involved in several cellular processes which need to adapt to oxygen 
deprivation such as glucose metabolism, angiogenesis, erythropoiesis, iron uptake and cell 
proliferation [219]. The HIF pathway is highly conserved across species, found in all 
metazoans and even in more ancient organisms like nematodes and corals [220]. Such 
evolutionary conservation might be explained by the fact that the HIF pathway plays a key 
role in the response to hypoxia at both cellular and systemic levels. An example is given by 
the enhanced transcriptional activation of the cytochrome oxidase subunits COX4-1 and 
COX4-2 that ameliorates the mitochondrial respiration at low O2 concentration [221]. 
Similarly, the switch from aerobic to anaerobic glycolysis due to decreased oxygen 
availability triggers the upregulation of either the glucose transporters Glut-1 and Glut-4 to 
optimize the glucose uptake and all glycolytic enzymes [200].    
The discovery of HIFs came from DNA-protein interaction studies at the downstream 
enhancer of the erythropoietin gene, the 3’ hypoxia response element (3’ HRE) in Hep3B 
cells in the laboratory of Gregg Semenza [222]. Successively, the characterization of the 
purified hypoxia inducible factor revealed that HIF is a heterodimer composed by a hypoxia-
inducible α subunit of ∼120 kDa and a constitutive β subunit of 91-94 kDa [223]. The HIF-α 
subunits comprise HIF-1α, HIF-2α or HIF-3α, which all present a similar basic protein 
structure (Figure 17). Starting from the N-terminus, the protein structure comprises: a helix-
loop-helix (HLH) domain involved in DNA binding, followed by a two Per-Arnt-Sim (PAS) 
domains, responsible for protein-protein interaction with the HIF-β subunit, the oxygen-
dependent degradation domain (ODDD) important for the HIF protein stability and the N- and 
C- terminal activation domains (NAD and CAD), conferring transcriptional activity. Finally, an 
inhibitory domain (ID) mediates normoxic repression of the CAD (Figure 17). The ODDD 
domain is missing in HIF-β, confirming its ubiquitous presence in normoxia [224]. While HIF-
1α and HIF-2α heterodimerize with HIF-β to form an active transcriptional complex, HIF-3α 
shows weak transcriptional activity and is thought to be a negative regulator of the other two 
isoforms. In contrast to HIF1A and HIF2A, the human HIF3A locus is subjected to alternative 
splicing leading to the formation of several variants such as the inhibitory PAS domain 
protein (IPAS) that, after dimerization with HIF-β, inhibits target genes as well as the 
neonatal and embryonic PAS (NEPAS) also able to heterodimerize with HIF-β. However, due 
to its weak transcriptional activity, it is believed that HIF-3α might have a role in modulating 






another category of proteins has been discovered to possess a crucial function within the HIF 
pathway, which are termed prolyl-4-hydroxylase domain (PHD) enzymes. Such prolyl-4-
hydroxylases are able to sense continuously O2 levels due to their high Michaelis constant 
(Km) for oxygen and low O2 affinity and are, thus, considered as cellular oxygen sensors 
[133].  





Figure 17. Structural domains of HIF-α, IPAS and HIF-β monomers. From [224]. 
Based on the sequence of the egl-9 gene, which encodes a HIF regulating prolyl-hydroxylase 
in C.elegans, Ratcliffe and co-workers discovered the mammalian homologs HIF hydroxylase 
enzymes named PHD1, PHD2 and PHD3 [226]. The PHD enzymes exert their action on the 
ODD domain of HIFs. In the presence of sufficient oxygen (normoxia), PHDs hydroxylate two 
proline residues of HIF-α subunits Pro402 and Pro564 in human HIF-1α and Pro405 and 
Pro531 in human HIF-2α. This reaction requires O2 and 2-oxoglutarate, converted to CO2 and 
succinate, as well as ferrous iron and vitamin C. Hydroxylated HIF-α is then recognized by 
the von Hippel-Lindau tumour suppressor protein (pVHL), being part of an E3 ubiquitin ligase 
complex, and targeted for polyubiquitination and subsequent proteasomal degradation 
(Figure 18) [227] [219]. In conditions where oxygen demand exceeds oxygen supply 
(hypoxia), all the available oxygen is used up by the oxidative enzymes in mitochondria to 
fuel the oxidative phosphorylation. Subsequently, the insufficient oxygen levels prevent the 
hydroxylation of HIF-α which is stabilized, accumulates in the cytoplasm, translocates into 
the nucleus and binds to HIF-β to form a transcriptional active heterodimer (Figure 18) [133]. 
The HIF-α/HIF-β heterodimer recruits the co-factors CBP/p300 in order to regulate the 
transcription of specific target genes involved in the adaptation to hypoxia [228]. The 
CBP/p300 cofactor is a histone acetyltransferase and modulates the chromatin structure 
toward an “open” conformation favouring transcriptional activity [219]. Another member of the 
HIF hydroxylase enzymes is the Factor Inhibiting HIF (FIH), which hydroxylates HIF at an 
asparagine residue within the CAD of HIF-α: Asn803 in human HIF-1α and Asn851 in human 
HIF-2α. Asparaginyl hydroxylation does not prevent HIF-α stabilization but blocks the 






believed that asparaginyl hydroxylation might provide a second oxygen-regulated 
mechanism by which the transcriptional activity of HIF-α is fine tuned [229]. PHD-mediated 
hydroxylation participates in the cross-talk between oxygen sensing and mitochondrial 
metabolism. Intermediates from the Krebs cycle such as malate/fumarate and succinate are 
inhibitors of PHDs as they compete with 2-oxoglutarate in binding the active site [230], while 
certain mutations in the gene encoding isocitrate dehydrogenase-1 (IDH-1), succinate 
dehydrogenase (SDH) and fumarate hydratase (FH) cause a reduction in 2-oxoglutarate 
levels increasing HIF-1α protein amounts [231] [232]. Additionally, PHD hydroxylase activity 
can be inhibited by divalent metal ions such as cobalt (Co2+) or nickel (Ni2+), which impede 
the entry of vitamin C into the cell as well as by reactive oxygen species (ROS) which, 












Figure 18. Overview of the PHD/FIH-HIF-pVHL pathway with its oxygen regulation and cross-
talk with mitochondrial metabolism. From [133]. 
As shown in Figure 18, PHD2 and PHD3, but not PHD1 and FIH, are HIF target genes with 
hypoxic induction of PHD3 preceding PHD2 and both can, in turn, downregulate HIF-α 
proteins suggesting the existence of an intrinsic negative feedback mechanism [233] whose 
relevance for Epo regulation remains to be elucidated. 
While HIF-1α mRNA is ubiquitously expressed in all nucleated cells of Metazoans, HIF-2α 
mRNA levels are particularly high in tissues relevant for the systemic delivery of O2 like lung, 






expression is variable. For example, hepatocytes, cardiomyocytes, and myocardial 
endothelial cells respond to hypoxia with up-regulation of both HIF-1α and HIF-2α, whereas 
in lung, kidney and brain the two subunits are found in different cell populations. Particularly, 
in the lung, HIF-2α protein is expressed in type II pneumocytes and pulmonary endothelial 
cells, while HIF-1α is not detectable; in the kidney HIF-1α is confined to renal tubuli, whereas 
HIF-2α is localized in peritubular interstitial cells, endothelial and glomerular cells [234] [235] 
and, in the brain, HIF-1α is expressed in neuronal cells and HIF-2α in glial cells [236]. 
The essential role played by the HIF pathway in the physiological adaptation to hypoxia is 
demonstrated by the fact that homozygous knock-out of either HIF-1α, HIF-2α, PHD2 or 
pVHL leads to embryonic lethality in mice [21] whereas embryos lacking PHD1 or PHD3 are 
viable [237]. Mice with homozygous deletion of Hif-1α die in utero between E8 and E11 due 
to neural tube defects and cardiovascular malformations [238]. Different phenotypes have 
been described for global Hif-2α knock-out: impaired catecholamine synthesis leading to 
heart failure and perinatal death [239], development of respiratory distress syndrome due to 
insufficient production of surfactant in the lung caused by deficient VEGF levels [240], 
mitochondrial abnormalities and deficiency in ROS homeostasis [241] and anaemia due to 
inadequate renal Epo production [242]. Phd3-/- mice show abnormal sympathoadrenal 
development and reduced systemic blood pressure [243], whereas Phd1-/- mice exhibited 
higher white adipose tissue (WAT) mass, despite lower body weight, hepatic steatosis and 
liver-specific insulin resistance [244]. In contrast to Phd3-/- and Phd1-/- mice, Phd2-/- mice 
display severe placental and heart defects followed by embryonic death. Moreover, two 
independent conditional PHD2 knock-out mouse models showed increased angiogenesis 
and erythropoiesis, demonstrating the dominant role of PHD2 in controlling renal Epo 
synthesis [245] [246] [247]. Mutations in VHL gene predispose to the development of a 
variety of tumours affecting most commonly retinal and central nervous system as well as 
kidney, leading to renal cancer of the clear cell phenotype [248]. In line with its central role in 
regulating the HIF pathway, specific mutations in the VHL gene provoke also erythrocytosis 
in mice [249] and humans as observed in Chuvash polycythaemia caused by a VHL R200W 
mutation in the absence of cancer [250].  
The final step of the HIF pathway consists in the binding of HIF-α/β heterodimer at specific 
DNA element called hypoxia response element (HRE), present in the regulatory regions of 
hypoxia-regulated genes. The HIF DNA binding site within the core of the HRE is also 
termed HIF binding site (HBS) whereas HRE refers to the minimal cis-regulatory elements 
required to induce gene transcription upon hypoxia. Therefore, the HBS is the minimal DNA 
sequence required for interaction with HIF while a functional HRE contains the HBS as well 






necessarily hypoxia inducible but their activity might amplify or block the hypoxia response 
and confer tissue-specific functions to the HRE [219] [251]. An example of interaction 
between HIF and TFs is the lactate dehydrogenase A gene, whose transcription is activated 
via cooperation of HIF, ATF-1 and CREB-1 at the HRE [252]. The analysis of validated HIF 
target genes has confirmed the consensus core HRE sequence to be 5’-RCGTG-3’ (R= A or 
G), followed after 8 nucleotides by the sequence 5’-CACA-3’ named the CACA repeat, to 
which no binding proteins have been identified yet. Intriguingly, regulatory regions of 
mammalian genes contain many more potential core HRE sequences compared to the ones 
effectively bound by HIF to regulate gene expression. How can HIFs discriminate between 
functional and non-functional HREs if the HRE core consensus sequence is identical? An 
explanation might be the presence of this 8 nucleotides sequence that is highly variable and 
could serve as DNA binding site of different TFs cooperating with HIFs, thus, conferring 
tissue and gene specificity [251]. An additional layer of complexity concerning the distinction 
of HREs by HIFs is found in epigenetic effects, which might contribute to reduce the number 
of functional HREs. In fact, the consensus core HRE contains CpG dinucleotide and its 
methylation would interfere with transcription factor binding to DNA via both direct steric 
hindrance and the binding of repressor proteins [253]. Surprisingly, two or three tandem core 
HREs are able to form a functional HRE as reported in genes encoding transferrin, several 
glycolytic enzymes and Glut-1 [251]. Using chromatin immunoprecipitation coupled to next-
generation DNA sequencing (ChIP-seq), a recent report examined the pan-genomic patterns 
of HIF-1 and HIF-2 binding in hypoxic conditions and showed that, despite many HBS can 
bind both HIF isoforms, the binding distributions depend on the intrinsic properties of each 
isoform as in vitro disruption of either HIF-α subunit had a weak effect on the binding of the 
other. Moreover, when comparing the binding of HIF-1 and HIF-2, it has been observed that 
HIF-2α binds in a more cell-type specific manner and that HIF-2 binds more distantly 
(enhancers) from the transcriptional start site whereas HIF-1 binds more closely to the 
transcriptional start site (promoters). Taken together, the authors conclude that the factors 
determining the HIF-α isoform binding specificity might be different from those determining 







1.7 Transcriptional regulation of erythropoietin in hypoxia 
 
1.7.1 Regulatory regions within the EPO locus 
 
Erythropoietin is exclusively regulated on the mRNA level and, despite its important 
physiological functions and its great therapeutical potential, the molecular mechanisms 
behind Epo regulation is only partially elucidated. As mentioned before, Epo regulation is 
tissue-specific and developmental stage-specific, being the liver the major site of Epo 
production during fetal life and the kidney the main Epo producing organ in adulthood [111]. 
Moreover, Epo gene expression is induced by hypoxia [129], hypoxia-mimetics such as 
CoCl2 [255] and by anaemia [256]. The EPO gene is localized as a single copy to the long 
arm of chromosome 7 in humans and to chromosome 5 in mice and it contains 5 exons and 
4 introns [257]. Comparison between human and mouse EPO genes revealed sequence 
homology >75% [258]. Particularly, three noncoding segments of the EPO gene are highly 
conserved between human and mouse: the promoter, the first intron and a 120 bp region 
located at 100 bp downstream to the polyadenylation site [259]. The tissue specificity of Epo 
expression in liver and kidney might be explained by distinct cis-acting regulatory DNA 
elements at which different transcription factors bind, driving the activation of Epo 
transcription in a tissue specific manner. Such regulatory DNA elements modulating Epo 
expression might also be responsible for the switch between hepatic and renal Epo 
production since, from a developmental point of view, the liver arises from the embryonic 
endoderm and the kidney from the embryonic mesoderm [256]. The investigation of the cis-
regulatory DNA elements controlling the tissue specificity as well as the hypoxia inducibility 
of Epo expression was accomplished by in vivo studies with transgenic mice carrying 
fragments of the human EPO gene encompassing different lengths of the 5’ and 3’ flanking 
regions as a renal cell line, able to produce Epo in a hypoxia-inducible manner, derived from 
the kidney was lacking. Semenza and collegues generated the first transgenic mouse 
(tgEPO4), which contained a 4 kb fragment containing human EPO gene, 0.4 kb upstream of 
the transcription start site (TSS) encompassing the EPO promoter, and 0.7 kb downstream of 
the polyA site (Figure 19A). Such transgenic mice were polycythaemic due to increased Epo 
mRNA levels in liver, kidney as well as other tissues. Moreover, hypoxia caused by anaemia 
induced Epo mRNA levels in liver, but not in kidney, suggesting the requirement of additional 
regulatory sequences for Epo induction in the kidney while the liver-inducible element (LIE) 
within the transgene construct conferred liver expression. The same group generated 
another transgenic mouse line (tgEPO10) that in addition to the 4 kb fragment included an 

























Figure 19. Overview of the human (A) and mouse (B) EPO gene constructs used to generate 
specific transgenic mice. Transgene expression pattern and references are displayed.  
Similarly to the tgEPO4 mice, after inducing anaemia, these animals maintained increased 
Epo mRNA levels in liver but not in kidney. Therefore, none of tgEPO4 and tgEPO10 display 
regulated renal Epo expression, despite the kidney is the major site producing Epo in 
adulthood. In contrast to the tgEPO4 mice, the tgEPO10 mice displayed reduced Epo ectopic 
expression, implying that the sequence between -0.4 and -6 kb is a negative regulatory 
element (NRE), involved in suppressing Epo expression in tissues other than liver and 
kidney. Interestingly, in eukaryotic genes, NREs contribute to tissue-specific expression by 
suppressing constitutively the gene transcription in other tissues, whereas the tissue-specific 
induction relies on other positive regulatory elements such as enhancers [256]. In this regard, 
the EPO gene is an interesting example as it contains both negative and positive regulatory 
elements that function in concert to finely tune Epo expression in liver and kidney [256]. 
Successively, Semenza and colleagues further increased the size of the 5’ flanking 






liver in response to anaemia. This study demonstrated that the regulatory sequence 
responsible for modulating renal Epo induction, the so-called kidney inducible element (KIE) 
must be located between -14 and -6 from the TSS of the human EPO gene. Transgenic 
animals generated with this longer construct developed more severe polycythaemia than 
tgEPO4 and tgEPO10, probably due to Epo production in both kidney and liver [43]. To 
localize the sequences necessary for specific kidney Epo induction, Madan and collegues 
generated transgenic mice containing the same 10-kb fragment used by Semenza et al. 
along with additional 3’ flanking sequence (7 kb from the polyA) and different 5’ flanking 
sequences, including a more extended upstream region up to position -20 kb from the TSS 
containing Semenza’s construct (-14 to -6 kb fragment of 8 kb) belonging to Epo33 mice or a 
smaller portion of Semenza’s construct of 3.5 kb belonging to Epo22 mice. Epo22 mice 
showed inducible Epo mRNA levels due to anaemia exclusively in the liver, whereas Epo33 
animals displayed Epo induction in both liver and kidney, confirming the findings of Semenza 
et al. and suggesting the localization of the KIE between -9.5 and -14 kb from TSS. 
Moreover, in contrast to the transgenic animals of Semenza et al., Epo22 and Epo33, having 
additional 7 kb of 3’ flanking sequence, showed normal haematocrit and were only mildly 
polycythaemic, suggesting the presence of a negative regulatory liver element (NRLE) 
between 0.7 and 8.5 kb downstream of EPO. To verify whether introns might have a role in 
Epo regulation, Epo3 transgenic animals containing an EPO minigene lacking introns II-IV 
but including 0.4 upstream and 0.7 downstream sequences, were generated: Epo ectopic 
expression with liver but not kidney inducible expression was detected, indicating that such 
introns do not contain regulatory sequences responsible for Epo regulation or Epo induction 
in the liver [44]. Later, DNaseI hypersensitive site (HS) mapping in nuclei of kidney and liver 
of anaemic mice revealed the presence of open chromatin structure within the putative KIE 
and LIE proving their potential role in regulating inducible Epo [260] [261]. Successively, a 
new series of vectors containing reporter genes were used to study Epo regulatory elements. 
The LacZ reporter construct encoding β-galactosidase permitted to identify the presence of a 
liver-specific silencing element within 1.2 kb from the polyA of the EPO gene (Figure 19B) 
[262]. The best approach to study Epo regulation revealed to be the generation of bacterial 
artificial chromosome (BAC) transgenic mice expressing GFP as reporter gene under the 
control of a 180-kb inserted 60 kb upstream and 120 kb downstream of the mouse Epo gene. 
Interestingly, such construct fully recapitulated inducible physiological Epo expression in a 
tissue-specific manner allowing the characterization and isolation of renal Epo-producing 
(REP) cells [149]. Furthermore, mutated versions of this model were employed to assess the 
functionality of different transcription factor binding sites, such as the GATAs and HIF itself  
[263]. Successively, the group of Yamamoto generated other transgenic animals carrying a 






showed a GFP expression pattern representing the physiological Epo expression and was 
used to study embryonic Epo expression in neural crest cells [264]. 
1.7.2. Tissue-specific Epo regulation 
 
The discovery of the two hepatoma cell lines Hep3B and HepG2, capable to produce Epo in 
a hypoxia-inducible manner has provided an invaluable tool in advancing the understanding 
of the molecular basis of EPO gene regulation and proved that even in vitro cells possess the 
necessary machinery for oxygen sensing and gene regulation [129]. The availability of such 
cellular models has allowed the characterization of the tissue-specific regulatory regions 
determined by transgenic animal studies. The discovery of HIF and its binding site was 
based on transient expression assay in Hep3B when Semenza and colleagues validated a 
50-bp sequence within the LIE as hypoxia inducible enhancer [222]. In parallel, Madan et al. 
reported that in Hep3B a 621-bp fragment containing Epo promoter along with 5’ flanking 
region was sufficient to drive a modest but statistically significant induction (2.4 fold) of 
luciferase activity in response to hypoxia. They also confirmed the presence of a HRE to a 
24-bp portion of the 3’ flanking region of EPO [265]. In line with these findings, Blanchard et 
al. identified a 117 bp fragment upstream of TSS containing the minimal human EPO 
promoter sequence required for hypoxic inducibility. Despite Epo promoter is per se a weak 
promoter (6-fold hypoxic induction), the combination of the EPO promoter and 3’ enhancer 
increased the induction from 50- to 100-fold in vitro, demonstrating synergistic cooperativity 
between these transcriptional elements [266-268]. Intriguingly, DNA sequence comparison 
between the EPO promoter and the 3’ enhancer revealed sequence similarities as the 10-bp 
sequence 5’-CACACAGCCT-3’ is conserved. Interestingly, the EPO promoter contains twice 
the 10-bp sequence CACGCACACA [266], which contains a HIF binding site and will be 
further discussed as relevant for this thesis work. In the Epo promoter, while the typical TATA 
box is absent, a GATA box is present which is recognised and bound by GATA factors [269], 
belonging to the family of zinc finger DNA-binding proteins and playing a role in regulating 
haematopoiesis [270]. In hepatoma cells, two GATA sites have been identified that repress 
Epo transcription under normoxic conditions and are downregulated in hypoxia to ensure 
hypoxic Epo. As a consequence of the high homology between the human and mouse Epo 
genes, a GATA motif has been found also within the mouse Epo promoter region to which 
GATA-2 and GATA-3 factors bind and repress mouse Epo transcription [271]. Similarly, 
knock-down and over-expression experiments performed in hepatoma cells demonstrated 
that GATA-2 and GATA-3 have an inhibitory transcriptional effect on EPO, whereas GATA-4 
revealed positive transcriptional effects on EPO gene [272] [273]. GATA-4 is highly 






confined to epithelial cells surrounding the biliary ducts. Given its strong binding activity to 
the EPO promoter as well as its developmental stage specificity, it has been suggested that 
GATA-4 contributes to the switch of Epo gene expression from the fetal liver to the adult 
kidney [273]. Furthermore, the relevance of the GATA binding site has been demonstrated 
by in vivo studies where the GATA motif within the EPO promoter was disrupted in a GFP-
reporter BAC construct: mutant animals displayed ectopic GFP expression in the epithelium 
of the lungs, kidneys and gallbladders, confirming the role of GATA factors in suppressing 
ectopic Epo expression by inhibiting its transcription [149]. A recent work showed that GATA 
factor inhibitors such as mitoxantrone and its analogues highly induced Epo expression in 
epithelial cells (normally non Epo-producing cells) derived from mouse and humans, 
independent of any hypoxic stimulus, further confirming the role of GATA factors as 
repressors of ectopic Epo expression and suggesting that mitoxantrone-mediated Epo 
induction occurs independently of the hypoxia response pathway [274].  
Another factor named hypoxia-associated factor (HAF) has been identified to bind a 17 bp 
sequence (-61 to -45 bp) within the minimal Epo promoter (117 bp). Interestingly, HAF 
antisense experiments in Hep3B showed reduced Epo expression in hypoxia without 
abrogating the basal level, indicating that HAF synergizes with other TFs to modulate 
oxygen-regulated Epo transcription [275].  
The Wilms tumour suppressor Wt1 is a transcription factor identified in paediatric renal 
carcinomas due to its inactivation and it has been suggested to be involved in Epo regulation 
for the following reasons: (I) The EPO promoter contains several predicted binding motifs for 
Wt1 (GnGGGnGnG) that are highly conserved in mice and humans; (II) Wt-1 deficient mice 
display defects in the haematopoietic system and Wt1-/- embryos show reduced Epo 
expression in the liver, linking Wt-1 with Epo regulation; (III) Wt1 developmental expression 
is confined in a spatial and temporal manner like Epo expression. Particularly, Wt1 encodes 
a zinc finger protein presenting 4 alternative Wt1 splice variants, among which the insertion 
of the lysine-threonine-serine (KTS) tripeptide into the zinc finger domain reduces the DNA 
binding affinity of Wt1 (Wt1(+KTS)), whereas the lack of KTS increases the DNA binding 
affinity of Wt1 (Wt1(-KTS)) [276]. Dame et al. reported that Wt1(-KTS) augmented Epo 
promoter activity by 25-fold in human osteosarcoma U2OS cells, 9-fold in human embryonic 
kidney HEK293 cells and 5-fold in HepG2 cells in reporter gene assays under normoxic 
conditions. Moreover, since Wt1 does not up-regulate Epo in response to hypoxia, the 
authors suggested that Wt1(-KTS), in addition to GATA-4, is a transcriptional activator of 
basal Epo expression in the fetal liver and might be involved in the switch of Epo synthesis 






In vitro studies in Hep3B and HepG2 cells allowed the molecular characterization of the 3’ 
enhancer within the LIE and three important sites have been found to be involved in the 
response to hypoxia: (I) an HRE consensus sequence 5’-CACGTGCT-3’ located at the 3’-
end containing the HIF binding site (underlined); (II) a highly conserved CACA repeat located 
7 bp after the HRE; (III) a direct repeat 2 (DR-2) site containing a binding site for hepatocyte 
nuclear factor-4α (HNF4α) consisting in a direct repeat of two steroid receptor half sites 
separated by 2 bp. As afore mentioned, this HRE within the 3’ enhancer, also termed 3’ 
HRE, is responsible for hypoxic induction of Epo mRNA by enhancing the minimal EPO 
promoter activity and has been demonstrated to be bound by HIF. In addition to bind the 
HBS, HIF binds also the constitutive coactivators p300/cAMP response element-binding 
protein (CREB)-binding protein (CBP), which are thought to indirectly interact with the 
promoter and the 3’ HRE in order to enhance Epo transcription [278] [222] [266] [268]. 
 
Figure 20. Scheme depicting the human EPO locus and its hypoxia response elements in liver 
and hepatoma cells. The EPO promoter is represented with a yellow box including the hypoxia-
associated factor (HAF) and GATA binding sites. The light blue box within the LIE represents the 3’ 
HRE region including the HBS (bold) bound by HIFs and the CACA repeat (bold) to which no binding 
factors have been identified yet. HIFs recruit p300/CBP co-activators at EPO promoter in order to 
enhance Epo transcription. The green box within the LIE represents the DR-2 sites to which HNF-4α 
bind ensuring hepatic specific Epo expression. Numbers indicate the distance in kb from the TSS (-: 
upstream, +: downstream). Adapted from [279].    
Although no factor binding to the CACA repeat (II) has been identified yet, this element is 
known to be necessary but not sufficient to induce Epo transcription in hypoxia, acting as an 
ancillary sequence to the HBS [222].  The DR-2 site (III) has been reported to bind non-
oxygen regulated protein complexes and its mutation markedly inhibited Epo transcription in 
hypoxia, confirming its involvement in hepatic Epo regulation. Several proteins are able to 
bind the DR2 site, among which HNF-4α has been detected [266]. HNF-4α is expressed in 
the renal cortex and liver like Epo and since its mutation abrogated Epo induction in Hep3B 
cells, it is believed that it may contribute to the hepatic Epo expression [280]. In vivo studies 
performed by the group of Volker Haase convincingly demonstrated that HIF-2α, but not HIF-
1α, preferentially regulates hepatic Epo expression in both Vhlh-deficient and WT anemic 






Immunoprecipitation (ChIP) analysis in Hep3B, the authors confirmed that also in cellulo HIF-
2α preferentially associated with EPO 3’ HRE in hypoxia and conclude that HIF-2α is the HIF 
isoform that mainly binds to the 3’ enhancer within the LIE [281]. Importantly, 3 bp mutation 
of the 3’ HRE in Epo-GFP reporter transgenic mice carrying a BAC construct caused 
abrogation of hypoxia-induced Epo expression in the liver, but not in the kidney with 
consequent anemia at late embryonic and neonatal stages due to defective hepatic 
erythropoiesis. Interestingly, the mutant mice were able to recover from the severe anemia 
during childhood when Epo production switched from the liver to the kidney [282]. This work 
validated that the 3’ HRE is necessary and sufficient for both the liver-specific and hypoxia-
responsive Epo expression after E14.5 and demonstrated that the 3’ HRE is dispensable for 
Epo regulation in the kidney, suggesting the involvement of an additional HRE regulating 
renal Epo expression [282]. Intriguingly, a putative HRE consensus sequence, including the 
HBS and the CACA repeat, homologous to the HRE sequence of the well-known 3’ HRE 
within the LIE has been mapped by a DNase I hypersensitivity assays in nuclei of anemic 
kidneys at -9.2 kb from the TSS within the KIE. These findings support the hypothesis that an 
additional regulatory element must be present within the KIE to control hypoxia-inducible Epo 
gene expression in the kidney [261]. The first study performing a functional characterization 
of this novel HRE, termed 5’ HRE was executed by our group. We could, indeed, verify that 
the 5’ HRE mapped to 9248 bp upstream from the TSS and that includes the HBS 3’-
CACGT-5’ (reverse strand) followed after 8 bp by the CACA repeat, in a very similar way to 
the established 3’ HRE. Furthermore, we confirmed that this putative 5’ HRE is strongly 
conserved in multiple vertebrate species and its sequence overlaps with the same DNase I 
hypersensitive-site as mentioned above. Moreover, we could show that the 5’ HRE is 
functionally active in hypoxia in both Epo-producing and non Epo-producing cells by reporter 
gene assays and observed hypoxia-induced HIF-2α enrichment at the 5’ HRE whereas both 
HIF isoform were found to bind the 3’ HRE [279]. 
The current knowledge on Epo regulation is summarized in Figure 21. In case of limited 
oxygen supply, HIF-α isoforms are stabilized and translocate to the nucleus where they bind 
HIF-β at the HBS within the 3’ HRE and recruit p300/CBP coactivators and HNF-4α at the 
DR2 site. Upon binding, the HIFs/p300/CBP/HNF-4α complex interacts with the transcription 
factors bound at the EPO promoter (e.g. GATA-4) by “bridging” the 3’ HRE to the promoter 
element (Figure 21), enhancing Epo transcription in hypoxia up to 100-fold. While the 
oxygen-regulated functionality of the 5’ HRE has been shown through our previous reporter 
assays [279], its endogenous activity and role in Epo regulation in the kidney remains to be 
validated. Due to the lack of a renal cell line able to induce Epo expression in a hypoxia-






within the relevant renal context. However, the evaluation of its endogenous relevance and 
its role in relation to the well-established 3’ HRE and EPO promoter could be carried out in 
other Epo-producing cell lines originating from organs known to produce Epo during hypoxia 
like the brain. Especially, the neuroblastoma cell line Kelly, derived from sympathetic 
neuroblasts of the peripheral nervous system, has been reported to express Epo in an 
oxygen-dependent and HNF-4α independent manner, and has thus been proposed as a new 







Figure 21. Scheme displaying oxygen-regulated hepatic Epo transcriptional regulation. The 
violet squared box represents the novel 5’ HRE localized at -9.2 kb upstream the TSS in 
correspondence of a DNaseI HS and its endogenous role in regulating Epo in the kidney is a matter of 
debate. The preferential HIF-α isoform binding the liver-specific 3’ HRE is HIF-2α as previously 
demonstrated in vivo and in vitro [281]. From [279]. 
An additional layer of complexity regarding Epo regulation is the potential role that 
methylation might have on the EPO locus. Methylation of CpG sites within EPO promoter 
represses Epo expression as methyl CpG-binding proteins are recruited and interfere with 
other TFs or interact with histone deacetylases and corepressors. Moreover, it has been 
demonstrated that in Epo-producing cells the CpG site at Epo promoter are less methylated 
compared to non Epo-producing cells and the methylation status seemed to be partly 
hypoxia-regulated [284]. Methylation of the HBS within the 3’ HRE prevents HIF binding and 
inversely correlated with Epo expression in cell lines and tissues [253] [283]. Therefore, it 
seems that both a methylation-free HBS and hypoxic conditions are necessary to have HIF 
binding at the 3’ HRE followed by Epo induction. Interestingly, treatment of several cancer 
cell lines with the DNA methylation inhibitor 5’-aza-2’-deoxycytidine (Aza) restored hypoxic 
Epo expression in neuroblastoma but not in Hep3B cells where likely the EPO locus is de-
methylated having then the chromatin in an “open status” ready to be transcribed [285]. In 
line with the results obtained in neuroblastoma cells, a recent work reported that Epo 
expression in kidney myofibroblast was recovered after treatment with low nontoxic doses of 






Finally, methylation affects tissue-specific Epo expression by repressing or silencing the EPO 
locus and is thus an important aspect of Epo regulation that deserves further investigation.  
1.7.3 HIF/PHD isoforms regulating Epo 
 
In situ hybridization studies performed by Rosenberger et al. analyzed the expression pattern 
of HIF-1α and HIF-2α in hypoxic rat kidneys, demonstrating that HIF-2α isoform is the only 
isoform localized in Epo producing peritubular fibroblasts. This finding demonstrated a role 
for HIF-2α in renal Epo regulation in line with in vivo studies where postnatal global removal 
of HIF-2α but not HIF-1α, resulted in anemia treatable with recombinant Epo. Further 
evidence supporting a role of HIF-2α in Epo regulation came from hepatic HIF-2α knock-out 
mouse models developing postnatal anemia that resolved in adulthood when the kidney 
replaced the liver in producing Epo; overexpression of HIF-2α but not HIF-1α led to 
erythrocytosis. Also a liver-specific VHL knock-out resulted in polycythemia that was rescued 
only by deleting HIF-2α but not HIF-1α. Moreover, by RNA interference, Warnecke et al. 
down-regulated HIF-1α or HIF-2α in Hep3B and Kelly cells and observed a significant 
decrease in Epo levels only when HIF-2α but not HIF-1α was silenced, confirming that Epo is 
a HIF-2α target gene in both hepatoma and neuroblastoma cell lines. Interestingly, mutations 
identified in human EPAS1 cause hereditary erythrocytosis while no mutations in HIF1A or 
HIF3A causing a similar phenotype have been reported.  
The cross-talk between iron metabolism and HIF-2α, demonstrated by the fact that genes 
involved in iron metabolism such as DMT-1 (divalent metal transporter 1) and DcytB 
(duodenal cytochrome b) are HIF-2α target genes, supports a major role of HIF-2α in Epo 
regulation. Genome wide association studies (GWAS) comparing lowlanders to highlanders 
found polymorphisms in the EPAS1 and EGLN1 associated with RBC mass, validating the 
association of HIF-2α as well as PHD2 with Epo regulation. In fact, among the PHD isoforms, 
inducible knock-out models only for PHD2 showed increased Epo levels, polycythemia and 
angiogenesis, indicating PHD2 as the enzyme that predominantly regulating HIF-2α stability 
upstream of Epo transcription. Finally, mutations in the gene encoding for PHD2 (EGLN1) 
but not in the gene encoding for PHD1 (EGLN2) or PHD3 (EGLN3) have been identified in 
families affected by congenital erythrocytosis, further confirming the crucial role of PHD2 in 
regulating Epo expression. Taken together, the above findings suggest that pVHL/HIF-







1.8 Pathophysiology of Epo 
 
The physiological regulation of erythropoietin is crucial to maintain correct Epo levels within 
the body. In fact, the dysregulation of Epo production causes pathological conditions such as 
erythrocytosis (or polycythemia) and anemia. While erythrocytosis occurs in case of Epo 
overproduction, anemia occurs when Epo is insufficiently produced. Besides erythrocytosis 
and anemia, injuries or medical procedures damaging the kidney can impair Epo production. 
An example is the kidney allotransplantation, which has been used in earlier times to treat 
anemia by restoring Epo production and, then, replaced by rhEpo treatment [21]. 
Erythrocytosis can be classified as primary, if the defects are related to the hematopoietic 
progenitors leading to excessive RBC synthesis, or secondary, when the impairment of Epo 
production causes increased RBC synthesis. Erythrocytosis can be acquired or congenital 
[287]. The most common form is called polycythemia vera, a primary acquired disease, 
whereas the rarest is a primary congenital form due to mutations in EpoR resulting in 
constant activation of the erythropoietic pathway that leads to exaggerated RBC formation 
[288]. Conditions that cause an increase in Epo levels lead to acquired secondary 
erythrocytosis: use of Epo-stimulating agents, tissue hypoxia due to different aetiology (e.g. 
cardiovascular disease, tumor), exposure to high altitude, chronic lung disease, carbon 
monoxide poisoning, smoking and kidney transplantation [289]. Secondary congenital 
erythrocytosis is instead due to inherited mutations in genes involved in oxygen sensing and 
transport. Mutations altering the bisphosphoglycerate mutase synthetizing 2,3-DPG, the 
haemoglobin gene or the pVHL/HIF-2α/PHD2 axis influencing EPO transcription have been 
reported in families affected by erythrocytosis [290]. The main symptoms of erythrocytosis 
include increased blood viscosity caused by high RBC mass causing fatigue, abdominal 
pain, headache and blurred vision. High blood viscosity raises the risk for thrombosis. The 
therapy against thrombosis consists in venesection to remove surgically the excessive RBC 
mass from the vein or the administration of anti-coagulants like aspirin, depending on the 
clinical case [289]. Curiously, homozygous R200W mutation in VHL causes an autosomal 
recessive form of polycythemia, termed “Chuvash polycythemia” so called as found for the 
first time in the Russian region Chuvash. Such mutation impairs the binding of pVHL to 
hydroxylated HIF-α isoforms, enhancing HIF stabilization. Surprisingly, despite having a 
defective VHL, the Chuvash polycythemia does not lead to cancer malignancy [291].  
Interestingly, a missense mutation (G269A substitution) in the BPGM gene encoding for 
bisphosphoglycerate mutase (responsible for the synthesis of 2,3-BPG from 1,3-BPG) has 






resulting in a leftward shift in the hemoglobin-oxygen dissociation curve and increase in O2 
affinity. [292]. 
Anemia is the most common haematological disorder due to reduced haemoglobin content of 
the blood (Hb < 13g/dL in men and <12g/dL in women). Anemia can be caused by several 
defects which are mainly grouped in two main categories: the amount of newly produced 
erythrocytes is inadequate to meet the oxygen demand of the tissues or the number of RBC 
is sufficient but the erythrocytes are not functional (e.g. sickle-cell anemia). Therefore, the 
primary symptom is insufficient delivery of oxygen to the periphery leading to pallor, fatigue 
and dyspnea. Anemia can be provoked as secondary pathology by nutritional deficiencies 
(iron or vitamin B12), acute or chronic blood loss, haemoglobinopathy, caused by mutations 
within the Hb-gene rendering oxygen transport inefficient, bone marrow failure and renal 
failure [293].  
Renal failure occurring for example in chronic kidney disease (CKD) leads to impaired Epo 
synthesis due to destruction of the renal architecture. CKD is a pathological condition caused 
by genetic and environmental factors such as hypertension, diabetes, age, obesity and 
smoking that increase the cardiovascular risk and ultimately renal failure. In fact, high blood 
pressure or toxic substances challenge the kidney in filtering the blood damaging the 
nephrons. In addition, infections or auto-immune disease can provoke kidney injury due to 
inflammation and fibrosis that eventually progresses to CKD. Renal damage is diagnosed by 
decreased glomerular filtration rate (GFR) and proteinuria. Patients at the last stage of CKD 
need dialysis, hemofiltration or transplantation to survive. Anemia is a complication of CKD 
that arises from renal dysfunction causing incorrect Epo production and erythropoiesis [294]. 
Consistently, Epo levels are blunted and do not respond appropriately to the anemic stimulus 
[295]. However, CKD patients are still able to produce Epo when exposed to hypoxia [296], 
while anemic patients require less doses of rhEpo when residing at high altitude as they 
respond more efficiently to the rhEpo treatment, probably due to increased endogenous Epo 
production [297]. The reason why Epo production is inappropriately low in diseased kidneys 
remains not fully understood. The current hypothesis suggests that during renal failure 
oxygen consumption decreases causing higher tissue pO2 that impede REP cells to reach 
the hypoxic threshold required to induce Epo [133]. Of note, in CKD inflammatory cytokines 
such as TNFα, known to inhibit Epo synthesis [298], trigger the transformation of REP cells 
to myofibroblasts, which loose the capability of producing Epo and, therefore, are considered 
the link between fibrosis and anemia. Intriguingly, a short-term reversible UUO model 
demonstrates that transformed myofibroblasts re-acquire after 12 days  their physiological 






plasticity, which awaits further molecular characterization but opens new possibilities in 
treating CKD by protecting or regenerating REP cells via epigenetical modifications [152].  
Finally, given the recent insights into the oxygen sensing mechanism, a new strategy in 
treating CKD based on small and cheap molecules analogous of 2-oxoglutarate has been 
developed. Such compounds, termed PHD inhibitors, compete with 2-oxoglutarate in binding 
the active site of the PHD enzymes, leading to increased activation of the HIF pathway and 
Epo transcription. Because the HIF pathway regulates the transcription of hundreds of 
genes, it is crucial to target specifically the PHD isoform that hydroxylates distinct HIF-α 
subunits regulating the gene of interest to avoid pleiotropic effects. As mentioned above, 
PHD2 is the PHD isoform that predominantly hydroxylates HIF-2α which drives the 
transcriptional activation of erythropoietin in both adult liver and kidney [299]. Therefore, the 
actual approach to treat renal anemia is the use of PHD2 inhibitors that showed efficient 
effects in vitro and proved to be beneficial in vivo as they ameliorated several diseases such 
as tissue ischemia, kidney injury and transplantation [300] [301]. The most advanced clinical 
studies (Phase III trials) use roxadustat (FG-4592) to correct renal anemia. Moreover, 
roxadustat reduces the hepcidin levels leading to higher iron availability as iron export (from 
the gut to the hepatic portal system), normally inhibited by hepcidin, becomes less 
constrained, and iron absorption increases to sustain RBC formation. Currently, clinical 
studies are examining the long-term cardiovascular outcomes and possible side effects of 
roxadustat [302]. In conclusion, despite roxadustat seems to be a promising drug for the 
treatment of renal anemia in CKD, its molecular mechanism and the repercussions of HIF-2α 
stabilization on other HIF-2α target genes need further investigations to figure out the risks 
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2. Aims of the thesis   
 
The availability of hepatoma and neuroblastoma cell lines helped to gain new insights into 
Epo regulation, whereas a reliable cell culture model derived from renal Epo-producing 
(REP) cells is currently lacking. While hepatic Epo expression is known to be regulated by 
the 3' HRE, the regulatory elements modulating Epo transcriptional activation in brain and 
kidney remain unknown. A kidney inducible region (KIE) located between -14 and -6 kb from 
TSS of EPO has been shown to be responsible for hypoxic-inducible renal Epo. Within this 
KIE, we previously identified a novel 5' HRE having similar features to the 3’ HRE and could 
show that both HREs direct exogenous reporter gene expression. However, the functional 
relevance of this HRE for endogenous Epo induction remained unknown. 
In this PhD work, I aim for the investigation of the transcriptional regulation of Epo in hypoxia. 
In particular, I am interested in:  
I. Dissecting the contribution of the endogenous distal 5' and 3' HREs as well as the 
promoter to endogenous EPO gene expression in hepatoma and neuroblastoma cell 
lines.  
II. Generating a novel transgenic mouse model to conditionally tag for active Epo locus 
and isolate fresh renal Epo producing cells.  
III. Detecting Epo mRNA at single cell level by highly specific and sensitive in situ 
hybridization method (RNA scope) to analyse cell-to-cell variability of the "hypoxic 
transcript pattern", defined as the cellular distribution of HIF induced single nascent 
and mature mRNA molecules in hepatoma, neuroblastoma and FAIK cell line.




3. Distal and proximal hypoxia response elements cooperate to regulate organ-
specific erythropoietin gene expression  
 
Ilaria M. C. Orlando1,2, Véronique N. Lafleur3, Federica Storti1,2, Patrick Spielmann1,2, Lisa 
Crowther1,2, Sara Santambrogio1,2, Johannes Schödel4, David Hoogewijs2,5, David R. Mole3, 
and Roland H. Wenger1,2,*  
 
1 Institute of Physiology, University of Zürich, CH-8057 Zürich, Switzerland 
2 National Center of Competence in Research “Kidney.CH”, Switzerland 
3 NDM Research Building, University of Oxford, OX1 7FZ, United Kingdom 
4 Department of Nephrology and Hypertension, Friedrich-Alexander-University Erlangen-Nuremberg, 
D-91054 Erlangen, Germany 








Roland H. Wenger, 
Institute of Physiology, 
University of Zürich, 
Winterthurerstrasse 190, 
CH-8057 Zürich, Switzerland. 
E-mail:  roland.wenger@access.uzh.ch 
Tel: +41 44 6355065; 









While it is well-established that distal hypoxia response elements (HREs) regulate hypoxia-
inducible factor (HIF) target genes such as erythropoietin (Epo), an interplay between 
multiple distal and proximal (promoter) HREs has not been described so far. Hepatic Epo 
expression is regulated by a HRE located downstream of the EPO gene, but this 3' HRE is 
dispensable for renal EPO gene expression. We previously identified a 5' HRE and could 
show that both HREs direct exogenous reporter gene expression. Here, we show that 
whereas in hepatic cells the 3' but not the 5' HRE is required, in neuronal cells both the 5' 
and 3' HREs contribute to endogenous Epo induction. Moreover, two novel putative HREs 
were identified in the EPO promoter. In hepatoma cells HIF interacted mainly with the distal 
3' HRE, but in neuronal cells HIF most strongly bound the promoter, to a lesser extent the 3' 
HRE, and not at all the 5' HRE. Interestingly, mutation of either of the two distal HREs 
abrogated HIF binding to the 3' and promoter HREs. These results suggest that a canonical 
functional HRE can recruit multiple, not necessarily HIF, transcription factors to mediate HIF 
binding to different distant HREs in an organ-specific manner. 
 
Article Summary  
Hypoxia-inducible EPO gene expression is regulated by a 3' HRE in the liver but this element 
is not required for EPO induction in other organs and the DNA elements required for EPO 
regulation remained elusive. Using CRISPR-Cas9 mediated gene editing we could 
demonstrate that a novel 5' HRE - despite not binding HIF - functionally cooperates with the 
3' HRE and newly discovered promoter HREs to direct inducible and organ-specific EPO 
gene expression.  
 
INTRODUCTION 
Erythropoietin (Epo) is indispensable for the maintenance of a normal blood oxygen 
concentration and Epo synthesis is induced under anemic and hypoxic conditions (1,2). In 
the adult, Epo production by the kidney and liver account for approx. 90% and 10%, 
respectively, of total circulating Epo, but ectopic Epo expression was also found in the brain, 
uterus and testis, among others (3-6). Renal Epo is synthesized by peritubular pericytes with 
fibroblastic and neuronal features, located in the juxtamedullary cortex (7-9). These cells 
respond to a decrease in tissue oxygen partial pressure by hypoxia-inducible factor (HIF)-
stabilization and HIF-2-dependent transcriptional induction of EPO gene expression (10). 
HIFs bind to a hypoxia response element (HRE) containing the essential core consensus 
sequence 5'-RCGTG-3' which, however, is not sufficient to confer hypoxia-inducible gene 
expression (11). Distinct regulatory DNA elements enhance EPO promoter activity in liver 
and kidney. Transgenic mouse models showed that in the liver 0.7 kb of the immediate 3'-




flanking region is required, whereas in the kidney the essential regulatory element resides 
between -14 and -6 kb in the distal 5'-region (12-15). The 3' HRE is well established and has 
been shown to be necessary and sufficient for liver-specific EPO gene expression after 
embryonic day 14.5 (16,17). However, the DNA element responsible for kidney-specific EPO 
gene expression is far less well characterized and nothing is known about the endogenous 
HREs in Epo-producing cells of other tissues.  
 We recently discovered a strongly conserved distal 5' HRE and suggested that it might 
contribute to oxygen-regulated EPO expression (18). This 5' HRE resides within a DNaseI 
hypersensitive site -9.2 kb upstream of the EPO transcriptional start site, contains both the 
5'-ACGTG-3' core HIF DNA binding site as well as the ancillary 5'-CACA-3' element (11), and 
confers hypoxia-inducible exogenous reporter gene expression in Epo expressing and non-
expressing cell lines (18). However, the organ-specific relevance of the endogenous 5' and 3' 
HREs as well as their functional interaction with the EPO promoter remained unknown. 
Considering the neuronal features that we and others reported for the renal Epo-producing 
cells (8,9), we hence analyzed the relative contribution of the 5' and 3' HREs in Kelly cells, a 
human neuroblastoma cell line that has previously been shown to regulate the EPO gene in 
an oxygen and HIF dependent manner (19). Endogenous HRE function was investigated by 
gene editing and HIF-DNA interaction studies. Intriguingly, novel promoter HREs were 
identified and profound differences in the functional cooperation between the 5', 3' and 
promoter HREs in Kelly cells were found when compared with the well-established human 
Hep3B hepatoma cell model (20). 
 
MATERIALS AND METHODS 
Cell culture 
Human Hep3B and HepG2 hepatocellular carcinoma (American Type Culture Collection, 
LGC Standards, Wesel, Germany) and Kelly neuroblastoma (kindly provided by J. Fandrey, 
Essen, Germany) cell lines were cultured in high glucose Dulbecco's modified Eagle's 
medium (DMEM) and RPMI-1640 medium, respectively (Sigma Aldrich, Saint Louis, MO, 
USA), supplemented with 10% heat-inactivated fetal bovine serum (FBS) (Thermo Fisher 
Scientific, Waltham, MA USA), 50 IU/ml penicillin and 50 μg/ml streptomycin (Sigma Aldrich, 
Saint Louis, MO, USA). Cells were exposed to hypoxic conditions using a workstation as 
described previously (21). 
 
Gene editing 
Clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated 9 
(Cas9) gene editing was performed as described (22) and is described in details in the 
Supplementary Methods. 




RNA and protein analyses 
RNA was extracted and quantified by reverse-transcription (RT) real-time quantitative (q) 
PCR as described previously (21,25). In brief, RT was performed with 2 μg total RNA and 
AffinityScript reverse transcriptase (Agilent), and the cDNA quantified using SYBR Green 
qPCR reagent kit (Kapa Biosystems, London, UK) in a MX3000P light cycler (Agilent). 
Transcripts levels were calculated through comparison with calibrated standard curves and 
normalized to human ribosomal protein L28 mRNA. Primers used for RT-qPCR are listed in 
Supplementary Table 1. Epo protein was detected by ELISA according to the manufacturer's 
protocol (R&D Systems, Minneapolis, MN, USA). Immunoblotting was performed as 
described previously (21) using the following primary antibodies: mouse monoclonal anti-
HIF-1α (#610959; BD Transduction Laboratories, San Jose, CA, USA), rabbit monoclonal 
anti-HIF-2α (#PAB12124; Abnova, Taipei, Taiwan), mouse monoclonal anti-HIF-α (D28F3; 
Cell Signaling Technology, Danvers, MA, USA), mouse monoclonal anti-β-actin (A5441; 
Sigma Aldrich). Secondary antibodies were HRP-conjugated goat polyclonal anti-rabbit or 
anti-mouse IgG (#31460 and #31430, respectively; Thermo Fisher Scientific). 
 
Luciferase reporter gene assays 
Reporter gene constructs have been described previously (18). Canonical 5'-RCGTG-3' 
promoter HREs were replaced by 5'-RAAAG-3' using site-directed mutagenesis. Following 
transfection with lipofectamine, cells were incubated under normoxic or hypoxic (0.2% O2) 
conditions for 24 hours. Reporter gene assays were performed as described before (21) 
using a luciferase assay kit (Promega, Madison, Wisconsin, USA). Luciferase activity was 
normalized to the protein content as determined by the Bradford assay (26).  
 
HIF chromatin immunoprecipitation 
Chromatin immunoprecipitation (ChIP) experiments were performed as described previously 
(21,27,28), using the following rabbit polyclonal antibodies: anti-HIF-1α (PM14), anti-HIF-2α 
(PM9), anti-HIF-β (NB100-110; Novus Biologicals, Littleton, CO, USA), normal rabbit serum 
(X0902; Dako, Glostrup, Denmark). Co-precipitated DNA was quantified by real-time qPCR 
using the primers listed in Supplementary Table 1.  
 
Statistical analysis 
All data are shown as mean + SEM. Unpaired two-tailed Student's t-tests were applied. 









Mutation of the EPO 5' and 3' HREs by gene editing 
CRISPR-Cas9 technology was used for the specific destruction of the endogenous EPO 
HREs to dissect the relative contribution of the -9.2 kb 5' HRE and the +3.0 kb 3' HRE to 
hypoxia-inducible EPO gene expression in neuronal and hepatic cell lines (Figure 1A). As 
shown in Figure 1B, sgRNAs were designed to target the HIF-binding core sequence 5'-
ACGTG-3' (11). The restriction enzyme TaiI was used to assess the presence of the 5'-
ACGT-3' sequence (24). Successful HRE destruction confers TaiI resistance to the PCR 
products as exemplified for Kelly cells in Figures 1C and D. Monoclonal cell lines were 
obtained by limiting dilution cloning of initial partially gene edited polyclonal cell pools. The 
HRE regions were again amplified by PCR, re-tested for complete TaiI resistance, and 
cloned into plasmid vectors. Multiple independent plasmids were sequenced to ensure 
biallelic HRE inactivation. Alternatively, amplicons were directly deep sequenced. Clone 
verification and sequence information is provided in Supplementary Figure 1. Note that in 
some cases (Kelly-3'B2, Hep3B-5'H11) more than two mutant alleles were detected which 
may be due to either polyclonal cell lines, polyploidy, gene amplification or genetic drift. 
Other clones maintained wild-type HRE sequences (Kelly-5'C4, Kelly-3'C4, Hep3B-5'A5, 
HepG2-5'H8, HepG2-3'D6; confirmed by sequencing of PCR products) and were included as 
additional controls in subsequent experiments.  
 
The 5' HRE contributes to hypoxic EPO induction in neuronal but not hepatic cells 
The neuroblastoma cell line Kelly has been reported to induce endogenous Epo mRNA 
levels, at 24 hours, by over 71-fold under hypoxic conditions (3% O2) and over 238-fold 
under anoxic conditions (19). Kelly cells hence recapitulate the well-known hypoxia-inducible 
EPO gene expression in the brain (4). As shown in Figure 2, Epo mRNA and secreted 
protein were induced by 1603-fold and 22-fold, respectively, following exposure of wild-type 
Kelly cells to hypoxia (0.2% O2) for 24 hours. However, due to the very low basal Epo 
transcript levels, the fold induction factor is subject to variation and must be interpreted with 
caution. Indeed, the wild-type HRE subclones Kelly-5'C4 and Kelly-3'C4 showed reduced 
Epo mRNA induction, while the hypoxic Epo mRNA levels were not significantly different 
from the maternal Kelly cells (Figure 2A). These results were confirmed on the protein level 
where the normoxic levels also varied greatly but the hypoxic levels were indistinguishable 
from the maternal cell line (Figure 2B). Therefore, only hypoxic Epo levels were considered 
for subsequent analyses. 
 Interestingly, all mutant 5' and 3' HRE Kelly clones showed significantly reduced 
hypoxic Epo expression, on the mRNA (Figure 2A) as well as on the protein (Figure 2B) 
level. This is in striking contrast to mutant Hep3B (Figure 2C, D) and HepG2 (Figure 2E) 




clones, where only 3' but not 5' HRE mutations strongly reduced hypoxic Epo mRNA and 
protein levels. Note that while Kelly and Hep3B cells were exposed to hypoxia for 24 hours, 
HepG2 cells showed maximal Epo mRNA induction already after 8 hours, with approx. 10-
fold lower mRNA levels, which was not sufficient for detectable Epo protein accumulation in 
the supernatant. To ensure that no general off-target effects caused these results, the mRNA 
levels of the HIF-1 and HIF-2 target genes CAIX and LOXL2 (Kelly) or PAI1 (Hep3B and 
HepG2), respectively (29), were measured in the same samples. As shown in 
Supplementary Figure 2, EPO HRE mutations did not significantly reduce the expression of 
these genes under hypoxic conditions. Moreover, also hypoxic HIF-1α and HIF-2α protein 
stabilization was not altered by the EPO HRE mutations (Supplementary Figure 3). These 
results suggest that both the 5' and 3' HREs contribute to hypoxia-inducible EPO gene 
expression in neuronal cells whereas in hepatic cells only the 3' HRE is required.  
 
The 5' and 3' EPO HREs cooperatively enhance hypoxic reporter gene expression in 
neuronal cells 
We had previously shown that the EPO 5' HRE confers hypoxia-inducible expression to a 
heterologous SV40 promoter-driven reporter gene in both Hep3B and Kelly cells (18). These 
results stand in apparent contrast to the 5' HRE mutation data presented above and imply 
differences between exogenous bacterial reporter gene plasmids and endogenous chromatin 
regulation. In fact, similar reporter gene results have been obtained even in non-Epo-
expressing HeLa and HK-2 cells (18) as well as in Hek293 cells (data not shown). We hence 
expanded these experiments by transiently transfecting Kelly cells with minimal (138 bp) 
EPO promoter-driven reporter genes, enhanced by various DNA fragments containing the 5' 
and/or 3' HREs. In contrast to our previous results obtained with Hep3B cells (18), EPO 
promoter-driven luciferase activity in Kelly cells was significantly further elevated if the 100 
bp fragment containing the 5' HRE was combined with a 126 bp fragment containing the 3' 
HRE (Figure 3A). While a longer 3 kb DNA fragment containing the 5' HRE reduced both 
hypoxic and normoxic reporter gene expression driven by the EPO promoter/3' HRE, it 
actually led to even higher hypoxic induction factors. These data imply a cooperation 
between the EPO 5' and 3' HREs specifically in neuronal cells, and suggest that additional 
distal and proximal 5' flanking elements contribute to tissue-specific and conditional EPO 
regulation. 
 
A novel EPO promoter HRE contributes to hypoxic reporter gene expression in 
neuronal cells 
Interestingly, a slight but significant hypoxic induction of the minimal EPO promoter could be 
seen in Kelly cells (Figure 3A) which we previously did not observe in Hep3B cells (18). 




Inspection of the 147 bp fragment containing the 138 bp EPO promoter revealed a tandem 
dimeric repeat with two previously not reported putative HREs (Figure 3B). These putative 
HREs are highly conserved and locate close to Wt1 and GATA binding sites (Supplementary 
Figure 4). In combination with the 5' and 3' HRE enhancers, luciferase expression driven by 
this promoter fragment was induced 152-fold by hypoxia in this experimental series. Mutation 
of either promoter HRE 1 (pHRE1) or pHRE2 significantly reduced hypoxic luciferase 
expression levels, whereas the effect on the hypoxic induction factors was less conclusive 
(Figure 3C). Double pHRE1 and pHRE2 mutation did not further decrease reporter gene 
expression, suggesting that this tandem dimeric sequence in the EPO promoter acts as a 
single HRE. 
 
HIF interacts with the EPO promoter and 3' HRE but not 5' HRE in neuronal cells 
To directly analyze the interaction of HIF with the various HREs of the endogenous EPO 
locus, chromatin immunoprecipitation followed by real-time PCR quantification (ChIP-qPCR) 
experiments were performed. Because of the contribution of the promoter to the hypoxic 
activation of reporter gene expression observed above, we also included the proximal 5' 
region in these ChIP-qPCR experiments (Figure 4A). Unexpectedly, Kelly cells did not show 
any significant binding of the HIF subunits HIF-1α, HIF-2α or HIF-β to the 5' HRE, whereas a 
significant hypoxic increase in HIF-2α /HIF-β binding to the 3' HRE could be detected (Figure 
4B). Surprisingly, however, the strongest HIF interaction in hypoxic Kelly cells was observed 
with the EPO promoter region, again with a preference for HIF-2α /HIF-β. In contrast, in 
hypoxic Hep3B cells the strongest HIF-2α/HIF-β interaction was found at the 3' HRE and only 
a weak interaction with the promoter region could be observed (Figure 4C). To control for 
ChIP efficiency, the presence of DNA fragments containing the HRE of the HIF-1/2 target 
genes NDRG1 and PAI1 (21,27) was quantified by qPCR in the same samples. HIF binding 
to the established NDRG1 and PAI1 promoter HREs was comparable to the Epo HREs, and 
anti-HIF-β antibodies precipitated roughly additive amounts of chromatin seen with the HIF-
1α and HIF-2α antibodies (Figures 4B, C). 
 
Functional distal 3' and 5' HREs are required for remote control of HIF binding to the 
EPO promoter 
Because ChIP resolution is insufficient to detect the precise protein-DNA interaction site, we 
next wanted to confirm that HIF actually bound the core sequence of the investigated HREs. 
Therefore, Hep3B 3' and 5' mutant HRE subclones were exposed to hypoxia and used for 
ChIP with anti-HIF-β antibodies to precipitate both HIF-1 and HIF-2. As expected, HIF bound 
the wild-type 3' HRE but did not interact anymore with the mutant 3' HRE (Figure 4D). Of 
note, the 3' HRE mutation apparently also decreased the weak HIF interaction with the EPO 




promoter region. Consistent with its non-functionality in Hep3B cells, mutation of the 5' HRE 
did not influence HIF binding to any of the tested HREs (Figure 4D). HIF-β binding to the 
PAI1 control HRE (Figure 4D) as well as HIF-β protein levels (Figure 4E) were not altered in 
these Hep3B subclones, confirming that HIF-β expression is not generally affected by the 3' 
and 5' HRE mutations and that HIF-β ChIP reliably detects HIF-DNA interactions. 
 To further investigate the unexpected inhibitory effect of the distal 3' HRE mutation on 
the HIF interaction with the proximal EPO promoter region in Hep3B cells, these experiments 
were repeated with Kelly 3' and 5' mutant HRE subclones. Intriguingly, the 3' HRE mutation 
(clone B2) not only completely abrogated the interaction between HIF and the 3' HRE, but 
also strongly decreased the interaction with the promoter region (Figure 5A). Moreover, the 5' 
HRE mutation (clone C3) similarly impaired HIF interaction with the 3' HRE and the promoter 
region (Figure 5A), while comparable HIF binding to the NDRG1 control HRE (Figure 5B) 
and HIF-β protein levels (Figure 5C) could be detected in these mutant Kelly subclones.  
 
Large but not small deletions of the 5' HRE abrogate Epo induction in 3'/5' HRE 
double-mutant neuronal cells 
Because there was residual HIF binding to the EPO promoter in the single 3' and 5' HRE 
mutant Kelly subclones, we wondered whether 3'/5' HRE double mutations would lead to a 
further decrease of the HIF interaction with the EPO promoter. The introduction of a 
secondary mutation was rather inefficient and worked only in the B2 3' HRE mutant Kelly 
subclone. Deep sequencing of the PCR products derived from the mutant 5' HRE revealed 3 
subclones with large (31 bp and 18 bp; varying ratios) and 3 subclones with small (1, 2 or 3 
bp; biallelic) deletions (Supplementary Figure 5A). Despite some reduction in CAIX mRNA 
and HIF-1α protein in the subclones containing the larger deletions, the double-mutant 
subclones did not show major general differences in mRNA levels of the HIF target genes 
CAIX and LOXL2, or in hypoxic HIF-1α and HIF-2α protein levels (Supplementary Figures 
5B-E).  
 In hypoxic Kelly cells, only the larger but not the smaller 5' HRE deletions further 
decreased HIF binding to the EPO promoter in the 3'/5' HRE double-mutant subclones 
(Figure 5A). The small core 5' HRE mutations partly reversed the inhibitory effect of the 3' 
HRE mutation on HIF promoter interaction. HIF-β binding to the NDRG1 control HRE (Figure 
5B) as well as HIF-β protein levels (Figure 5C) remained at similar levels, confirming that 
HIF-β expression is not generally affected in these Kelly subclones, and that HIF-β ChIP 
reliably detects HIF-DNA interactions. Consistent with the ChIP data, the additional larger or 
smaller 5' HRE deletions further decreased or partly reversed, respectively, Epo mRNA 
(Figure 5D) and protein (Figure 5E) levels in hypoxic 3' HRE mutant Kelly cells.  
 





The data presented reveal a complex and organ-specific interplay between various HREs at 
the EPO locus. The previously described mechanisms of EPO regulation in hepatic cells 
were mostly confirmed by our experiments, including a strong functional dependence on the 
endogenous 3' HRE with a robust HIF interaction, and a complete lack of requirement for the 
endogenous 5' HRE despite a strong hypoxic enhancer function in exogenous reporter gene 
experiments. In neuronal cells, the endogenous 5' HRE seems to be as important as the 3' 
HRE for hypoxic induction of EPO gene expression and the 5' and 3' HREs cooperate in 
hypoxic enhancement of exogenous reporter gene expression, but the 5' HRE does not 
directly interact with HIF. In contrast to hepatic cells, where the EPO promoter is only slightly 
bound by HIF and does not confer hypoxic reporter gene induction (18), in neuronal cells it is 
the EPO promoter that most strongly interacts with HIF, consistent with a weak hypoxic 
induction of reporter genes. EPO minimal promoter fragments spanning at least -91 bp 
upstream of the transcriptional start site have previously been shown to be hypoxia 
responsive in reporter gene experiments also in Hep3B cells (30,31).  
 It is currently unclear why we repeatedly found significant hypoxic promoter induction 
only in Kelly but not Hep3B cells. Inspection of the minimal EPO promoter region revealed 
two potential HREs characterized by the presence of evolutionary conserved HIF core 5'-
GCGTG-3' binding motifs. Mutation of either of these two HREs in Kelly cells reduced both 
basal and hypoxia-inducible promoter activity enhanced by the 5' and 3' HREs. Tissue-
specific transcriptional co-activators and/or co-repressors may be involved in the difference 
in hypoxic promoter activity and HIF binding between hepatic and neuronal cells. Indeed, a 
cooperative interaction with additional transcription factors binding in close proximity to HIF is 
typical for HREs and has also been found in other HIF target genes (21). Specifically, while 
the ancillary 5'-CACA-3' element (11) is missing, its supportive function may be replaced by 
the neighbouring DNA binding sites for GATA factors and Wilms tumor suppressor (Wt1), 
which are well-known to regulate the EPO promoter (32-35). Alternatively, it is possible that 
binding of HIF to the promoter and/or transcriptional activation may be blocked by binding of 
a currently unknown tissue-specific factor in Hep3B cells. Of note, we have previously shown 
that ATF/CREB family members are able to directly interact with the HRE core motif (36), 
and it may be that such an interaction also occurs at the promoter HREs. 
 How could it be explained that a conserved HRE consensus core sequence, including 
the ancillary element, is functionally relevant for hypoxic induction of gene expression but not 
directly bound by HIF, as it appears to be the case for the EPO 5' HRE? We have previously 
shown for PAG1, another HIF-2 target gene, that a single distal -82 kb 5' HRE resides in an 
isolated DNA region, bound by many additional transcription factors, and forms multiple 
chromatin loops both locally and over a long distance with the promoter region (21). While in 




this case HIF-2α did interact with the HRE, neither hypoxia nor the presence of HIF was 
needed for the long-range chromatin interaction with the promoter region. Only the presence 
of the core 5'-ACGTG-3' HIF binding DNA sequence was required to maintain this 
interaction, suggesting that pre-formed chromatin loops enable oxygen-regulated conditional 
gene regulation. This model has subsequently been confirmed for many other HIF target 
genes by genome-wide approaches (37,38). Therefore, the EPO 5' HRE might well be 
functionally required for hypoxia-inducible gene expression by maintaining a constitutive 
chromatin architecture that supports promoter activity in a cell type-specific manner. The 
finding that only additional large but not small 5' HRE deletions fully abrogated endogenous 
Epo induction and HIF:promoter interaction in 3' HRE mutant Kelly cells suggests that, like in 
the case of the PAG1 gene, additional transcription factors bind close to the consensus HRE 
sequence and are involved in chromatin looping and trans-activation of the EPO promoter. 
We have currently no explanation why a small 5' HRE deletion alone inhibited HIF:promoter 
interaction, but in combination with a 3' HRE mutation partially rescued the inhibitory effect of 
the 3' HRE mutation. Nonetheless, it is without precedent that the extended 5' HRE strongly 
cis-enhanced HIF binding to the promoter and 3' HREs.  
 The differences between Epo-producing hepatic and neuronal cells raise the question 
of how EPO is regulated in renal Epo-producing (REP) cells, the main source of circulating 
Epo. The overlap of neuronal markers with genetically tagged mouse REP cells (8,9) 
suggests that Kelly cells may represent a better model than hepatoma cells to recapitulate 
human oxygen-regulated EPO gene expression in the kidney, at least concerning the 
enigmatic 5' regulatory regions. Indeed, deletion of the endogenous 3' HRE in the mouse 
suppressed only hepatic but not renal Epo expression, suggesting the presence of one or 
more additonal HREs in REP cells (17). Consistently, deletion of a -17.4 to -3.6 Epo 5' region 
in transgenic mouse models abrogated Epo gene expression specifically in REP cells 
whereas it was dispensable for Epo expression in the brain (31). Mutation of the mouse -8.3 
kb 5' HRE (corresponds to the human -9.2 kb 5' HRE) within this Epo 5' region, did not 
abrogate transgenic Epo gene expression in the kidney (brain was not analyzed) and a 
minimal 0.3 kb fragment containing this 5' HRE was not sufficient to drive transgenic GFP 
expression in the mouse kidney (31). Our results on the cooperation between 5', 3' and 
promoter HREs in neuronal and hepatic cell lines may help to explain these findings in 
transgenic mice: while the deletion of the 3' HRE in the liver is sufficient to abrogate hypoxic 
Epo expression, only the combined deletion of the extended 5' and the minimal 3' (and 
maybe the promoter) HREs may affect Epo expression in the kidney. 
 Altogether, these results demonstrate that several HREs are involved in oxygen-
regulated EPO gene expression. While in the liver the 3' HRE is both necessary and 
sufficient, in the kidney the 3' HRE is dispensable and a 5' HRE acts in concert with 




additional long-range enhancer elements and probably local chromatin structure. Although 
transgenic mouse models are still lacking, our results suggest that in the brain, both of these 
distal HREs functionally cooperate with HIF binding to promoter HREs. Our results further 
illustrate that not all HREs act in a canonical way by directly binding HIF, and that HRE-
promoter cooperations in oxygen-regulated gene expression need to be analyzed in a cell 
type-specific context and cannot be generalized based on the results obtained with a single 
cell line. Similar results have recently been reported for the MALAT1 locus, expressing a 
lncRNA which is strongly hypoxia-inducible (39), where HIF-dependent and independent 
long-range interactions contribute to hypoxia-inducibility in a cell-type specific manner (40). 
Finally, our findings are also relevant for disease-associated polymorphisms that either 
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Figure 1. EPO 5' and 3' HRE gene editing. (A) Scheme depicting the human EPO locus 
(HRE, hypoxia response element; HSS, hypersensitivity site; TSS, transcriptional start site; 
KIE, kidney inducible element; NRE, negative regulatory element; LIE, liver inducible 
element; NRLE, negative regulatory liver element). (B) Single-guided (sg) RNA sequences 
designed to target the EPO 5' and 3' HREs by CRISPR-Cas9 (bold, consensus HIF binding 
site; arrows, PCR primers used to amplify the HRE regions; fwd, forward; rev, reverse; wt, 
wild-type; mt, mutant). Mutation of the consensus HRE confers resistance to TaiI restriction 
digestion as shown by agarose gel analysis of digested or undigested PCR products using 
as template genomic DNA isolated from Kelly neuroblastoma cells following 5' (C) or 3' (D) 
HRE gene editing (M, marker; PL, polyclonal pool of cells; B4 and C3, 5' HRE mutant clones; 
T1 and F3, 3' HRE mutant clones; ctr, non-template control). 
 
Figure 2. Hypoxia-inducible EPO gene expression in 5' or 3' HRE mutant neuroblastoma and 
hepatoma cells. EPO expression under normoxic or hypoxic conditions (0.2% O2; 24 h for 
Kelly and Hep3B, 8 h for HepG2) was measured in Kelly (A, B), Hep3B (C, D) and HepG2 
(E) cells by RT-qPCR on the mRNA level (A, C, E) and by supernatant ELISA on the protein 
level (B, D). Epo mRNA levels were normalized to ribosomal protein L28 mRNA levels. 
Numbers above the columns indicate hypoxic induction factors. Data are shown as mean + 
SEM of 3 independent experiments. Student's t-tests were used to statistically evaluate the 
difference to hypoxic wild-type (WT) cells (*, p<0.05; **, p<0.01; ***, p<0.001; n.d., not 
detectable; Pool, polyclonal pool of cells; +/+, subclones containing two wild-type alleles; -/-, 
subclones with biallelic HRE mutation). 
 
Figure 3. EPO promoter-driven and HRE-enhanced luciferase reporter gene expression. (A, 
C) Kelly cells were transiently transfected with the indicated reporter gene constructs and 
exposed for 24 hours to normoxic or hypoxic (0.2% O2) conditions. Luciferase activities were 
normalized to the protein content and shown as mean values + SEM of 6 independent 
experiments. Numbers on the right of the bars indicate hypoxic induction factors. Student's t-
tests were used to statistically assess the hypoxic induction of the EPO promoter (EpoProm, 
wild-type; mtpHRE, mutant) and the effects of combining the 5' with the 3' HRE (**, p<0.01; 
***, p<0.001). (B) Sequence of the 147 bp human EPO promoter fragment (starting 138 bp 
upstream of the transcription start site; TSS), indicating a conserved tandem dimeric repeat 
(underlined), each containing a putative promoter HRE (pHRE1 and pHRE2). 
 




Figure 4. HIF binding to the EPO locus in 5' or 3' HRE mutant neuroblastoma and hepatoma 
cells. (A) Scheme depicting the regions of the EPO locus analyzed for HIF interaction by 
chromatin immunoprecipitation (ChIP), including the 5' and 3' HREs, the minimal promoter 
and a negative (neg.) control region devoid of any HIF binding. Kelly (B) and Hep3B (C) cells 
were exposed for 24 hours to normoxic or hypoxic (0.2% O2) conditions, followed by ChIP 
using antibodies derived against HIF-1α, HIF-2α or HIF-β, or a negative control serum. The 
promoter HRE of the established HIF target genes NDRG1 and PAI1 served as control for 
ChIP efficiency. The amount of co-precipitated DNA was determined by qPCR and displayed 
relative to input. (D) These experiments were repeated with hypoxic wild-type (WT), 5' or 3' 
HRE mutant Hep3B cells. Mean values + SEM of 3 (Kelly) or 4 (Hep3B) independent 
experiments are shown. Student's t-tests were performed to statistically evaluate the 
difference between the hypoxic ChIP samples and hypoxic serum controls (*, p<0.05; **, 
p<0.01, ***, p<0.001). (E) Immunoblot confirmation of similar HIF-β protein levels in the 
hypoxic Hep3B subclones used above. β-Actin was used as loading and blotting control. 
 
Figure 5. HIF binding to the EPO locus and Epo regulation in 3'/5' HRE double-mutant 
neuroblastoma cells. (A, B) ChIP of hypoxic WT or mutant (as indicated) Kelly cells using 
antibodies derived against HIF-β or negative control serum. The amount of co-precipitated 
DNA was determined by qPCR covering the indicated regions of the EPO locus (A) or the 
HRE of the NDRG1 control locus (B) and displayed relative to input. Data are shown as 
mean + SEM of 4 independent experiments. Student's t-tests were performed to statistically 
evaluate the difference to hypoxic WT (*, p<0.05) or 3' B2 (#, p<0.05) or 5' C3 cells (§, 
p<0.05; §§, p<0.01). (C) Immunoblot confirmation of similar HIF-β protein levels in the hypoxic 
Kelly subclones used above. β-Actin was used as loading and blotting control. (D, E) Epo 
production in wild-type (WT), single 3' B2 or double 3' B2 5' HRE mutant Kelly cells exposed 
for 24 hours to normoxia or hypoxia (0.2% O2) was measured by RT-qPCR on the mRNA 
level (D) or by ELISA on the protein level (E). Data are shown as mean + SEM of n=3-6 (D) 
or n=5-10 (E) independent experiments. Student's t-tests were used to statistically evaluate 
the difference to hypoxic WT (**, p<0.01; ***, p<0.001) or 3' B2 cells (##, p<0.01; ###, p<0.001; 




































































Supplementary Table 1. Oligonucleotide sequences. 
 
sgRNA construction oligonucleotides (only sense strands 
shown) 5'hre-sgrna 5'-ccctgcacgtatgtgctccgggc-3' 
3'hre-sgrna 5'-ccctacgtgctgtctcacacagc-3' 
EPO HRE PCR amplification primers 
5'hre-fwd 5'-tggctgcggacatttctatc-3' 
5'hre-rev 5'-gatgcaggagcctggttcac-3' 








3' 3'hre-xhoi-rev 5'-ccccctcgagctgggcagggttggcag-3' 











ChIP qPCR quantification primers Used for: 
EPO-5'HRE-fwd 5'-gatggagctgtgtctccctg-3' Figure 4 
EPO-5'HRE-rev 5'-agtggcaatgtggaggtctg-3' Figure 4 
EPO-5'HRE-fwd 5'-ggctgcggacatttctatca-3' Figure 5 




3' EPO-promoter-rev 5'-gctgttatctgcatgtgtgcgt-3' 
EPO-3'HRE-fwd 5'-cagcagtgcagcaggtccaggtcc-3' Figure 4 
EPO-3'HRE-rev 5'-cgagaggtcagacaggctgtgtgag-3' Figure 4 
EPO-3'HRE-fwd 5'-cttcaacctcattgacaagaactg-3' Figure 5 
















Clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated 9 
(Cas9) gene editing was performed as described.(1) The EPO locus was screened for single 
guide RNA (sgRNA) binding sites using CRISPR Design Tool. (2) Oligonucleotides 
containing the sgRNA sequences (Supplementary Table 1) were synthesized (Microsynth, 
Balgach, Switzerland), annealed and ligated into plasmid MLM3636 (#43860; Addgene, 
Middlesex, UK). Cells were co-transfected with expression vectors for sgRNA, Cas-9 
(ToolGen, Seoul, South Korea) and puromycin resistance (linearized pBabe vector; #1764; 
Addgene) using polyethylenimine (Polysciences, Warrington, PA, USA) for Hep3B and 
HepG2, and lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA) for Kelly cells. Puromycin 
(1.5 µg/ml, Hep3B; 1 µg/ml, HepG2; 0.2 µg/ml, Kelly) was added two days after transfection 
for up to two weeks. Gene edited cells were cloned by limiting dilution and genotyped by 
PCR using High Fidelity Phusion Polymerase (Thermo Fisher Scientific) and the primers 
listed in Supplementary Table 1. Amplicons were analyzed either by TaiI digestion (Thermo 
Fisher Scientific) followed by 2% agarose gel electrophoresis to check for HRE destruction, 
(3) or by sub-cloning into pBluescript vector (Agilent, Santa Clara, CA, USA) and plasmid 
DNA sequencing (Microsynth), or by direct DNA deep sequencing (Functional Genomics 
Center Zurich). 
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Erythropoietin (Epo) is essential for erythropoiesis and is mainly produced by the fetal liver 
and the adult kidney following hypoxic stimulation. Epo regulation is commonly studied in 
hepatoma cell lines, but differences in Epo regulation between kidney and liver limit the 
understanding of Epo dysregulation in polycythaemia and anaemia. To overcome this limit, 
we have generated a novel transgenic mouse model expressing Cre recombinase 
specifically in the active fraction of renal Epo-producing (REP) cells. Crossing with reporter 
mice confirmed the inducible and highly specific tagging of REP cells, located in the 
corticomedullary border region that displays a steep drop in oxygen bioavailability. A novel 
method was developed to selectively grow primary REP cells in culture and to generate 
immortalized clonal cell lines, called fibroblastoid atypical interstitial kidney (FAIK) cells. FAIK 
cells show a very early hypoxia-inducible factor (HIF)-2α induction which precedes Epo 
transcription. Like known for the kidney, Epo induction in FAIK cells reverses rapidly despite 
ongoing hypoxia, suggesting a cell autonomous feedback mechanism. In contrast, HIF 
stabilizing drugs resulted in chronic Epo induction. RNA-sequencing of three FAIK cell lines 
derived from independent kidneys revealed a high degree of overlap and suggests that REP 
cells represent a unique cell type with properties of pericytes, fibroblasts and neurons, known 
as telocytes. FAIK cells will be helpful to investigate myofibroblast differentiation in CKD and 
the molecular mechanisms of HIF stabilizing drugs currently in clincial phase III studies to 




Erythropoietin (Epo) regulated red blood cell homeostasis is crucial for oxygen delivery in 
vertebrates and Epo dysregulation causes anaemia or polycythaemia [1] [2]. While the liver 
is the main site of Epo production in the embryo, the kidney produces about 90% of 
circulating Epo in the adult and only the remaining 10% is of hepatic origin [3] [4]. Local 
tissue oxygenation appears to be the major factor triggering Epo production. Intriguingly, Epo 
is almost exclusively regulated on the mRNA level by hypoxia-inducible factor (HIF)-
dependent trancriptional activation [5]. Whereas hepatic and neuronal cell lines are used to 
study Epo gene regulation, [6] [7] a reliable cell culture model derived from renal Epo-
producing (REP) cells is currently not available. 
Under normal conditions, REP cells are located in the peritubular interstitial space of the 
inner cortex [8]. A number of attempts to generate REP cell models have been reported. Cell 
lines derived from renal cell carcinoma occasionally produce Epo but oxygen-regulated Epo 
expression has not been found in these cancer cells [9]. Transgenic mice bearing a SV40 





large T antigen in the Epo locus principally allowed for the isolation and immortalization of 
REP cells, but cultured cells showed no inducible Epo or large T expression [10]. Kidney-
derived mesenchymal progenitor cells were differentiated in vitro to produce cell lines 
capable of oxygen-regulated Epo expression [11]. Transgenic mouse lines expressing 
fluorescent proteins under the control of regulatory elements derived from the Epo locus 
(knock-in allele in a background of severe neonatal anaemia) or from the Col1a1 locus were 
used to isolate primary REP cells by flow cytometry [12] [13]. Human mesenchymal-like 
CD133+/CD73+ progenitor cells isolated from the inner medulla showed increased Epo 
production following hypoxic stimulation [14]. Finally, several conditional knock-out mouse 
models with constitutive HIF (over-)expression resulted in ectopic renal Epo synthesis, 
including models that involve the promoters derived from the genes encoding for CD68, 
renin, connexin 40, PDGFRβ and FOXD1 to drive Cre expression [15] [16] [17] [18] [19] [20] 
[21].  
In conclusion, none of these attempts resulted in a reliable renal cell culture with permanent 
capability of regulated Epo expression, maybe due to the transient nature of Epo locus 
activation by differentiation and oxygen-dependent signals. We hence reasoned that isolation 
of freshly isolated cells acutely tagged for an active Epo locus may enhance the chance of 
obtaining REP cells. Therefore, we generated novel transgenic mouse lines to conditionally 




Specific conditional targeting of active REP cells in vivo 
A CreERT2 expression vector was constructed using 220 kb of the mouse Epo locus as shown 
in Figure S1. This construct was first tested in vitro to confirm hypoxia-inducible Cre 
expression and tamoxifen-dependent Cre activation (Figure 1A). Several transgenic founder 
lines were then generated and crossed with reporter mice which allowed for the permanent 
tagging of REP cells by red fluorescent tdTomato expression. While under normoxic 
conditions no or only very few fluorescent cells could be observed in the absence or 
presence, respectively, of tamoxifen (data not shown), this number increased following 
exposure to hypoxic conditions (Figure 1B). Pixel area quantification demonstrated that 
hypoxia clearly activated more REP cells in founder lines #1, #240 and #241 than in #244 
(Figure 1C). Epo-CreERT2 #1 and #241 were chosen for subsequent analyses. As depicted in 
Figure 1D, tdTomato expression overlaps with immunoreactivity of CD73, an established 
marker of REP cells [22]. Furthermore, the CD73 surface marker revealed the long 
processes typical for REP cells [8]. High resolution microscopy showed in more detail the 





irregular shape and the long processes of REP cells, extending between multiple tubular 
cells (Figure 1E), which further confirms the reported phenotype [8]. 
Whole-genome DNA sequencing revealed that both strains show single integration sites, but 
whereas the vector integrated in strain #1 into an intergenic region of chromosome 14 with 
the loss of only 330 bp, in strain #241 it integrated into chromosome 9 with the loss of 52.2 
kb, including exons 4 to 13 of the Pou2f3 gene. The remaining Epo flanking regions in the 
integrated BAC vectors were 45.9 kb and 98.2 kb in #1, and 75.2 kb and 52 kb in #241, 
upstream and downstream, respectively, of the Epo-coding region (Figure S2A). Both, the 5' 
and 3' boundaries of the integrated vectors were confirmed by PCR (examples shown in 
Figure S2B). Although the gross phenotypes of both founder strains were indistinguishable 
from wild-type mice, and despite identical REP cell tagging by tdTomato expression, strain 
#1 was chosen for further analyses due to the gene-disrupting nature of the vector 
integration into strain #241, which potentially could have deleterious effects [23].  
 
REP cells localize to areas with abrupt decline in O2-bioavailability 
Renal Epo expression is exceptionally hypoxia-sensitive even though the HIF system and its 
hundreds of target genes are ubiquitously expressed [5]. While the underlying molecular 
mechanisms remain to be elucidated, the unique oxygen distribution in the adult kidney is 
likely involved in REP cell activation. Indeed, mice ubiquitously expressing a fusion protein 
between the HIF-1α oxygen-dependent degradation (ODD) domain and the luciferase (Luc) 
reporter gene showed a strikingly kidney-specific bioluminescence, as reported previously 
[24]. Only distal extremities and the normally hypoxic testis but no other inner organs showed 
a comparable hypoxia-induced bioluminescence (Figure 2A). Because whole-body imaging 
cannot reveal the intra-organ ODD-Luc distribution, we analyzed fresh organ slices of the 
kidneys shown in Figure 2A. Despite the now uniform tissue thickness, bioluminescence 
intensity in the medulla was still much stronger than in the cortex. Both, medulla and cortex 
displayed a quite homogenous bioluminescence distribution, with a steep O2-bioavailability 
gradient mainly located in the corticomedullary border region (Figure 2B).  
We next analysed the localization of REP cells in Epo-CreERT2#1xtdTomato mice. In order to 
compare the delayed reporter protein accumulation with the short-lived Epo mRNA levels, we 
used two relatively strong hypoxic stimuli (each 4 hours of 0.1% CO inspiration) with one 
week recovery inbetween. While the first stimulus was used to permanently tag REP cells, 
the subsequent second stimulus was used to analyze acutely induced Epo mRNA. Both, 
tdTomato (Figure 2C) as well as endogenous Epo mRNA (Figure 2D) localized to peritubular 
interstitial cells of the corticomedullary border region. Strikingly, a much higher number of 
REP cells was observed by histochemical Epo mRNA in situ hybridization than tdTomato 
immunofluorescence, most likely due to the single-molecule sensitivity of the former method 





which detects Epo mRNA levels far below the corresponding Cre expression threshold 
required for recombination of the tdTomato reporter locus. Therefore, we analysed Epo 
mRNA by the same technique following a more physiological hypoxic stimulus (3 hours of 
8% O2 inspiration). As shown in Figure 2E, this treatment results in a REP cell pattern similar 
to the tdTomato-tagged REP cells shown in Figure 2C. While no red cells were detected in 
wild-type (wt) mice, only sporadic cells were seen in transgenic mice following tamoxifen 
treatment. This number did not further increase after 4 hours of 8% O2 inspiration (Figure 
2F), suggesting that this stimulus is sufficient for Epo mRNA induction but borderline for 
functional Cre expression. However, there was a clear increase in REP cell numbers 
following 16 hours of 8% O2 inspiration, demonstrating that this mouse model faithfully 
recapitulates the spatio-temporal conditional regulation of the Epo gene.  
 
Isolation of primary REP cells by negative selection 
Because the results shown above revealed that only a very small fraction of all cells of the 
kidney are active "on" REP cells, we reasoned that selection against Epo negative cells may 
be a more suitable strategy to isolate primary REP cells than selection for Epo positive cells. 
Therefore, Epo-CreERT2#1xtdTomato reporter mice were crossed with the Terminator strain 
which allowed for the killing of non-Cre expressing cells using diphtheria toxin [25] (Figure 
S1). To select the acutely Epo expressing cells, freshly isolated renal cell suspensions were 
immediately exposed to hypoxia and tamoxifen to induce Cre-mediated recombination, 
followed by treatment with diphtheria toxin. While only few red cells were visible after 1.5 
days of isolation, the abundance of tdTomato positive REP cells increased after 7 days of 
normoxic cultivation (Figure 3A). Most but not all of the viable cells were tdTomato positive 
after 10.5 days, suggesting that some cells may not have recombined the tdTomato allele. 
Epo mRNA was induced by hypoxia in primary REP cells after 6 days of isolation (Figure 
3B), demonstrating that these proliferating primary REP cell cultures maintained the capacity 
to express and regulate the Epo gene. 
 
Oxygen, DNA methylation and HIF-2 mediated Epo regulation in REP cell-derived FAIK 
cell lines 
Because primary REP cells ceased to proliferate and lost inducible Epo expression after 
approx. 12-14 days of culture (data not shown), we generated permanent REP cell lines. 
Therefore, independent primary REP cell preparations were immortalized with SV40 large T 
antigen 3 or 6 days after isolation. Limited dilution cloning resulted in fibroblastoid atypical 
interstitial kidney (FAIK) cell lines. Three independent clones were chosen for further 
analysis. FAIK cells maintained hypoxia-inducible Epo protein for at least 30 passages 
(Figures 3C and S3).  





Since the Epo signal intensity was rather weak we reasoned that during propagation some of 
the cells may have lost Epo expression due to epigenetic silencing by DNA methylation of 
Epo-regulatory loci or the Epo locus itself. DNA methyltransferase inhibition may hence 
restore Epo expression in these cells as recently shown in fibrotic kidneys in vivo [13]. 
Indeed, 5-azacytidine could enhance both basal and hypoxia-inducible Epo protein levels in 
FAIK3-5 cells (Figure 3C). These results were confirmed by ELISA using supernatants as 
well as cell lysates derived from the same cells (Figure 3D). A typical well-known feature of 
Epo gene expression is the early decrease after an initial strong induction, despite ongoing 
hypoxia and long before any change in haematocrit occurs [26] [27]. Interestingly, this 
feature could also be seen in FAIK cell lines as exemplified by Epo immunoblot detection in 
FAIK3-5 cells independent of whether 1 or 5 passages went by since the 5-azacytidine 
treatment (Figure 3E). Bisulfite sequencing of the Epo promoter region revealed mostly 
methylation-free proximal CpG dinucleotides whereas the more distal CpGs remained mostly 
methylated, independent of hypoxia or 5-azacytidine treatments (Figure 3F), suggesting that 
increased Epo expression following 5-azacytidine treatment is not due to direct action on the 
Epo promoter in FAIK cells.  
mRNA levels in FAIK3-5 cells could efficiently be blocked using lentiviral transduction with 
shRNA constructs (Figure 3G and Supplementary Methods and corresponding Figures). 
shHIF-2α but not shCtrl or shHIF-1α blunted Epo expression, confirming HIF-2 dependent 
Epo regulation. 
 
Faithful recapitulation of hypoxic Epo expression kinetics in FAIK cell lines 
A well-established difference between HIF-1α and HIF-2α is the delayed (after 2 to 3 days) 
and prolonged hypoxic induction of HIF-2α protein often observed in cancer cell lines [28]. 
However, such a delayed HIF-2α induction would not be consistent with the rapid induction of 
its target gene Epo in REP cells in vivo and FAIK cell lines in vitro. Intriguingly, while HIF-1α 
showed maximal protein levels after 12 hours, HIF-2α induction was even faster in REP cells, 
reaching maximal levels after 3 to 6 hours of hypoxia (Figure 4A). Because such rapid 
kinetics is dominated by the slow oxygen diffusion and exchange rates [29] these 
experiments were repeated using cell culture media that had been pre-quilibrated with 0.2% 
O2. While HIF-2α was already induced at the earliest time point (1.5 hours), the 
phosphorylated high molecular weight form of HIF-1α maximally accumulated after 12 hours 
(Figure 4B, upper panel). Under these conditions, Epo protein followed the HIF-2α kinetics 
with a maximal level already after 1.5 hours followed by a gradual decrease, as shown by 
immunoblotting (Figure 4B, lower panel), ELISA (Figure 4C) and mRNA quantification 
(Figure 4D). Of note, this rapid reversal of hypoxic Epo induction could not be observed 
using the PHD inhibitor FG-4592 (roxadustat), which led to a permanent Epo expression until 





the end of the observation period after 48 hours (Figure 4E). As shown in Figure 4F, a single 
bolus of FG-4592 maintained Epo mRNA and protein levels for up to 72 hours, suggesting 
that chemical PHD inhibition blocks a potential negative feedback loop seen in prolonged 
hypoxia [30]. 
 
Transcriptomics of FAIK cell lines reveals metabolic adaptation to hypoxia 
The three independent FAIK cell lines were further phenotyped by RNA sequencing 
(RNAseq) following exposure to hypoxia for 24 hours. Statistical evaluation confirmed the 
reproducibility of the REP cell isolation method (Figure S4A). Nevertheless, unsupervised 
cluster analysis showed that FAIK2-5 were more distant from FAIK1-10 and FAIK3-5, with 
normoxic and hypoxic FAIK2-5 being more closely related than the distinct normoxic and 
hypoxic clusters formed by the two other cell lines (Figure S4B). However, with a total of 
16,357 expressed mRNA and lncRNA species, the majority (84.8%) was commonly 
expressed in all three cell lines. There was less overlap in the sequence read numbers of the 
hypoxically regulated (i.e. at least a 2-fold change) RNA species between the three cell lines, 
with 14.7% regulated, 21.1% induced and 8.8% repressed RNA species, respectively (Figure 
S4C). A rank order list of the 100 most strongly induced genes is shown in Figure S5. In 
addition to the approx. 700 to 950 mRNA species also 120 to 200 lncRNA species 
accumulated under hypoxic conditions in the three FAIK cell lines (Figure S4D), in line with 
our previous reports on hypoxic inducibility of lncRNAs [31][32]. Gene ontology analysis 
revealed metabolic reprogramming towards HIF-1 dependent glycolysis under hypoxic 
conditions (Table S1). 
Established HIF target genes, [33] including VEGFa, Glut1, DEC2 and NDRG1, showed a 
very robust hypoxia-inducible expression, while housekeeping ribosomal protein rpL28 was 
constitutively expressed (Figure 5A). However, CAIX which is commonly induced in virtually 
all cancer cell lines, is almost completely absent even in hypoxic FAIK cells (data not shown), 
underlining the non-transformed nature of these cell lines. Of the mRNAs involved in the 
oxygen signalling cascade, PHD2 was most prominently expressed, in line with its 
predominant function in renal Epo regulation [34]. PHD2 and PHD3 but not PHD1 were 
significantly induced by hypoxia, consistent with a role in an intrinsic negative feedback loop 
[30]. Intriguingly in this context, also VHL (but not FIH) was induced by hypoxia, at least in 
the FAIK cell lines analysed (Figure 5B). Epo mRNA did not reach the threshold of 10 
normalized sequence reads. Considering (i) the basal levelsclose to zero, (ii) the non-optimal 
time point for Epo mRNA induction, (iii) the small size of the Epo mRNA, and (iv) the low Epo 
versus housekeeping control ratio usually observed by reverse-transcription quantitative 
polymerase chain reaction, RNA sequencing was not sensitive enough for Epo detection 
under these experimental conditions. However, manual inspection revealed Epo mRNA 





sequencing reads below the threshold in all 3 FAIK cell lines under hypoxic conditions only 
(data not shown). 
 
FAIK cells resemble the telocyte subtype of pericytes/fibroblasts 
To characterize the developmental origin of FAIK cell lines, a panel of cell-type specific 
markers was analysed. All FAIK cell lines were positive for the fibroblast markers PDGFRβ 
[19], CD73 [22] and Col1A1 [13] (Figure 5C). Also FSP1 [35] as well as the myofibroblast 
marker αSMA [36] were expressed, indicating that at least a subpopulation of these cells may 
have differentiated during cell culture. 
REP cells have recently been shown to express the neuronal markers MAP2 and NFL [8]. 
While we could confirm the expression of MAP2, NFL was not found in FAIK cell lines, in line 
with a previous report [19]. However, they were clearly positive for the neuronal markers 
NGF, BDNF and nestin, as well as for the pericyte marker NG2/CSPG4 (Figure 5D) that has 
recently been used to trace brain pericytes as a major source of Epo in the mouse brain [37]. 
The neural crest markers P0 and Pax3, which have been used for the lineage tracing of REP 
cells, [38] [39] could either not be detected in FAIK cells or only at low levels (data not 
shown). 
The transcription factors FoxD1 and WT1 are markers of the mesenchymal stroma precursor 
cells of the developing kidney which give rise to renal interstitial cells, including fibroblasts 
and pericytes. FoxD1 has previously been used to trace REP cells [20]. Both markers are 
expressed in all FAIK cell lines and WT1 was strongly induced by hypoxia. Because WT1 is 
known to regulate the Epo promoter [40], hypoxia-inducible WT1 may potentiate Epo 
induction in REP cells. The macrophage marker CD68 is weakly expressed in a hypoxia-
inducible manner in all FAIK cell lines. Notably, CD68 promoter-driven Cre transgenic mice 
have previously been used to trace REP cells [15]. Furthermore, FAIK cells were also 
positive for the stemness marker CD24, also known as mouse heat-stable antigen [41], and 
the hematopoietic progenitor marker CD34 [42], although the latter could not be detected in 
FAIK2-5 cells (Figure 5E). However, endothelial cell marker CD31 as well as markers of 
leukocytes (CD45), dendritic cells (CD8α, CD11b, CD103) and macrophages (Mac1, F4/80) 
could not be detected, clearly demonstrating that FAIK cell lines are not of myeloid origin. 
The morphology of primary REP cells as well as FAIK cell lines showed some characteristic 
features (e.g. few long and thin membrane protrusions partially forming cell-cell connections, 
large nuclei and an apparent lack of nucleoli in DAPI stainings) which are reminiscent of a 
subpopulation of pericytes/fibroblasts also referred to as "telocytes" [43]. Telocytes can be 
found in most organs, including in the kidney cortex (but not medulla) [44] [45] [46]. Telocytes 
display a number of phenotypical and transcriptomic properties that distinguish them from 
"classical" fibroblasts [43] [47] [48]. As shown in Table S2, there is an intriguing overlap 





between markers expressed in telocytes and in FAIK cell lines. These markers were 
compiled from reports on telocytes derived from various organs, and some of the 
mismatches may hence be explained by the fact that only little information about telocytes 
isolated from the kidney is available. 
FAIK cell lines kept in low density culture commonly form long and thin membrane 
protrusions (nanotubes), some of which apparently establish cell-cell connections (Figure 
6A). These nanotubes can reach lengths of more than 100 μm and are positive for TOM20 
(mitochondria), β-actin (microfilaments) and α-tubulin (microtubuli) (Figures 6B-D), typical for 
tunneling nanotubes [49]. Such mitochondria-containing nanotubes represent another 
hallmark of telocytes where they are referred to as "telopodes" [43]. Of note, while REP cells 
in vivo contain far less mitochondria than the neighbouring tubular epithelial cells, 
mitochondria could also be detected in the membrane protrusions of REP cells (Figure 6E). 
Finally, all three FAIK cells lines are positive for CD73 as well as for CD34 and PDGFRβ 




The renal Epo source has been discussed in the literature quite controversially over the past 
decades. Not only peritubular interstitial cells, [22] [50] [51] [52] but also proximal and distal 
convoluted tubules, intercalated cells of the collecting ducts and glomerular cells [53] [54] 
[55] [56] have been reported to contain Epo mRNA. These findings were apparently 
consistent with transgenic mouse models expressing reporter genes under the control of 
DNA fragments derived from the Epo locus [57][58] However, these data were all obtained 
by "classical" mRNA in situ hybridization or by using genomic Epo DNA fragments of limited 
length. With the recent refinement of the in situ hybridization technique, exclusively 
peritubular interstitial cells at the corticomedullary border were found to be Epo mRNA 
positive [59]. These findings have been confirmed by transgenic mouse models expressing 
reporter genes under the control of longer regions of the Epo locus,[10] [60] with approx. 200 
kb long BACs most faithfully recapitulating the endogenous Epo expression pattern [8]. The 
results presented in our study confirm corticomedullary peritubular interstitial cells as sole 
REP cell type. The corticomedullary region showed the deepest drop in O2-bioavailability 
which may expand into the cortex upon decreased tissue oxygenation, a prerequisite for the 
recruitment of additional REP cells [61].  
Our animal model allowed for the conditional tagging of acutely recruited REP cells, whereas 
in previously established constitutively Cre-driven REP models it remained unknown whether 
labelled REP cells were still active [8] [39] [12] [62]. Whole-genome sequencing of two Epo-
CreERT2 founder strains revealed that 45.9 kb 5' and 52 kb 3' flanking regions are sufficient to 





confer accurate tissue-specific and oxygen-regulated Epo gene expression in the kidney. 
While Epo is known to be expressed in several other organs [2], we only occasionally 
detected tagged cells in liver and brain (data not shown). This may be explained by 
comparably low Epo levels per cell, but quite high overall Epo expression per organ, because 
a far higher percentage of liver (hepatic and stellate) and brain (neuronal, glial and pericytic) 
cells are (mildly) Epo positive compared to the proportion of (strongly) Epo positive cells in 
the kidney. Overall, these findings suggest that our novel conditional mouse model 
selectively labels only those cells with strong acute Epo transcription rates, ideally suited for 
the generation of primary active “on” REPcells. 
While we did not obtain any detectable Epo expression in previously published REP cell lines 
[11] [63] (data not shown), the strong transcriptomic correlation of three independent REP-
derived FAIK cell lines demonstrated the reproducibililty of the described procedure. More 
than 50% of the isolated FAIK clones still showed hypoxia-inducible Epo expression, but 
even these clonal cell lines apparently kept the typical REP cell property of the "on-off" 
behavior of Epo gene expression [64] [65]. This REP cell feature is poorly understood and 
may involve intrinsic transcriptional negative feedback loops as well as epigenetic 
mechanisms [13] [30]. Indeed, treatment with 5-azacytidine increased Epo levels, suggesting 
an at least partial epigenetic silencing in "off" REP cells by DNA methylation. Intriguingly, FG-
4592/roxadustat, the most advanced PHD inhibitory drug currently in clinical phase III studies 
for the treatment of renal anaemia [66] led to a constitutive Epo induction in FAIK cells, 
whereas hypoxia only transiently induced Epo, suggesting differences in the negative 
feedback regulation and/or interference with myofibroblast differentiation [67]. However, our 
findings on HIF-2α/Epo kinetics clearly demonstrate that the transient Epo expression in 
chronic hypoxia is a cell autonomous effect and does not require e.g. altered blood 
composition or microenvironmental changes. 
RNAseq of FAIK cells allowed for a thorough characterisation of the cellular identity of REP 
cells. Based on these data, we suggest that REP cells represent a unique subset of 
interstitial pericytes/fibroblasts which are also known as telocytes and which were found to 
express a number of neuronal markers. While further analyses will be required to confirm this 
suggestion, it is an intriguing idea that also telocytes residing in other organs may represent 
major sources of non-renal Epo. Of note, while both neurons and astrocytes have been well-
established as Epo-producing cells of the brain [68] [69], a recent report demonstrated that 
brain pericytes actually represent a major source of cerebral Epo upon hypoxic stimulation 
[37]. It will be of interest to analyse whether Epo-producing pericytes of the brain also share 
features of telocytes. 
 
 





Material and Methods 
 
Animals 
Epo-CreERT2 transgenic mice were generated according to previously published methods, 
[70] using a newly constructed expression vector as detailed in Supplementary Methods. All 
animal experiments were approved by the veterinary office of the canton Zurich (license 
numbers ZH126/13 and ZH233/15). 
 
Tissue analyses  
Mouse kidney sections were analyzed by immunofluorescence or in situ hybridization using 
RNAscope technology (see Supplementary Methods for antibody and imaging details). 
 
Cell culture 
Primary REP cells and clonal cell lines were generated and characterized as outlined in 
Supplementary Methods. 
 
Protein and transcript analyses 
Mouse Epo protein was detected by ELISA and immunoblotting as described previously [71] 
[72] mRNA levels were quantified by RT-qPCR as described previously [28] using the PCR 
primers provided in Table S3. Poly-A selected RNA was sequenced as detailed in 
Supplementary Methods and the RNAseq data were deposited in the European Nucleotide 
Archive (www.ebi.ac.uk/ena; study accession number PRJEB19328). 
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Figure 1. Conditional targeting of renal Epo-producing (REP) cells in vivo. (A) In vitro analysis of the 
Epo-Cre
ERT2 BAC transgenic vector in Hep3B cells by co-transfection of the BAC construct together 
with Cre-inducible and constitutive reporter genes. Dual luciferase reporter gene assays were 
performed following exposure to tamoxifen and/or hypoxia (0.2% O2 for 20 hours). (B) Red fluorescent 
tdTomato expression in REP cells of Epo-CreERT2#241xtdTomato mice following exposure to 
tamoxifen and hypoxia (0.1% CO for 4 hours). Nuclei were stained with DAPI (blue) and tubuli were 
visualized by their autofluorescence (green). (C) REP cell labelling of the initial Epo-CreERT2 founder 
lines following crossing with tdTomato reporter mice and exposure to tamoxifen and hypoxia. 
tdTomato was detected using an anti-RFP antibody and 7 to 11 sections of two female mice (3 to 5 
months old) for each founder line were scanned on a slidescanner. The pixel areas of tdTomato and 
DAPI fluorescence over a manually defined threshold were quantified and the tdTomato area is shown 
as percentage of the DAPI area (mean + SEM). (D) REP cell co-staining (yellow) by anti-CD73/ecto-5'-
nucleotidase antibodies (green) together with tdTomato fluorescence (red) following exposure to 
tamoxifen and hypoxia (8% O2 for 16 hours) of Epo-Cre
ERT2#1xtdTomato mice. Triple staining together 
with the DAPI nuclear stain (blue) results in white signals. (E) Deconvolution of laser scanning 
fluorescence microscopy of Epo-CreERT2#241xtdTomato mice following exposure to tamoxifen and 



































Figure 2. Hypoxic activation and localization of REP cells. (A) Bioluminescence in vivo imaging 
following s.c. injection of luciferin into a male mouse ubiquitously expressing the oxygen-labile ODD-
Luc fusion protein. (B) Bioluminescence imaging of a transversal thick slice (500 μm) of the kidney 
shown in (A). Bright field microscopy (left), in vivo imaging system (IVIS) camera in bright light 
(middle), and IVIS bioluminescence (right) pictures are shown, demonstrating that the highest 
bioluminescence (red) is located in the medulla, medium bioluminescence (green) in the cortex, and 
lowest bioluminescence (blue) in the large vessels and outer cortical rim. (C) Immunofluorescence 
microscopy to localize tdTomato-positive REP cells detected using an anti-RFP antibody (white) in a 
kidney derived from a Epo-CreERT2#241xtdTomato mouse after tamoxifen treatment (daily oral gavage 
of 5 mg tamoxifen for 5 consecutive days) followed by a repeated exposure to 0.1% CO for 4 hours 
with 1 week recovery inbetween. (D-E) Kidney Epo mRNA in situ hybridization of Epo-CreERT2#241 
mice exposed to CO as described above (D) or to inspiratory hypoxia (8% O2) for 3 hours (E). (F) 
Relative numbers of tdTomato-positive REP cells per kidney slice in non-treated (n.t.) Epo-
Cre
ERT2#1xtdTomato mice, or after vehicle (DMSO; Veh) or tamoxifen (Tmx) pre-treatment (daily oral 
gavage of 2 mg tamoxifen for 4 consecutive days) followed by exposure to inspiratory hypoxia as 
indicated. Each bar represents average values +SEM of 6-20 slices derived from one mouse as 

















































Figure 3. Generation and characterisation of FAIK cell lines derived from primary REP cells. (A) Bright 
field (upper panel) and tdTomato fluorescence (lower panel) microscopy of the same primary REP cell 
preparation 1.5, 7 and 10.5 days after isolation following 3 days of selection with diphtheria toxin. (B) 
Hypoxic Epo mRNA induction in primary REP cells 6 days after cell isolation by exposure to 0.2% O2 
for 24 hours. Ratios between Epo (measured by exon 4-5 RT-qPCR) and ribosomal protein L28 
mRNA levels were normalized to the normoxic control of each individual experiment. Shown is the 
mean induction factor +SEM (n=6). (C) Immunoblot detection of Epo protein in FAIK cell lines. FAIK3-
5 cells at passage 9 or 10 were either left untreated or were pre-incubated with 1 μM 5-azacytidine (5-
Aza) for 6 days, passaged once more, and then exposed to hypoxia (0.2% O2) for 24 hours. (D) ELISA 
measurements of mouse Epo (mEpo) protein in the supernatant (upper panel) and cell lysates (lower 
panel) of the same cells as shown in (C) (nd, not detectable). (E) Time course of hypoxic Epo protein 
induction in FAIK3-5 cells after pre-incubation with 5-Aza as in (C), followed by exposure to hypoxia 
for the indicated time periods 1 or 5 passages later. (F) CpG methylation of the Epo promoter region in 
FAIK1-10 cells determined by bisulfite sequencing. An example PCR product sequencing track is 
shown in the lower panel (red arrows, CpG sites). (G) Knock-down of HIF-2α or Epo by shRNA 
expression (shCtrl, unrelated control shRNA). β-Actin served as loading and blotting control in all 
immunoblots. 











































Figure 4. HIF and Epo expression kinetics. Time course of hypoxic HIF-1α, HIF-2α and Epo levels in 
FAIK3-5 cells following exposure to 0.2% O2 in a conventional incubator (A) or after medium 
replacement by pre-equilibrated medium in a hypoxic workstation (B). (C) ELISA determination of Epo 
concentrations (left panel) and total amounts (right panel) in lysates and supernatants (n above 
background is indicated) prepared from cells treated as in (B). Shown are mean values + SEM of n=4 
independent experiments. Hypoxic increase vs. normoxic control was evaluated using unpaired two-
tailed T-tests (*, p<0.05). (D) Ratios between Epo (measured by exon 3/4-4 RT-qPCR) and ribosomal 
protein S12 mRNA of cells treated as in (B) (shown are mean hypoxic induction factors + SEM; n=3). 
(E) Time course of hypoxic HIF-1α, HIF-2α and Epo protein induction in FAIK3-5 cells following 










































Figure 5. Oxygen-regulated and cell type specific marker gene expression in FAIK cell lines. 
Normalized RNA sequence read numbers in FAIK1-10 (F1-10), FAIK2-5 (F2-5) and FAIK3-5 (F3-5) 
cell lines determined by RNAseq as shown in Figures S4 and S5. (A) Transcript levels of established 
hypoxia-inducible and control genes. Vascular endothelial growth factor a, VEGFa; glucose 
transporter 1, Glut1/Slc2a1; differentially expressed in chondrocytes, Dec2/Bhlhe41/Sharp1; N-myc 
downstream regulated 1, NDRG1; ribosomal protein L28, rpL28. (B) Transcript levels of genes 
involved in the oxygen signalling cascade. Prolyl-4-hydroxylase domain (PHD) 1 to 3; von Hippel-
Lindau, VHL; factor inhibiting HIF, FIH/HIF1AN. (C) Transcript levels of marker genes of the fibroblast 
lineage. Platelet-derived growth factor receptor β, PDGFRβ; cluster of differentiation (CD) 73, 
CD73/Nt5e; collagen 1A1, Col1A1; fibroblast-specific protein 1, FSP1/S100A4; α smooth muscle actin, 
αSMA/Acta2. (D) Transcript levels of marker genes of the neuronal lineage. Microtubule-associated 
protein 2, MAP2; nerve growth factor, NGF; brain-derived neurotrophic factor, BDNF; neuron-glial 
antigen 2, NG2/CSPG4. (E) Transcript levels of hematopoietic marker genes. Forkhead box D1, 
FoxD1; Wilms tumor protein 1, WT1; macrosialin, CD68; mouse heat-stable antigen, HSA/CD24; 
hematopoietic progenitor cell antigen, CD34. Shown are mean values + SEM of 3 independent 
experiments. Hypoxic regulation was evaluated using paired two-tailed T-tests (ns, not significant; *, 
p<0.05; **, p<0.01; ***, p<0.001). 












































Figure 6. Telocyte phenotype of FAIK cell lines. (A) Live microscopy showing thin membrane 
protrusions (nanotubes) formed in low-density FAIK cell culture. (B-D) Localization of mitochondria in 
FAIK cell lines following immunodetection by polyclonal (pAb) or monoclonal (mAb) anti-TOM20 
antibodies using epifluorescence (B,C) or confocal (D) microscopy in combination with anti-β-actin 
(B,D) or anti-α-tubulin (C) immunodetection. (A-D) Arrows, nanotubes containing mitochondria; arrow 
heads, nanotubes forming cell-cell contacts; tube lengths are indicated in μm. (E) TOM20 
immunofluorescence of Epo-CreERT2#1xtdTomato mouse kidney. Arrows indicate mitochondria in REP 
cells. (F) Immunofluorescence detection of the telocyte markers CD34 and PDGFRβ. β-actin was 
stained with phalloidin.  
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Introduction 
Hypoxia is a condition occurring when the oxygen demand exceeds the oxygen supply and 
represents a harmful threat for the physiological functions of our body. As multicellular 
organisms need a constant supply of oxygen for their survival, they evolved specific 
mechanisms based on systemic and cellular responses by which to adapt to hypoxia [1]. The 
master regulator of this adaptation is the transcription factor hypoxia-inducible factor (HIF), 
discovered in hepatoma cells by its binding to a hypoxia response element (HRE) located 
downstream of the erythropoietin gene (EPO) [2] [3]. HIF controls the activation of hundreds 
of genes involved in several cellular processes that need to adapt to oxygen deprivation such 
as glucose metabolism, angiogenesis, erythropoiesis, iron uptake and cell proliferation [4]. 
Within the HIF pathway, the three prolyl-4-hydroxylase domain (PHD1/2/3) enzymes, the 
asparagine hydroxylase factor inhibiting HIF (FIH) and the ubiquitin E3 ligase von Hippel 
Lindau (VHL) protein recognizing hydroxylated HIF-α subunits, have been discovered to play 
a crucial role in regulating HIF-α protein stability, hence, modulating the HIF pathway 
activation by sensing oxygen levels [5] [6] [7]. The two main HIF isoforms, HIF-1 and HIF-2 
recognise and bind the same DNA consensus sequence, the so-called HIF binding site 
(HBS) within the HRE but their target genes are only partially overlapping [7] [8]. 
Interestingly, HIF-1α and HIF-2α recruit diverse transcriptional co-activators in a cell-type 
specific manner and show different kinetics of protein stabilization, indicating that the 
duration of the hypoxic exposure needs to be considered in target gene expression studies. 
Despite many cell lines co-express both HIF-1α and HIF-2α, it has been observed by knock-
down experiments that suppression of either isoform increases the abundance of the other 
isoform [9]. This mechanism of mutual inhibition, probably evolved to gain more flexibility in 
the hypoxic response, is still poorly understood as in several batch systems both HIF-α 
isoforms are still co-expressed; thus, it needs to be investigated by a single cell-based 
approach.   
Erythropoietin (Epo) is the main hormone maintaining the RBC homeostasis and its 
regulation occurs mostly on the mRNA level in a HIF-2 dependent manner. While the fetal 
liver is the organ synthetizing Epo during development, the kidney is the main organ 





producing Epo during adulthood [10] [8]. Ectopic Epo expression can also be found in cells 
belonging to brain, uterus and testis but they do not substantially contribute to circulating Epo 
[11]. In the kidney, Epo is synthetized by juxtamedullary cortical interstitial cells, termed renal 
Epo-producing (REP) cells, which display features of fibroblasts, pericytes and neurons [8] 
[11] [12]. The availability of hepatoma and neuroblastoma cell lines, capable of producing 
Epo in a hypoxia inducible manner, allowed the study of oxygen-regulated Epo 
transcriptional regulation in both liver- and brain-derived in vitro models [13]. However, these 
insights cannot be extended to renal Epo transcriptional regulations as no reliable cell culture 
model for REP cells was available until recently. In fact, previous reporter renal cell lines did 
not display regulated Epo expression and kidney-derived cells from knock-in mice containing 
a SV40 large T antigen within the Epo locus did not permanently express Epo [14]. 
Therefore, to study endogenous renal Epo transcriptional regulation, we generate a novel 
transgenic mouse model to conditionally tag for active Epo locus and isolate fresh renal Epo 
producing cells as new reliable renal cell culture system. Three clonal Epo-producing 
fibroblastoid atypical interstitial kidney (FAIK) cell lines deriving from “on” tagged mouse 
primary REPCs were generated in our lab that showed HIF-2α-dependent Epo kinetics in a 
similar way to the in vivo kinetics [15]. While immunoistochemical approaches and “classical’’ 
in situ hybridization methods displayed Epo expression not only in interstitial peritubular renal 
cells but also in other cell types of the kidney, the recent development of single mRNA 
molecule detection by chromogenic (HRP-DAB) and fluorescent (FISH) detection methods 
(RNAscope) [16], allowed us and other groups to finally demonstrate that Epo mRNA is 
expressed only in a subpopulation of juxtamedullary cortical interstitial cells [15] [17]. 
Because both renal Epo mRNA and circulating Epo protein transiently increase upon hypoxia 
by hundred-folds [21], it is generally thought that, depending on the presence or absence of 
Epo mRNA, REPCs can be either in an “on” or “off” state, indicating Epo-producing or non 
Epo-producing state, respectively [10] [11]. Thus, REP cells are characterized by high cell-to-
cell variability, a feature that under hypoxia has not been yet studied. In normoxic conditions, 
cell-to-cell variability has been demonstrated to be determined by on-off kinetics and “bursty” 
transcription [19] [20]. This raises the question about the nature of Epo transcription in 
hepatoma, neuroblastoma and REP cells. It would be of great interest to examine whether 
the induction of Epo, (or more generally, the induction of a given HIF target gene) in a single 
cell is completely random (stochastic) or whether currently unknown factors influence the 
cellular adaptation to the hypoxic environment (deterministic) and if its expression is bursty or 
continuous. Additionally, it remains still unclear whether the loss of Epo production is caused 
by a definitive differentiation toward non Epo-producing cells or a transient switch to the “off” 
state, which might be reverted to “on”, reflecting the physiological switch of Epo expression in 
response to the hypoxic stimulus. Of note, despite severe hypoxic conditions (8% O2 for 3 





hours), only a small fraction of interstitial cells located at the renal cortex and outer medulla 
initiated Epo transcription, implying that Epo transcription is bursty rather than continuous 
[15]. Taken together, such open questions suggest that Epo expression needs to be studied 
on a single cell level as so far, in vitro Epo transcription has been analysed only in batch-
experiments, neglecting the transient “on-off behaviour”.  
Therefore, in this work, we aimed to understand the impact of oxygen levels and time of 
hypoxic exposure (extrinsic factors) as well as mRNA distribution (intrinsic factor) on the cell-
to-cell variability of the “hypoxic transcript pattern”, defined as the cellular distribution of 
single nascent and mature mRNA, in Epo-producing hepatoma, neuroblastoma and non-
transformed renal mouse (FAIK) cell lines by chromogenic in situ hybridization of single 
mRNA molecule (RNAscope).    
Material and Methods 
Cell culture 
Human Hep3B and HepG2 hepatocellular carcinoma (American Type Culture Collection, 
LGC Standards, Wesel, Germany) and Kelly neuroblastoma (kindly provided by J. Fandrey, 
Essen, Germany) cell lines were cultured in high glucose Dulbecco's modified Eagle's 
medium (DMEM) and RPMI-1640 medium, respectively (Sigma Aldrich, Saint Louis, MO, 
USA), supplemented with 10% heat-inactivated fetal bovine serum (FBS), 50 IU/ml penicillin 
and 50 μg/ml streptomycin (Thermo Fisher Scientific, Waltham, MA USA). Cells were 
exposed to hypoxic conditions using a workstation as described previously [21]. 
In situ hybridization 
Epo mRNA was detected by in situ hybridization according to the manufacturer’s instructions 
(RNAscope; Advanced Cell Diagnostics, Hayward, CA, USA) as reported previously [303]. 
Briefly, the human Epo (Cat No. 414201) and the mouse Epo (Cat No. 315501) consist of 12 
double Z probe pairs and target the region between 252 and 1334 as well as 39 and 685 of 
human and mouse Epo, respectively. Human PPIB (Cat No. 313901) and mouse Ppib (Cat 
No. 31391) as well as DapB (Cat No. 310043) were used as positive and negative control 
probes, respectively. Cells were fixed with 4% PFA on a 8-chamber glass dishes (Lab-Tek; 
Thermo Fisher Scientific) and prepared according to the manufacturer’s recommendations. 
The probes were hybridized for 2 hours at 40°C in a HybEZ oven (Advanced Cell 
Diagnostics, Hayward, CA, USA), followed by a series of signal amplification and washing 
steps. For horseradish peroxidase (HRP) labelled hybridization probes, signals were 
detected with 3,3'-diaminobenzidine (DAB) using the 2.5 HD reagent kit BROWN (Advanced 
Cell Diagnostics). FastRed turnover by alkaline phosphatase was detected using the 2.5 HD 





reagent kit RED (Advanced Cell Diagnostics) [16]. Cells were counterstained with 50% Gill's 
hematoxylin, dehydrated by baking at 60°C for 15 minutes and mounted with the xylene 
based mounting medium Eukitt (Sigma Aldrich, Saint Louis, MO, USA).   
Microscopy and data analysis 
Cells were imaged at bright field with a Nikon Eclipse TE300 inverted microscope or a slide 
scanner (Axio Scan.Z1; Zeiss) (Center for Microscopy and Image Analysis, University of 
Zurich). Quantitative image analysis was performed by selecting randomly ∼ 3 visual fields 
per each slide including ∼ 500 cells. The number of cells and mRNA molecules (brown or 
fluorescent dots) per cell were counted by using the open-source cell image analysis 
software CellProfiler [22]. GraphPad Prism software was used for the preparation of the 
displayed graphs.  
Results 
To characterize the hypoxic Epo transcript pattern on a single cell level, we performed 
chromogenic Epo mRNA in situ hybridization (ISH) (RNAscope) on the well-established 
human Epo-producing Hep3B and HepG2 hepatoma and Kelly neuroblastoma as well as on 
our recently generated immortalized but non-transformed renal mouse FAIK3-5 cell line. 
Cultured cells were seeded on 8-chamber glass dishes and incubated in normoxia (21% O2) 
or hypoxia (0.2% O2) for 24 hours or 8 hours (only HepG2). To verify the functionality of the 
ISH method in our conditions, positive and negative controls, the constitutively expressed 
low-copy housekeeping gene PPIB (peptidylprolyl isomerase B) and the bacterial gene dapB 
(4-hydroxy-tetrahydrodipicolinate reductase), respectively, were included. To quantify the 
number of cells and the number of mRNA targets per cell, computer-assisted and cell line 
specific-profiles were designed by using the Cell Profiler software.  
As shown in Figure 1E, the housekeeping gene PPIB was homogenously and highly 
expressed in HepG2, whereas the bacteria gene dapB was absent, indicating that no 
bacteria contamination was present during cell culture. In HepG2 cells, Epo mRNA was 
successfully induced under hypoxia at both 8 and 24 hour time points as highlighted by the 
numerous dots in Figure 1 A-B. Surprisingly, HepG2 cells did not show a homogenous 
expression of Epo mRNA but rather a cell-to-cell variability suggested by the fact that, while 
some cells display many Epo mRNA molecules (brown dots), some other show less dots per 
cell. As shown by the histograms of Figure 2A, about 40% of hypoxic HepG2 cells display 
one Epo mRNA molecule, whereas ∼20% of the HepG2 express 21 dots per cell at both at 8 
and 24 hours. Only less than 10% of cells resulted to express more than 100 dots per cells. 
To investigate the hypoxic transcript pattern of other HIF target genes, we focused on the 





HIF-2α target gene PHD3 (prolyl-4hydroxylase domain 3) as involved, together with PHD2, in 
forming a negative feedback loop that has been reported to reverse the hypoxic response but 
that it is poorly characterized at the molecular level. For PHD3, we observed a similar 
hypoxic transcript pattern as found for Epo (Figure 1C-D) with uneven distribution of PHD3 
mRNA molecules among hypoxic HepG2 cells (Figure 2B). The negative control gene dapB 
was histogram-quantified to verify the reliability of the cell type-specific software profile that 
was assessed by manual comparison between imaged and quantified dot (Figure 2C). 
Successively, we aimed to visualize and quantify Epo mRNA single molecules in Hep3B 
cells. In contrast to HepG2, hypoxic Hep3B cells displayed generally lower gene levels as 
seen by reduced amounts of dots associated with Epo, PHD3 and PPIB mRNA molecules. 
However, in line with HepG2, the “cell-to-cell behaviour” was observed in Hep3B as well, 
indicating that both hepatoma cell lines express hypoxic genes in a cell-to-cell variable 
manner compared to more homogenous expression of the PPIB housekeeping gene.  
Unexpectedly, Kelly neuroblastoma cells, which express 10-fold and 100-fold more Epo 
transcripts compared to Hep3B and HepG2, respectively, showed a more profound non-
homogenous Epo mRNA expression pattern. While hepatoma cells displayed a dotted Epo 
and PHD3 mRNA pattern that was unambiguously quantified, the signal detected in Kelly 
was more intense and presented an undefined non-dotted shape (Figure 4A-B) that was not 
possible to quantify by computer-assisted method. Consistently, also the PPIB gene was 
highly expressed with non-dotted signal feature (Figure 4C).  
We, next, validated the ISH method in FAIK cells, which were recently generated in our lab 
and that showed HIF-2α-dependent Epo kinetics. As our first attempt in these non-
transformed cells, the detection of mEpo and mHIF-2α was, unfortunately, inefficient due to 
oxygen-unregulated and weak signal (data not shown). However, we could successfully 
detect mHIF-1α, mPHD2, mPHD3 (Figure 5A) and mVEGF (Figure 5B). Especially, we 
observed hypoxic regulation of mPHD2 and mPHD3 after 6 hours (peak of Epo induction in 
FAIK cells), whereas mHIF-1α expression resulted to be stable between both hypoxic and 
normoxic conditions, consistently with a regulation of HIF-1α at protein level. Similarly to 
hepatoma and neuroblastoma, FAIK cells also showed high cell-to-cell variability as 
highlighted by the irregular distribution of dots per cell (Figure 5A-B). Like REPCs, FAIK cells 
display long projections, probably required to form cell-cell contacts in the interstitial space 
between blood vessel and renal tubules. Intriguingly, we could observed mHIF-1α mRNA 
molecules within these projections in either hypoxic or normoxic conditions (Figure 5).  
 
 






In this work, we established a recently developed ISH chromogenic method, ensuring the 
detection of single mRNA molecules that are imaged as single dots [16] in hepatoma, 
neuroblastoma and non-transformed FAIK cell lines to investigate the hypoxic transcript 
pattern of Epo and other HIF target genes on a single cell level. By comparing the transcript 
pattern of hypoxia-inducible genes to the constitutively expressed housekeeping gene PPIB, 
we observed, for the first time, that differences between these two different classes of genes 
exist, with a strong cell-to-cell variability of Epo and the HIF-2α target gene PHD3 in HepG2, 
Hep3B, Kelly and FAIK cells. Particularly, these cell lines showed a heterogeneous 
distribution of mRNA molecules with cells having a complete absence of target mRNA 
molecules, cells having little amount of mRNAs or cells with massive number of transcripts, 
implying that few cells produce most of the mRNA molecules. While for HepG2 and Hep3B 
we could faithfully quantify the distribution of single mRNA molecules per number of cell by 
computer-assisted approach, we were, unfortunately, unsuccessful with Kelly and FAIK cells. 
Specifically, we experienced difficulties in designing a personalized profile for Kelly cells as 
their strong chromogenic signal lost the dotted pattern during its accumulation and expansion 
among the cells. Additionally, we had problems in optimizing the FAIK cells profile as their 
typical long processes were not counted by Cell profiler when drawing the cell border. 
Therefore, we are planning to repeat the in situ hybridization in both Kelly and FAIK cells by 
using a fluorescence-based ISH with higher resolution that allows the detection of 
simultaneous mRNA targets as well as the design of a new profile to precisely quantify the 
fluorescent dots representing the mRNA transcripts. Surprisingly, in FAIK cells we could 
detect mRNA transcripts within their thin processes, indicating that, eventually, they might 
have a role in transferring mRNA molecules to other cells by interacting through cell-cell 
contacts. However, we have no evidence to prove this hypothesis so far and further 
investigations are currently ongoing in our group. Nevertheless, it is without precedent that 
single mRNA molecules are observed within the processes of renal interstitial cells. Taken 
together, our first attempt in performing a chromogenic ISH in vitro, provided evidence for a 
not yet reported strong cell-to-cell variability of the hypoxic transcript pattern of HIF target 
genes but not housekeeping genes.      
Our future plans include hypoxia titration in order to test oxygen sensitivity of hepatoma, 
neuroblastoma and FAIK cells to test which is the best oxygen concentration for Epo mRNA 
induction and how the Epo transcription pattern is affected by graded hypoxia. In addition to 
Epo, we would like to analyse also HIF-α isoform specific target genes such as CAIX and 
mVEGF (HIF-1α target gene) and PHD2 and PHD3 (HIF-2α target genes). It would be also 
interesting to perform hypoxia kinetics studies in Hep3B, HepG2, Kelly and FAIK cells to 





verify whether the pattern of cell-to-cell variability changes with ongoing hypoxia. Since we 
found that mVEGF mRNA was strongly localized in the nucleus of hypoxic FAIK cells (Figure 
5B), we would like to investigate this observation by elucidating the nuclear hypoxic 
transcription initiation pattern. Especially, we would like to understand whether the nuclear 
hypoxic transcription initiation pattern determines the occurring hypoxic transcription pattern 
or whether post-transcriptional events influence the cell-to-cell variability of the HIF target 
genes. We would approach this question by designing intronic ISH probes that should be 
detected only in the nucleus. Then, it would be intriguing to compare the nuclear hypoxic 
transcription initiation pattern with the general hypoxic transcript pattern for a given HIF 
target gene in each cell line. Importantly, we generated in our group Hep3B, HepG2 and 
Kelly cells with endogenous mutations within the 5' or 3' hypoxia response element (HRE) 
and could demonstrate that while in hepatoma the 3' HRE is the only element required for 
hypoxic Epo induction, in Kelly cells both the 5' and the 3' HREs enhance hypoxic Epo 
transcription in cooperation with the newly discovered promoter HREs (see Manuscript I). 
The availability of such mutant clones gives us the chance to study the cell-to-cell variability 
of the hypoxic Epo transcript pattern in a context of mutual functionality of the HIF-dependent 
(3' HRE and promoter HREs) and the HIF-independent (5' HRE) enhancers to verify whether 
Epo HREs contribute to its hypoxic transcription pattern. Finally, because HIF-1α and HIF-2α 
knock-down batch experiments suggest a mutual inhibition behaviour showing up-regulation 
of one isoform when the other is down-regulated [9], we are interested in testing whether at 
the single cell level both isoforms can be expressed equally. For this experiment we would 
opt for a fluorescent ISH method in order to simultaneously image both isoforms in Hep3B, 
HepG2, Kelly wt cells or stable HIF-1α and HIF-2α knock-down cells. The latter condition will 
be useful to validate whether down-regulation of the respective HIF-α isoforms influence the 
HIF-1α and HIF-2α transcription patterns. 
In conclusion, this work was a first attempt to apply the chromogenic ISH method to cultured 
cells in order to study the hypoxic transcription pattern of Epo and other relevant HIF target 
genes. We could successfully detect Epo transcripts in hepatoma and neuroblastoma as well 
as quantify the distribution of the mRNA molecules per cell in both Hep3B and HeG2. Finally, 
by this new ISH method, we provided initial in vitro evidence for inherent cell-to-cell variability 
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Figure 1. Single cell analysis of the hypoxic transcript pattern in human HepG2 hepatoma cells. 
RNAscope ISH technology (histochemical HRP-DAB stain with hematoxylin counterstain) was applied 
to in vitro cultured cells exposed to normoxic or hypoxic conditions for 8 or 24 hours as indicated. 
(A,B) Example ISH for human Epo and PHD3 (C,D) in HepG2 cells are shown. (E) The bacterial 
negative control gene DapB and the housekeeping positive control gene PPIB in normoxic condition 
are shown. Hypoxic levels (not shown) of DapB and PPIB were indistinguishable. The image 
processed by Cell profiler is shown next to the bright field pictures. Yellow lines delineate cell borders 
and the red circles indicate single mRNA transcripts detected by the software.  














































Figure 2.  Quantification of the mRNA molecules per number and percentage of HepG2 cells. (A) 
Histogram analysis of single-cell mRNA distribution for Epo (A), PHD3 (B) and the negative control 
gene DapB (C) used to assess the functionality of the quantification method. (A,B,C) The y-axis 
































Figure 3. Single cell analysis of the hypoxic transcript pattern in human Hep3B hepatoma cells. 
RNAscope ISH technology (histochemical HRP-DAB stain with hematoxylin counterstain) was applied 
to in vitro cultured cells exposed to normoxic or hypoxic conditions for 24 hours as indicated. Example 
ISH for human Epo (A) and PHD3 (B) in Hep3B cells are shown. Histogram analysis of single-cell 
mRNA distribution for Epo (A) and PHD3 (B) are displayed. The y-axis provides absolute number of 
cells (#), while the right axis provides the percentage cell number (%). The bacterial negative control 
gene DapB (C) and the housekeeping positive control gene PPIB (D) in normoxic and hypoxic 
conditions are shown. The image processed by Cell profiler is shown next to the bright field pictures. 
Yellow lines delineate cell borders and the red circles indicate single mRNA transcripts detected by 
the software.   
















Figure 4. Single cell analysis of the hypoxic transcript pattern in human Kelly neuroblastoma cells. 
RNAscope ISH technology (histochemical HRP-DAB stain with hematoxylin counterstain) was applied 
to in vitro cultured cells exposed to normoxic or hypoxic conditions for 24 hours as indicated. Example 
ISH for human Epo (A) and PHD3 (B) in Kelly cells are shown. (C) The bacterial negative control gene 
DapB and the housekeeping positive control gene PPIB in hypoxic condition are shown. Normoxic 


































Figure 5. Single cell analysis of constitutive (mHIF-1α, ppib) and hypoxically induced (mPHD2, 
mPHD3, mVEGF) in mouse FAIK3-5 cells. RNAscope ISH technology (histochemical AP-FastRed 
stain with hematoxylin counterstain) was applied to in vitro cultured cells exposed for 6 hours in 
hypoxia as indicated. (A) Arrows indicate HIF-1α mRNA in processes. Note that mVEGF but not the 











6. Conclusions and future perspectives 
 
Oxygen is essential for the survival of all aerobic organisms. In mammals, oxygen sensing 
through the prolyl-4-hydroxylase domain (PHD1/2/3) enzymes is fundamental to drive the 
activation of the HIF pathway that controls the adaptation to hypoxia, a condition in which 
oxygen demand exceeds the oxygen supply [1]. The master regulator of this adaptation, the 
transcription factor hypoxia-inducible factor (HIF) has been discovered in hepatoma cells by 
its binding to the 3' hypoxia response element (HRE) located downstream of the 
erythropoietin (EPO) gene [2]. Epo is the main regulator of red blood cell homeostasis. The 
main Epo producing organs are the fetal liver and the adult kidney but ectopic Epo 
expression is found also in other organs including the brain as Epo has either erythropoietic 
or non-erythropoietic functions [3]. Importantly, EPO is a unique example of a gene regulated 
in a hypoxia-inducible and tissue-specific manner. In fact, distinct regulatory tissue-specific 
DNA elements enhance EPO transcription in liver and kidney, whereas Epo regulation in the 
brain is completely unexplored. Previous in vivo studies demonstrated that while the 3’ HRE 
is necessary and sufficient for liver-specific EPO induction after embryonic day 14.5 [4], the 
essential regulatory element for Epo regulation in the kidney resides between -14 and -6 kb 
upstream of the transcription start site (TSS) of the EPO gene [5] [6]. However, the precise 
molecular mechanism underlying the transcriptional regulation of erythropoietin in the kidney 
remains undefined due to the lack of an appropriate renal cell culture system capable of 
hypoxia-inducible Epo expression [7]. Given the above observations, the aim of the thesis 
was to investigate the DNA regulatory elements modulating the transcriptional regulation of 
erythropoietin in hypoxia in well-established liver- and brain-derived in vitro cell culture 
models.  
In particular, we were able to dissect the contribution of the distal 5' and 3' HREs as well as 
the promoter to endogenous EPO gene expression in hepatoma and neuroblastoma cell 
lines by employing the cluster regularly interspace short palindromic repeat 
(CRISPR)/CRISPR-associated protein (Cas) technique (CRISPR/Cas) to mutate the novel 5' 
and the well-established 3' HRE generating single (Hep3B, HepG2, Kelly) and double mutant 
clones (Kelly).  
Role of distal 5' and 3' HREs and promoter in regulating hypoxia-inducible Epo in hepatoma 
and neuroblastoma cell lines 
We recently discovered a strongly conserved distal 5' HRE within a DNase I hypersensitive 
site located at -9.2 kb upstream of the EPO TSS, containing both the 5'-ACGTG-3' core HIF 
DNA binding site as well as the ancillary 5'-CACA-3' element. We found that this 5' HRE is 





functional in hypoxia as it drives hypoxia-inducible exogenous reporter gene expression in 
both Epo expressing and non-expressing cell lines. Therefore, we suggested that the novel 5' 
HRE could be the putative oxygen-regulated DNA element modulating renal Epo expression 
[8]. Due to the lack of a renal Epo-producing cell culture model and considering the neuronal 
features that REPCs possess, we analysed the relative contribution of the 5' and 3' HREs in 
Kelly cells, a human neuroblastoma cell line capable of producing Epo in a hypoxia-inducible 
manner that might recapitulate Epo transcriptional regulation in the brain [9]. While we 
confirmed that the 3' HRE is the only required element regulating Epo induction in hepatic 
cells, in neuronal cells, both the 5' and 3' HREs appear to be important to regulate hypoxic 
Epo induction. In contrast to Hep3B, where the Epo promoter is only slightly bound by HIF 
and no hypoxic induction could be detected in reporter gene assays, in Kelly cells, 
surprisingly, the Epo promoter is the DNA element that is most strongly bound by HIF, in line 
with a weak hypoxic induction observed in luciferase assays and the presence of two HIF 
binding sites (HBS) (5'-GCGTG-3') termed pHRE1 and pHRE2 behaving as one unique 
HRE. Remarkably, although mutation of the 5' HRE in Kelly cells heavily reduced 
endogenous Epo mRNA and protein levels, no HIF binding at the 5' HRE was detected in 
Kelly wt cells, suggesting that the 5' HRE is functionally relevant for hypoxic EPO gene 
induction but not directly bound by HIF. This finding might be explained by the observation 
that some HIF target genes like, for instance, PAG1 gene possess HREs to form chromatin 
loop locally or over a long distance to interact with the promoter without necessarily binding 
HIF but rather to keep a pre-formed chromatin loop ready to interact with other regulatory 
elements in case of hypoxic stimulus [10]. Therefore, we think that the 5' HRE might maintain 
a constitutive chromatin structure supporting the promoter activity in Kelly and, generally, in a 
cell-type specific manner. When generating the 5'/3' HREs double mutant Kelly clones, we 
obtained large and small 5' HRE deletions within the 3' HRE mutants. Intriguingly, large 5' 
HRE deletions fully abrogated endogenous Epo induction as well as binding of HIF-β at the 
EPO promoter region, indicating that the binding of putative transcription activators as well as 
HIFs is impaired. In contrast to large 5' HRE deletions, small 5' HRE deletions rather rescued 
Epo endogenous levels and HIF-β binding at EPO promoter, suggesting that additional 
transcription factors (TFs) might bind close to the consensus HRE sequence and be involved 
in chromatin looping and trans-activation of EPO promoter. Because single 5' HRE deletions 
strongly reduced Epo endogenous mRNA and protein levels as well as HIF-β binding at EPO 
promoter, it is currently unknown why small 5' HRE deletions in 3' HRE mutants rescue 
instead endogenous Epo levels and the interaction of HIF to the promoter. A scheme 
summarizing the proposed molecular mechanism of Epo transcriptional regulation in Kelly 
cells is displayed in Figure 1.     





























Figure 1. Proposed molecular mechanism of Epo transcriptional regulation in Kelly 
neuroblastoma cells. A. In wt cells, the heterodimer HIF-2α/HIF-β binds the 3' HRE as well as the 
two promoter HREs, whereas unknown transcriptional factors (TFs) bind the 5' HRE. A complex 
interplay between the 3' HRE looping to Epo promoter (black arrow on the right) and the 5' HRE 
looping to the Epo promoter (black arrow on the left) enhance Epo transcription up to 100-fold in 
hypoxia. B-C. In 5'/3' HREs double mutants, the interaction between the distal 3' HRE and the Epo 
promoter is impaired. While in double mutants with small 5' HRE deletions (1, 2 or 3 bp as indicated in 
B) unknown TFs can still bind the neighbour HRE consensus core ensuring the interaction with Epo 
promoter (black arrow on the left), a big deletion within the 5' HRE (31 bp as indicated in C) impedes 
the binding of any putative TFs, blocking the looping to Epo promoter.      





These new findings in neuroblastoma cells shed light, for the first time, on the molecular 
mechanisms underlying the oxygen-regulated Epo transcription regulation in the brain. 
Although, Epo transcriptional regulation in the kidney remains elusive, the observation that 
REP cells express neuronal markers [11] renders the Kelly cells a better model than 
hepatoma cells to recapitulate human hypoxic EPO gene expression in the kidney. A recent 
study reported that transgenic mice having a deletion of the region -17.4 to 3.6 kb upstream 
of EPO showed abrogation of Epo expression in REP cells but not in brain, indicating that 
such region contained regulatory elements relevant exclusively for the kidney. However, 
deletion of the 0.7 kb sequence containing the mouse -8.3 kb 5' HRE (corresponding the 
human -9.2 kb 5’ HRE) within this Epo 5' upstream region did not abrogate transgenic GFP 
expression in the kidney whereas the brain was not evaluated. In contrast, a minimal 0.3 kb 
fragment encompassing the mouse 5' HRE was insufficient to drive transgenic GFP 
expression in mouse kidney (again the brain was not analysed) [12]. Altogether, our findings 
on the complex interplay between the distal 5' and 3' HREs and EPO promoter in Kelly cells 
could help to understand in vivo renal Epo regulation: in the kidney Epo transcription might 
be regulated by the cooperative action of an extended 5' element, the minimal 3' HRE and 
the Epo promoter. To test this hypothesis it would be useful to generate transgenic mice with 
deletion of either the 0.7 kb sequence containing the mouse -8.3 kb 5' HRE or the 3' HRE 
and verify transgenic GFP expression not only in kidney but also in brain in order to confirm 
our findings about brain Epo regulation in vivo. In case the combined deletion of the 0.7 kb 
sequence and the 3' HRE would not be sufficient to abrogate the reporter gene expression, it 
would be still worth to delete combinations of extended 5' sequences as the region -17.4 to 
3.6 kb upstream of EPO has been proven to be involved in renal Epo regulation.  
In the future, to prove that the distal 5' and 3' HREs loop to Epo promoter and that the HIF-
independent 5' HRE contain a pre-formed chromatin loop, it would be necessary to perform a 
chromosome conformation capture (3C). Additionally, to validate the contribution of the Epo 
promoter to endogenous Epo expression in Kelly, it would be worth to mutate Epo promoter 
sequence by CRISPR/Cas9. However, because the two newly reported promoter HREs, 
pHRE1 and pHRE2, are separated by only 29 bp, it will be difficult to target separately such 
HREs by sgRNA. On the other hand, in reporter gene assays pHRE1 and pHRE2 behave as 
one unique HRE, therefore, it would be still useful to target both promoter HREs by 
CRISPR/Cas9.  Another important aspect to follow up is the identification of the TFs binding 
the 5' and 3' HRE in neuroblastoma in order to define the details of Epo transcriptional 
regulation in brain. As an example, predicted binding sites of putative TFs binding the 
enigmatic 5' HRE through in silico analysis by JASPAR database are depicted in Figure 2. 
Currently, our collaborators are employing a 5' HRE-dependent reporter gene assay to 





screen a library of TFs to identify possible factors binding the novel 5' HRE. Multiple 
candidates have been found to enhance 5' HRE-driven luciferase activity and evaluation of 











Figure 2. Predicted binding sites for putative TFs at the 5' HRE by JASPAR database. The 
predicted binding sites within the 5' HRE region are highlighted in grey, whereas the CACA element 
and the HRE core consensus ACGTG are showed in the reverse strand orientation and highlighted in 
bold. Putative TFs include small mother against decapentaplegic 2/3/4 (SMAD2/3/4), transcription 
factor AP-2 alpha/gamma (TFAP2A/C), THAP domain-containing protein 1 (THAP1), Zinc Finger 
Protein 354C (ZNF354C), Forkhead Box C1 (FOXC1).  
Additionally, a strategic approach that could be considered in the near future, once one or 
more TFs binding the 5' HRE will be defined, is the pull-down of unknown proteins binding 
the 5' HRE using as bait the putative TF, followed by Mass Spectrometry analysis to discover 
more interactors at the 5' HRE. It would be worth to adopt this method in both Kelly 
neuroblastoma and in our non-transformed renal FAIK cell line as TFs binding the 5' HRE 
might be tissue-specific and, thus, different between brain and kidney. As mentioned before, 
methylation of CpG sites is an additional layer of regulation of Epo transcription; therefore, it 
would be interesting to evaluate the methylation status of the novel 5' HRE in hepatoma and 
neuroblastoma. In fact, methylated 5' HRE would explain its dispensable role in hepatic cells, 
whereas un-methylated 5' HRE would be expected in Kelly cells consistent with its important 
role in regulating endogenous Epo. Furthermore, we would like to repeat the CRISPR/Cas9 
mutation of 5' and 3' HREs as well as Epo promoter in FAIK cells in order to decipher the 
contribution of these regulatory elements to renal Epo expression. Finally, as already 
mentioned in the unpublished data section, we would like to verify whether the HIF-
dependent (3' HRE) and the HIF-independent (5' HRE) enhancers influence the cell-to-cell 





variability of the Epo hypoxic transcript pattern by applying the ISH method to 5' and 3' HREs 
single and double mutant Kelly cells.  
Final remarks 
The transcriptional regulation of Epo in the kidney remains the main open question within the 
Epo research field and we hope to contribute soon in deciphering such mechanisms by 
performing the enhancers and promoter mutation analysis in our recently generated non-
transformed renal FAIK cell lines, benefitting from the new discovered roles of 5' and 3' 
HREs in Kelly neuroblastoma cells.  
Investigating the regulation of erythropoietin is important not only from a physiological 
prospective but, especially, for its clinical implications. Up-regulation of Epo levels causes, 
indeed, erythrocytosis whereas low Epo levels provoke anemia or anemia associated with 
chronic kidney disease (CKD). Nowadays, the therapy employed to cure patients affected by 
CKD relies on the injection of human recombinant Epo (rhEpo) that is, however, expensive. 
Therefore, PHD inhibitors have been developed and are currently in Clinical Trial III phase as 
possible substitute of rhEpo, being cheaper than rhEpo and orally administered. These drugs 
will enter the market in 1-2 years for the treatment of renal anemia but their mechanism of 
action needs to be further analysed as well as their potential side effects. Within such 
scenario, identifying the DNA regulatory elements involved in Epo transcriptional regulation 
opens the possibility to discover the TFs binding at such regulatory sites that, in the future, 
may be employed as novel drugs to enhance the endogenous levels of Epo, being smaller 
and cheaper than rhEpo and able to reduce the therapy costs and the side effects of patients 
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